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ABSTRACT 
 The pathogenesis of lupus and other autoimmune diseases driven by 
antibody-antigen complexes involves interactions between genetic and 
environmental factors. The genetic factors can be separated into factors that 
dysregulate adaptive immunity, innate immunity or cell death.  One genetic risk 
factor that can affect both innate and adaptive immunity is the inhibitory Fcγ 
receptor, FcγRIIB. Reduced or loss of function mutations in FcγRIIB lead to an 
increased risk of autoimmunity. Using the murine IgG2a specific B cell receptor 
(BCR) transgenic (Tg) mouse, AM14, our lab discovered that delivery of nucleic 
acid ligands via the BCR activates B cells by dual engagement of the BCR and 
endosomal toll like receptors (TLR) 7 and/or 9. Mechanistic studies interrogating 
the role of downstream signaling effectors and intracellular trafficking in the 
attenuation of BCR-TLR responses by FcγRIIB were limited by our inability to 
deliver immune complexes (IC) to non-Tg B cells or form brightly fluorescent IC.  
To deliver IC to non-Tg B cells, I developed a BCR adapter (BCRAM) that 
delivers IC to IgM-positive B cells. To track the uptake and trafficking of IC, I 
		
	
viii 
developed a panel of antibodies specific for streptavidin (SA). Complexes formed 
with biotinylated molecules and fluorescent streptavidin could be delivered to 
AM14 B cells or macrophages and tracked via flow cytometry and/or confocal 
microscopy. BCRAM and fluorescent IC were used to understand how FcγRIIB 
attenuated BCR-TLR responses. I found that both DNA IC and RNA IC 
responses were enhanced by FcγRIIB ablation.  Interestingly, a naturally-
occurring somatic mutation in the Fc domain of the nucleic acid-binding antibody 
PL2-3 prevented regulation by FcγRIIB and reduced binding to activating FcγR. 
Paradoxically, I found that SHIP-1, a negative regulator activated downstream of 
FcγRIIB engagement, promoted BCR-TLR9 responses independent of FcγRIIB. I 
hypothesized that FcγRIIB attenuates BCR-TLR9 responses by interfering with 
sensing by the endosomal TLRs. Using a pH sensing IC, I found that 
engagement of FcγRIIB leads to residence of the IC in a higher pH compartment.  
These findings demonstrate that FcγRIIB regulates the activation of autoreactive 
B cells by modulating the trafficking of nucleic acid containing IC to TLR7 and 
TLR9 associated intracellular compartments in B cells.  
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CHAPTER ONE 
 
 
 
I. Introduction  
     The immune system of higher vertebrates evolved over 100 millions of years 
(1).   The most ancient arm represents innate immunity whereas the most 
recently evolved arm is adaptive immunity. The adaptive immune system can be 
further divided into cellular and humoral immunity. The different arms of the 
immune system are not siloed but rather a connected complex network.  The 
separate parts function together to identify threats to the host and coordinate the 
appropriate response. The common theme among host defense strategies in 
vertebrates and invertebrates is discriminating self from non-self.  The humoral 
immune system evolved a means to generate receptors capable of recognizing 
nearly any molecule by genetic rearrangement and somatic mutations.  Class 
switched antibodies (e.g. IgG) not only recognize antigens but also coordinate 
effector functions via binding to complement and Fcγ receptors.  After a 
successful antibody response has been raised, a negative feedback loop 
quarterbacked by the inhibitory FcγR attenuates antibody production. Reduced or 
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loss of function alleles of this negative feedback pathway predisposes to the 
development of autoimmunity.  
 
A. The B Cell Receptor  
     Humoral immunity refers to antibody-mediated immunity. Antibodies are 
expressed on the cell surface as the BCR and then secreted by differentiated 
plasma cell lineage cells.  The diverse repertoire is generated by gene 
rearrangements resulting in significant N-terminal sequence variability in the 
antibody molecule. In mice, N-termini of both heavy and light chains pair to form 
an antigen recognition domain, also called the variable domain.  The C-terminal 
end of an antibody molecule is termed the constant domain, which confers 
effector functions. Via class-switch recombination, an existing antigen recognition 
domain is combined with a different constant domain thereby changing the 
effector functions associated with that antibody.  Antigen specific B cells that 
express a plasma membrane associated-antibody can also secrete that molecule 
as a soluble antibody (2).  The cell surface bound antibody in complex with 
CD79a and CD79b forms the B cell receptor (BCR) (3).   It is the BCR that 
transmits signals that drive the survival and selection of antigen specific B cells 
(4). The systems that balance receptor diversity with autoimmunity operate at all 
stages of B cell development.  The topic of this dissertation is how a negative 
feed back system that restrains B cell activity also protects against development 
of autoimmune diseases.  
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B. B cell development  
     The development of B cell receptor diversity occurs in the bone marrow and 
in peripheral lymphoid organs.  The development of B cells starts in the bone 
marrow with the common lymphoid progenitors cells. The first receptor 
expressed on the cell surface of immature B cells is the pre-BCR.  The pre-BCR 
is a complex between a rearranged heavy chain, a surrogate light chain and the 
associated signaling molecules CD79a and CD79b. The function of the pre-BCR 
was thought to select for heavy chains that were capable of forming a functional 
BCR with a light chain. The importance of signaling in this process was 
demonstrated when inactivation of CD79a led to an absence of mature B cells in 
the periphery (5).  Furthermore, ablation of surrogate light chain also arrested 
development at this stage reinforcing the notion that the pre-BCR selects for 
heavy chains that are capable of forming a functional BCR (6).  If the rearranged 
heavy chain is poorly expressed or resulted in a stop codon, the other heavy 
chain allele can be rearranged.  After a functional heavy chain is rearranged, a 
light chain locus is rearranged and expressed on the cell surface in complex 
with the heavy chain and the signaling components forming a potentially 
functional BCR (7). It is at this stage that engagement of the BCR shapes the 
repertoire and as a checkpoint for autoreactive cells.  
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     Engagement of the BCR at this point in development can have a variety of 
outcomes, which are likely determined by the strength of the interaction. If the 
rearranged light chain pairs poorly with the heavy chain or is poorly expressed, 
the other light chain allele can be rearranged.    In the case of a weak 
engagement of the BCR, the B cells are positively selected and exit the bone 
marrow as surface IgM positive immature B cells (8).  By contrast, strong or 
intermediate strength engagement of the BCR in the bone marrow would 
suggest an autoreactive receptor.  Depending of the strength of the autoreactive 
BCR engagement, the host has three mechanisms to eliminate autoreactive B 
cells from the repertoire: 1) anergy, 2) deletion and 3) receptor editing.   
     Using transgenic (Tg) mice to introduce a rearranged heavy and light chains 
leads to the development of B cells with a preformed B cell receptor in those 
mice.  In fact, much of what is known about the fate of autoreactive B cells was 
elucidated using Tg B cells with autoreactive BCRs or a BCR reactive with 
antigen that can be expressed in trans. On example of the latter is a BCR Tg 
that is specific for hen egg lysozyme (HEL). In mice expressing soluble HEL, 
MD4 B cells were able to pass this checkpoint and were found in peripheral 
lymphoid organs. On the other hand there was no antibody detected in the sera 
of these mice.  The cells were phenotypically similar to normal B cells except for 
lower surface staining for IgM and expression of the immature marker CD93.  
On the other hand, they did not become activated by BCR crosslinking or 
secrete antibody (9). This paralysis termed anergy was thought to arise from 
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antigen receptor engagement in the absence of a second signal. It was 
hypothesized that lymphocytes required two signals to become activated, one 
from the BCR and the other from a T cell or innate immune receptor (10).  The 
molecular underpinning of anergy was thought to arise from chronic BCR 
occupancy by the antigen. For example, when the mature MD4 B cells that 
matured in the absence of pseudo-autoantigen were injected into HEL 
expressing hosts, they acquired the anergic phenotype. Furthermore, using the 
Ars Tg BCR that reacts both with the hapten arsonate (Kd~2x10-5) and the 
autoantigen, ssDNA (Kd~2x10-3) it was found that dissociation of the 
autoantigen, ssDNA, from the BCR reversed the anergic phenotype. The 
reversibility of the anergic phenotype led Gauld et al. to speculate that anergy 
was not a genetic change but rather a reversible change in signaling (11). 
Supporting the notion that anergy was reversible, was the finding that 
expression of negative signaling molecule, SHIP-1 was required to establish 
anergy (12). Another model where autoreactive cells exit the bone marrow was 
the AM14 BCR Tg, which is specific for self-IgG2aa/j.  The AM14 B cells matured 
normally but were functionally similar to anergic B cells in that they did not 
respond to their cognate antigen, monomeric IgG2as/j.   In contrast to anergic B 
cells, AM14 B cells were capable of full activation by BCR crosslinking.  This 
was termed ignorance, because the B cells seemed to be unaffected by the 
presence of their cognate antigen, presumably due to the low affinity of this 
interaction. These results demonstrated a mechanism where autoreactive cells 
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can escape tolerance and regain and or retain BCR responsiveness in the 
periphery.  
     Alternative to a soluble pseudoautoantigen, HEL was expressed as a 
membrane protein with the MD4 BCR Tg.  Coexpression of the 
pseudoautoantigen as a membrane protein led to deletion of the autoreactive 
cells. In the absence of the membrane pseudoautoantigen, the B cells 
developed normally. In the presence of membrane HEL, there was an 
accumulation of immature B cells (13). The studies on membrane bound HEL 
demonstrated that the extensive BCR crosslinking led to deletion while lower 
crosslinking led to anergy (14). This was consistent with previous work where 
membrane bound autoantigen, H2-Kb (MHC-I), and a Tg receptor specific for 
H2-Kb led to deletion of autoreactive cells in the bone marrow (15, 16).  
     Alternative to deletion, autoreactive cells can be rescued by receptor editing. 
In the case of autoreactive cells, it is the BCR that is driving deletion. One 
mechanism to escape deletion is to edit the BCR by rearranging the other light 
chain allele. This has been shown in many murine BCR Tg with autoreactive 
BCRs. One example that is especially relevant to lupus is the 3H9 BCR Tg.   
When the 3H9 heavy chain was paired with a wide range of light chains, it binds 
ssDNA or dsDNA.  Mice expressing only the 3H9 heavy chain lacked anti-
dsDNA or anti-ssDNA antibodies in the sera. Sequencing of the light chain 
genes of B cells in peripheral lymphoid organs revealed that only a very limited 
number of light chains were used that did not result in dsDNA or ssDNA 
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reactivity (17). This suggested that the receptor had been edited through a 
mechanism that involved a secondary light chain rearrangement that modified 
the BCR specificity and led to a loss of self-reactivity. This mechanism has been 
subsequently shown in other BCR Tgs.  Based on the results of studies 
examining multivalent ligands, it was proposed that in the bone marrow, 
intermediate engagement of the BCR led to receptor editing and strong 
engagement of the BCR led to deletion (14).  
 
C. B cell Activation via BCR Engagement  
     When the BCR is crosslinked it transmits information via signaling that leads 
to activation, antibody secretion, cytokine production and differentiation. The 
BCR complex is membrane anchored splice variant of the secreted antibody in 
complex with the signaling molecules CD79a and CD79b that have cytoplasmic 
ITAM domains (3). Signaling via the BCR is initiated by crosslinking of the 
receptor upon antigen binding.  Antigen binding leads to receptor clustering in 
lipid rafts and phosphorylation of the ITAM of CD79a and CD79b by Lyn. Double 
phosphorylation of CD79a or CD79b leads to binding of Syk via its SH2 domains 
and activation of Syk. Next, BLNK binds to CD79a and is phosphorylated by Syk. 
Phosphorylated BLNK binds other components including Btk and PLCγ2.  Btk is 
phosphorylated by Syk and in turn phosphorylates PLCγ2 (18).  Association of 
BTK and PLCγ2 with the plasma membrane via their pleckstrin homology (PH) 
domains required phosphatidylinositol (3,4,5)-trisphosphate (PIP3). The 
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formation is initiated when Syk phosphorylates BCAP that in turn activates PI3K 
by binding its p85 regulatory subunit. In addition to BCAP, phosphorylated CD19 
can activate and sustain PI3K signaling by binding p85.  Activated PI3K 
catalyzes the phosphorylation of PIP2 (4,5) to PIP3 (3,4,5) at the plasma 
membrane. The importance of the PH domain of Btk was highlighted by the Xid 
mouse (19). This mouse expresses a full length mutant Btk protein that contains 
a single amino acid change in the PH domain which abrogated binding to PIP3 
(3,4,5).  B cells from Xid mice were unable to respond to crosslinking of the BCR. 
The same was found to be true for PLCγ2, where inactivation of the PH domain 
abrogated activity (20). The recruitment of Btk and PLCγ2 to the plasma 
membrane leads to PLCγ2 activation by Btk.  
     The signaling cascade branches after PLCγ2 catalyzes the hydrolysis of PIP3 
(3,4,5) to diacylglycerol (DAG) and IP3.  Binding of IP3 to the IP3 receptor leads 
to Ca2+ efflux from the endoplasmic reticulum. Higher intracellular concentration 
of Ca2+ leads to activation and nuclear import of the transcription factor NFAT. 
Protein kinase C is activated by DAG binding, which activates NFκB dependent 
transcription via CARD11. Binding of DAG to RasGRP activates the MAPK/JNK 
signaling cascade, ERK phosphorylation and AP-1 dependent transcription. 
Activation, of AP-1, NFκB and NFAT dependent transcription leads to cellular 
activation, proliferation and differentiation.  In addition to activating transcription, 
PIP3 also contributes to the activation of Akt and pro-survival signals (21).   
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     Not only does the BCR function to transmit signals but it also orchestrates the 
internalization of bound antigen.  The clustering of cell surface receptors, 
signaling and internalization requires coordination with the cytoskeleton.  
Internalization of the BCR occurs via clathrin-coated pits, which is consistent with 
the requirement of dynamin for efficient internalization (22).  The internalization of 
the BCR via CCP requires the reorganization of the actin cytoskeleton.  In 
addition to internalization, BCR signaling also required coordination with the 
cytoskeleton (23-25).  It was shown that actin polymerization is enhanced by Btk 
activation.  The Xid mutation retarded BCR internalization and significantly 
reduced actin polymerization. These effects were connected to the activation of 
the actin nucleation factor WASP (26). Together these studies demonstrated the 
link between receptor crosslinking and signaling via cytoskeletal rearrangement.  
 
D. Negative Regulation of B cell responses by FcγRIIB Colligation 
     The central role of PI3K and PIP3 (3,4,5) in activation via the BCR made it a 
node to restrain B cell activation via endogenous and pharmacological means. 
Endogenous pathways to antagonize B cell activation are the phosphatases 
PTEN and SHIP-1. These inositol phosphatases hydrolyze the 3’ and 5’ 
phosphates of PIP3 respectively.  Although both phosphatases would inhibit the 
recruitment of PH domains that bind PIP3, the reaction products could have 
divergent consequences.  The product of PTEN, PIP2 (4,5) can be regenerated 
by the PI3K to PIP3 (3,4,5) (27).  On the other hand, SHIP-1 dephosphorylates 
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the 5’ phosphates with the product PIP2 (3,4). In the context of BCR signaling, 
activated SHIP-1 would inhibit the recruitment of Btk to the plasma membrane 
thereby having pleiotropic effects on downstream signaling (28, 29).  
     A successful humoral immune response leads to the production of antigen 
specific IgG antibodies. One way of secreted IgG molecules to transmit signals is 
by binding Fc receptors that bind with varying affinities depending on antibody 
isotype and Fc receptor.  The only FcγR expressed by B cells is the inhibitory 
receptor, FcγRIIB1.  This is contrast to myeloid lineage cells that express 
activating FcγR and the FcγRIIB2 isoform.  The two isoforms of FcγRIIB differ in 
that FcγRIIB1 has an additional 47 amino acids on the cytoplasmic tail proximal 
to the membrane.  When an antigen specific B cell binds its antigen that is also 
antibody bound, the BCR and FcγRIIB1 are coengaged (30). The subsequent 
activation of antigen specific B cells is inhibited by two overlapping mechanisms. 
It was shown that co-engagement of BCR-FcγRIIB1 inhibited the clustering of the 
BCR (31). This observation was reinforced by the finding that FcγRIIB1 inhibited 
the colocalization of CD19 with the BCR (32). Furthermore, inhibition of BCR 
clustering by FcγRIIB was found to be independent of the ITIM motif of FcγRIIB.  
Rather, co-engagement of BCR-FcγRIIB1 led to phosphorylation of the ITIM by 
Lyn and recruitment and activation of SHIP-1.  Activated SHIP-1 then inhibits 
PIP3K dependent downstream events by dephosphorylation of PIP3 (33, 34).  
For example, coengagement of BCR-FcγRIIB inhibited the plasma membrane 
recruitment of Btk (28). As a negative regulatory mechanism restraining B cell 
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responses, it was not surprising that reduced expression or reduced activity 
alleles of FcγRIIB were associated with the development of autoimmune 
diseases.  
 
E. FcγRs, Toll Like Receptors and Murine Models of Lupus 
     Some of the pathogenic manifestations of lupus are directly associated with 
the production of class switched antibodies for autoantigens. IgG autoantibodies 
can contribute to pathogenesis via cytokine production and tissue damage. The 
main effector mechanism of IgG antibodies on myeloid cells is via binding FcγRs. 
In addition to the inhibitory Fc receptor, FcγRIIB, mice also express two low 
affinity receptors FcγRIIIA and FcγRIV and a single high affinity receptor FcγRI. 
Like the inhibitory FcγR, the activating receptors bind the Fc portion of IgG 
antibodies.  However, instead of a cytoplasmic ITIM motif, the FcγRI, FcγRIIIA 
and FcγRIV utilize the common FcγR dimer to transmit activating signals via 
cytoplasmic ITAM motifs (35-37).  In addition to their differing affinity for antibody 
isotype, the murine FcγRs also differ in the pattern of expression.   The high 
affinity FcγRI is expressed by dendritic cells. The inhibitory receptor FcγRIIB1 is 
expressed solely on B cells. The FcγRIIB2 isoform is expressed by 
monocyte/macrophages, dendritic cells and granulocytes (38). The activating 
FcγRIII receptor is expressed by natural killer cells, monocyte/macrophages and 
granulocytes.  The activating receptor FcγRIV is only expressed on 
		
12 
 
monocyte/macrophages and neutrophils (38). The expression of a single 
inhibitory receptor suggests that inactivation would have a profound effect.  
     In humans, a loss of function allele of FcγRIIB was found to be strongly 
associated with development of autoimmune disease. This mutation is located in 
the transmembrane domain (I232T) of FcγRIIB and prevents the receptor from 
entering lipid rafts (39, 40). Consequently, this mutant receptor cannot inhibit 
BCR crosslinking, recruit SHIP-1, or activate SHIP-1.  Similar to human disease, 
when FcγRIIB was ablated using 129 ES cells and backcrossed to C57BL/6 
mice, the mice develop spontaneous autoimmune diseases characterized by 
autoantibodies and immune complex deposition in the kidneys (41).  On the other 
hand, when the murine knockout was made using C57BL/6 ES cells, the mice did 
not get as severe a disease.  This was attributed to the fact that FcγRIIB KO 
allele derived from 129 ES cells still retain expression of the genes around the 
KO allele even after backcrossing (42). These results highlight the complex 
polygenetic nature of autoimmune diseases, which require contributions from 
multiple genetic elements. The genomic interval surrounding the FcγRIIB was 
characterized as part of the sle1 locus from the NZM2410 murine model of 
spontaneous immunity.  In addition to FcγRIIB, the locus also contains the SLAM 
gene family, which are also autoimmune susceptibility genes.  
     In addition to the NZM2410 strain, another autoimmune prone strain is the 
MRL. When combined with the lpr gene, a FasL mutation that severely impairs 
central tolerance in B cells and T cells, the mice develop anti-nucleic acid 
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antibodies  (ANAs), splenomegaly, and glomerulonephritis.  The FcγRIIB allele 
from this strain has a promoter polymorphism that leads to lower levels of 
expression (43).  Despite the polygenic nature of the disease in the MRL/lpr 
model of spontaneous lupus, overexpression of FcγRIIB on B cells led to 
suppression of autoimmune disease in that model (44). This supported the idea 
that FcγRIIB was an important factor in restraining autoreactive B cell activity in 
the periphery.  Studies using a floxed FcγRIIB allele and Cg1Cre that deletes 
floxed genes in germinal center (GC) and post-germinal center B cells, reinforced 
the importance of restraining peripheral autoreactive cells. Deletion of FcγRIIB in 
GC or post-GC B cells led to the spontaneous development of antinuclear 
antibodies (45). The protective role of functional FcγRIIB in multiple murine 
models of spontaneous lupus support a causal relationship of the loss of function 
in humans and susceptibility to autoimmune diseases.  This suggested that 
reduced FcγRIIB expression on B cells was sufficient to cause autoimmunity.  
 
F. Role of B cells in Lupus Pathogenesis  
     In addition to the production of isotype switched antibodies, B cells can also 
secrete cytokines and activate T cells via antigen presentation. Therefore B cells 
could contribute to the pathological manifestations of lupus by: i) IgG IC 
deposition in tissues, ii) cytokine production or ii) activation of autoreactive T cells 
that produce cytokines.  One-way to understand the contribution of B cells to 
disease in the MRL/+ model would be to ablate B cells and examine the effect on 
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disease development.  The JhD KO is a B cell knockout because the mice are 
unable to form a pre-B cell receptor. When backcrossed to MRL/+ background, 
the JhD mice were protected from nephritis and proteinuria (46). Interestingly, 
there was a defect in the accumulation of memory B cells, which suggested a 
role for B cell antigen presentation.  
     Using a B cell deficient model of murine lupus answered the gross question 
regarding the role of B cells.  On the other hand, these experiments did not 
differentiate between antibody secretion, antigen presentation or cytokine 
production by B cells.  The role of B cells in murine lupus, independent of 
secreted auto-antibodies, was interrogated using a murine model where the B 
cells only express membrane IgM (mIgM). Therefore, the B cells can bind their 
antigen and present to antigen specific T cells but cannot secrete antibody. 
When bred onto the MRL/lpr background, the mIgM mice developed significantly 
worse disease than the JhD KO mice. Furthermore, the accumulation of memory 
T cells was similar to the wild type MRL/lpr.  This demonstrated that B cell 
antigen presentation and or cytokine production were important for the 
accumulation of memory T cells.  Interestingly, in the absence of secreted 
antibody, the mIgM mice still developed nephritis in the absence of antibody 
deposition in the kidney (47).  In addition, there was a modest protection from 
mortality in the mIgM mice, which suggested a specific role for class switched 
antibody in disease. These studies directly addressed the role of secreted 
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antibody in disease progression. Furthermore, they alluded to an important role 
for B cell cytokine production and antigen presentation in murine SLE.   
     To directly address the role for B cell antigen presentation in the pathogenesis 
of murine SLE, Giles et al., 2015 generated MRL/lpr mice that could conditionally 
delete MHC-II in B cells via CD19-Cre that drive Cre expression in B cells (48).  
Although dendritic cells were thought of as primary antigen presenting cells, 
there was reduced frequency of activated T cells in the CD19-Cre mice following 
deletion of MHC-II in the B cell compartment.  Furthermore, there was a 
reduction in class switched antibodies specific for RNA ICs but not nucleosome 
specific autoantibodies.  These studies demonstrated a crucial role for B cells as 
antigen presenting cells in murine SLE. Furthermore, they suggested that 
production of class switched RNA antibodies and therefore, RNA ICs required T 
cell help.  
 
G. Antibody Dependent Pathogenesis in Lupus 
     In multiple models of antibody mediated diseases, the effector functions of 
murine IgG isotypes was dependent on the ratio of their affinity for activating 
receptors versus the affinity for the inhibitory receptor, the A/I ratio (49).  The 
murine isotypes most commonly isolated from murine models of lupus are IgG2a 
and IgG2b. The IgG2a antibodies have a significantly higher A/I ratio than the 
IgG2b because the IgG2b antibodies bind better to the FcγRIIB (49).  It is via 
FcγR that myeloid lineage cells can internalize and respond to antibody 
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complexes. Due to their low affinity, FcγRIIB, FcγRIIIA and FcγRIV were thought 
to primarily respond to polyvalent immune complexes. These are precisely the 
kinds of ICs found in lupus formed between autoantibodies and self-nucleic acids 
or nucleic acid associated proteins.  
     In lupus, one of the pathogenic cytokines is IFN-α. This was confirmed in 
human trials where a blocking antibody against IFNARI ameliorated disease. The 
cell type that is primarily known to make IFN-α is plasmacytoid dendritic cells 
(pDC). In response to virus-antibody complexes, pDCs secreted IFN-α in an 
FcγR and TLR dependent manner.  This was not restricted to microbial nucleic 
acids.  In response to IC formed between apoptotic cells and IgG from lupus 
patients, pDC secreted type I interferon (50).   It was subsequently shown that 
this is due to sensing of self nucleic acids by endosomal Toll-like receptors 
specific for RNA and DNA. The significance of in vitro studies was demonstrated 
in murine models where restriction of pDC development ameliorated disease in 
lupus prone mice (51).  These studies were extended to myeloid derived DCs 
and pDCs, where immune complexes formed between RNA and/or DNA and IgG 
antibodies (52-54).  Interestingly, the production of inflammatory cytokine by 
murine cDCs to these complexes was dependent on FcγRIIIA (52). The 
importance of FcγRIIIA to disease was confirmed in the NZB x NZW murine 
model of lupus where inactivation of the common gamma chain attenuated the 
development of kidney disease and significantly enhanced survival. Interestingly, 
these mice still had immune complex deposition in the kidneys (55).  This was in 
		
17 
 
contrast to the MRL/lpr model where inactivation of the common gamma chain 
did not affect kidney disease or survival (56).  This could be a result of the NZB X 
NZW model being FcγR driven as evidenced by the requirement for Sle1, a 
susceptibility locus encoding multiple genes associated with the development of 
spontaneous autoimmunity. The importance of FcγR’s in the pathogenesis of 
murine lupus suggested a cell dependent mode of tissue damage.  
     Bone marrow chimeras using mice that expressed Fcγ in only the 
hematopoietic compartment demonstrated the cell type dependent kidney 
damage. By transferring bone marrow from an Fcγ deficient host, it was 
demonstrated that the pathogenic Fc expressing effectors were not tissue 
resident but rather bone marrow derived (57). The local immune response of ICs 
led to the kidney damage. The FcγR dependent tissue damage could occur via 
several mechanisms, including direct tissue damage mediated by inflammatory 
cytokine production such as TNF-α and/or recruitment of activated lymphocytes 
via chemokine production.  In response to immune complexes, neutrophils form 
neutrophil extracellular traps (NETs) a mixture of chromatin and cytosolic 
contents (58). The degradative components of the neutrophil granules such as 
elastase and gelatinase can degrade the extracellular matrix leading to tissue 
destruction (59).  Furthermore, NETs contain known autoantigens and this could 
be a source of additional immune complex formation (59, 60).  
     Rather than a comprehensive discussion of the mechanisms of FcγR 
mediated pathogenesis it is important to appreciate the role of activating FcγR in 
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the pathogenesis of lupus.  The connection between FcγR and disease 
strengthens the importance of class switched antibodies and therefore B cells in 
lupus.  This made it crucial to understand the mechanisms underlying the 
development of class switched autoantibodies from autoreactive cells that 
escape tolerance.   According to the theory of self-non-self discrimination, 
lymphocytes require two signals to become activated, one from the BCR and a 
second from a T cell or the innate immune system.  As the cells were 
autoreactive, the BCR engagement (i.e. first signal) was via self-antigen.  The 
discovery of innate immune receptors that recognize microbial patterns 
suggested a possible second signal to explain the unique specificity of the 
autoantibodies (61-63).  
     The secretion of high affinity isotype switched IgG antibodies from naïve B 
cells occurs in peripheral lymphoid organs. Engagement of the BCR by the 
cognate antigen, productive interaction with T cells and expression of activation 
induced cytidine deaminase (AID) leads to class switch recombination (CSR) and 
somatic hypermutation (SMH). AID catalyzes the deamination of cytosine to 
uracil in ssDNA, which leads to CSR and/or SHM. Within the Ig locus, the switch 
regions are targeted for CSR and the Ig V regions are targeted for SMH. The 
consensus target sequence for AID is RGYW where the complementary C on the 
non-coding strand is deaminated (64, 65). If the uracil is replicated prior to repair 
of the lesion, a transition mutation occurs where a G:C pair becomes A:T. On the 
other hand, if lesion is repaired by base excision or mismatch repair, both 
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transition and transversion mutations can occur. In the case of CSR, there are 
multiple RGYW target sequences within the switch regions leading to double 
stranded DNA breaks and recombination by nonhomologous end joining between 
switch regions (66). This brings the rearranged immunoglobulin gene adjacent to 
new constant region exons. In addition to engagement of FcγR, the importance of 
CSR and SHM in pathogenesis in murine lupus was demonstrated by inactivation 
of AID in the MRL/lpr model.  When the activation induced cytidine deaminase 
gene was inactivated, the mice had reduced mortality and nephritis (67).  
  
H. Structure and Function of endosomal TLRs  
     The coordination of innate and adaptive immune responses is required for the 
development of productive cellular and humoral immune responses. Although the 
receptors used to discriminate between self and non-self by adaptive immune 
system were understood, the receptors used by the innate immune system were 
unknown.  It was this missing link that led to the proposition that the innate 
immune system possessed receptors that discriminated self and non-self (68).  
The proposed parameter for these innate immune receptors was that they would 
recognize patterns associated with microbes but not the host organism. Nearly a 
decade after this proposition the first receptor in mice was discovered, toll-like 
receptor 4 (TLR4).  It recognized lipopolysaccharide a ligand associate with 
Gram-negative bacteria (61). Subsequently, a family of receptors, signaling 
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molecule and adapters that function to sense microbial patterns were discovered 
(63, 69, 70).  
     In lupus the autoantibodies are specific for DNA and/or RNA and associated 
proteins.  Therefore, the endosomal TLR7 and TLR9 that sensed RNA and DNA 
respectively were most likely to contribute to the activation of autoreactive B cells 
(63, 71). This is because their BCR would bind and deliver the nucleic acid for 
sensing by TLR7 or TLR9 in a series of endolysosomal compartments. The 
engagement of the BCR by the ligand would represent signal one whereas 
engagement of the TLR would represent signal two. Furthermore, endocytosis 
and delivery of nucleic acids via the BCR would eliminate the problem of 
topological exclusion of the extracellular ligand and the endosomal receptor.  
     The endosomal TLRs that sense RNA and DNA are TLR7s and TLR9 
respectively. After translation on the ER, the receptors are transited via the Golgi 
to the cell surface, internalized and trafficked to endolysosomal compartments.  
One protein that was essential for this trafficking pattern was the adapter 
UNC93B1, a point mutation in UNC93B1 led to the inability of cells to respond to 
endosomal TLR ligands. The mechanism was that the receptors were unable to 
exit the ER to transit to endolysosomes (72).  Although it was originally 
suggested that the endosomal TLRs were trafficked directly to the 
endolysosome, subsequent work demonstrated that TLR7 and TLR9 first 
trafficked to the surface prior to being internalized and trafficked to 
endolysosomes (73-75).  
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     The surface expression of TLR7 and TLR9 removed topological exclusion as 
a barrier to sensing of self-DNA and RNA by B cells. Therefore, an additional 
mechanism was required to restrict sensing of self nucleic acids.   In order to 
function, TLR7 and TLR9 required cleavage by cathepsins that function in acidic 
milieus (76, 77). Although asparagine endopeptidase was proposed to also 
cleave TLR9, this was confounded because mice deficient in asparagine 
endopeptidase were also deficient in cathepsin activity (78).  Furthermore, using 
mice with a gfp tagged TLR9, it was demonstrated that the majority of TLR9 with 
in B cell was cleaved and localized to acidic compartments (79). This was in 
contrast to work that suggested that TLR9 was “called” to the endosome by 
engagement of BCR. The importance of endosomal localization was 
strengthened by the finding that sensing of DNA required ligand degradation by 
DNaseII, which was optimally active at acidic pH (80, 81). These studies 
demonstrated that sensing of RNA and or DNA required localization of the ligand 
and the receptor to an acidic compartment.  Restraining enzymatic activity and 
function via targeting to an endosomal milieu is a common strategy (82).  
     Upon receptor engagement, the endosomal TLR7 and TLR9 recruit the 
adapter MyD88 which acts via TBK1 to initiate proinflammatory cytokine 
production via NFκB activation or interferon production via IRF activation.  It is 
the transmission of these signals that tunes the appropriate response for the 
respective ligands (83).  It is via the intersection of the BCR and TLR7/TLR9 
signaling that autoreactive B cells can become activated.  Although the signaling 
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cascades, and trafficking of the endosomal TLRs 7 and 9 were thought to be 
similar, cellular differentiation or diseases states following engagement of either 
receptor were different (84). This suggested that fungible differences existed 
leading to bifurcated consequences of engaging TLR7 versus TLR9. Although 
this was suggested to occur via differential trafficking (74), it was subsequently 
demonstrated that both TLR7 and TLR9 take the same route to the 
endolysosomal system (75). Although the molecular mechanisms of TLR7 and 
TLR9 bifurcation have not been elucidated, the bifurcation of the cytokine 
responses to TLR7 or TLR9 engagement was elucidated.  
     A novel mechanism to bifurcate TLR9 signaling was discovered based on 
intracellular localization of TLR9 when it engaged DNA. In the absence of the 
intracellular trafficking adapter, AP3B1, dendritic cells were unable produce type I 
interferon but proinflammatory cytokine production was unaffected in dendritic 
cells stimulated with TLR9 or TLR7 ligands (85). This suggested that spatial 
localization was a possible mechanism to bifurcate TLR7 from TLR9 signaling.  
Although, the localization of TLR7 was not interrogated in this study. 
   
I. What distinguishes autoantigens from other self-proteins 
     In lupus and other autoimmune diseases, the antibodies detected are specific 
for RNA, DNA or protein associated with RNA and DNA.  At the cellular level, 
autoantigens are localized both in the cytoplasm and nucleus and can be post 
translationally modified. The RNA autoantigens include both naked RNA and 
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proteins that are localized within the nucleus.   For example, α-smith (α-Sm) is an 
autoantibody that has high diagnostic specificity for SLE in human. It is not a 
single antigen but rather a complex of 7 proteins (i.e. snRNPs) that associate with 
the spliceosome within the nucleus (86). The spliceosome is a nanomachine 
composed of RNA and over 30 proteins that function to remove introns from 
premRNA via a complex multistep process. It is important to highlight the multiple 
RNA-RNA interactions that are required for the function of the spliceosome.  The 
RNA components of the machine: U1, U2, U4, U5, and U6 associate during the 
splicing process. For example, U4, U5 and U6 form a tri-snRNP complex with the 
premRNA during splicing via intra U RNA base pairing in addition to binding with 
the premRNA (87).  
     Another class of RNA-associated autoantigens are associated with nucleoli. 
Similar to the spliceosome, nucleoli are located in the nucleus and are centers of 
RNA processing. In the nucleosome, ribosomes are assembled via the concerted 
action of multiple RNAs and proteins. The autoantigen Ago2 (Su) antigen is part 
of the RISC complex that processes miRNA from precursors (88). In contrast to 
the other RNA associated autoantigens, it is located in the cytoplasm. Despite 
the diversity of RNA associated autoantigen, they generally have the common 
theme that they are frequently associated with RNA in a processing role.    
     The association of the RNA with proteins could serve to protect the RNA from 
degradation. In addition as IC are polyvalent, it was possible that pre-assembled 
RNA complexes contributed to IC formation in these RNA machines. By contrast, 
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the DNA autoantigens are primarily DNA binding proteins or DNA complexed 
with histones in the form of nucleosomes.  In the nucleus, DNA is condensed into 
chromatin via wrapping around octamers of histones. Two histone octamers 
separated by a ~200bp of dsDNA is termed a nucleosome. In humans and 
murine models of lupus, antibodies against the histones themselves or histone 
octamer in complex with dsDNA are common (89-91). In addition, antibodies 
against DNA are also found.   
     Due to the divergent functions associated with the RNA and DNA-associated 
antigens, it is likely that they differ in size, shape or even valency.  The structural 
properties of IC formed with naked DNA and RNA could also differ based on 
strandedness and the ability to form hydrogen bonds.  DNA and RNA differ in the 
polymer units, which are deoxyribonuleotides (dNTPs) and ribonucleotides 
(rNTPs) respectively. The rNTPs posses an additional hydrogen that can 
participate in hydrogen bonding.  This greatly expands the ability for the 
formation of secondary structures.  In addition, DNA is normally found as a 
dsDNA whereas RNA is single stranded, which promotes secondary structure 
formation and trans interactions.  Therefore, in addition to being composed of 
different polymers, IC formed from RNA, DNA or associated proteins could differ 
in size, shape and structure.  
     The paradox of both the DNA and RNA autoantigens was that the 
autoantibody targets were largely sequestered in the nucleus and therefore 
complicated IC formation.  It was demonstrated by several groups that dead and 
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or dying cells expose autoantigen that are accessible for antibody binding (92-
94). In addition to function associated modifications, the nucleic acids and 
proteins in autoantigens can also be modified as a consequences of apoptotic 
cell death. For example, chromatin is fragmented into pieces that represent 
multiple of nucleosomes (i.e. 200bp, 400bp, 600bp)(95). The exposure and 
release of autoantigens suggested a source of antibody targets to make IC.  On 
the other hand, sensing of self-nucleic acid as microbial, could lead to 
inappropriate sensing of self nucleic acid by self-innate immune receptors. 
   
J. Evidence for TLR recognition of endogenous ligands 
     In the MRL/lpr model of lupus, in addition to antibodies against nucleic acids 
and associated proteins, the mice also develop antibodies against autologous 
IgG, referred to as rheumatoid factors (96-98). The BCR from a rheumatoid 
factor (RF) hybridoma derived from an MRL/lpr mouse was cloned and the heavy 
chain, called AM14, paired with the Vκ8 light chain resulted in a low affinity 
receptor specific for IgG2aa/j (99).  Expression of the heavy and light chain as a 
murine BCR Tg, resulted in a mouse where a majority of the splenic B cells 
expressed the AM14 receptor. In response to monomeric IgG2aa/j, AM14 B cells 
did not become activated and proliferate (100). The AM14 B cells also did not 
respond to an immune complex formed between an IgG2aa/j antibody and a 
protein antigen. On the other hand, in response to an IgG2aa/j specific for 
nucleosomes or RNA, the AM14 B cells proliferated. Presumably, the DNA in the  
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nucleosome ICs was being sensed by an innate immune receptor specific for 
DNA (100).  This was confirmed by using AM14 mice where MyD88 was ablated 
thereby preventing signaling from the endosomal TLRs, TLR7 and TLR9. 
Leadbetter et al demonstrated that autoreactive B cells were responding to self 
nucleic acid (100).  In response to either monomeric IgG2aa/j or a protein IC 
formed between an anti-hapten antibody and haptenylated protein, AM14 B cells 
do not proliferate. By using biotinylated fragments of mammalian DNA between 
100bp-800bp in length, and an IgG2a antibody specific for biotin, it was 
demonstrated that mammalian DNA stimulated AM14 B cell proliferation via 
engagement of TLR9 (101, 102).  When TLR9 was ablated, the AM14 B cells 
failed to respond to defined DNA ICs.  By sequencing the mammalian DNA, 
Uccellini et al., 2008 demonstrated that it was the PuPuCGPyPy sequence motif 
that determined if a DNA fragment was stimulatory (101). Although mammalian 
genomes are CpG poor, there are regions that are CpG rich termed CpG islands. 
The stimulatory mammalian DNA originated from these CpG islands. 
Additionally, TLR9 cannot sense DNA that is methylated.  Although bacteria 
methylate their DNA, the pattern of bacterial methylation is different from 
mammalian methylation (103). Interestingly, CpG islands are hypomethylated.  
Therefore, TLR9 does not sense all mammalian DNA but rather DNA that is most 
similar to microbial, CpG rich and unmethylated.  
     In addition to sensing self-DNA, the response of AM14 B cells to RNA 
containing ICs was shown to be dependent on sensing of self-RNA.  Lau et al., 
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2005 used AM14 B cells that fail to express functional TLR7, an RNA specific 
TLR (104).  Interestingly, priming with type I IFN enhanced the responses to 
spontaneous RNA ICs (104, 105).  In addition, the responses to some RNAs 
were dependent on another endosomal RNA sensing TLR, TLR3 or TLR13, 
which was likely dependent on RNA secondary structure (106). This still left open 
the question of how innate immune receptors sensed mammalian RNA and DNA 
without deleterious effects.  
     A similar strategy to that described previously by Uccellini et al., 2008 was 
used to understand how mammalian RNA was sensed by TLR7.  The 
mammalian RNAs that were found to be normally associated with protein 
autoantigens were in vitro transcribed and biotinylated.  Defined RNA ICs were 
formed using an anti-biotin antibody and AM14 and AM14 TLR7 KO B cells were 
stimulated.  It was demonstrated that the mammalian ssRNAs were stimulatory 
depending on the content of uridine. Furthermore, RNAs, with dsRNA secondary 
structure were also sensed via TLR3 that evolved to sense viral RNA (106).  As 
RNA of viral origin has a higher uridine content then mammalian RNA this is one 
method that TLR7 could use to distinguish mammalian RNA from viral RNA.  In 
addition to RNA sequence, TLR7 also does not sense capped and 
polyadenylated RNA, mRNA.  The mammalian RNAs that were sensed by TLR7 
are neither polyadenylated nor capped in cells.   Therefore, TLR7 does not sense 
all mammalian RNA but rather RNA that is most similar to microbial, U rich and 
uncapped (106) 
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     The in vitro studies demonstrated that mammalian DNA and RNA could be 
sensed by the innate immune receptors, TLR9 and TLR7 respectively.  It was 
consistent with the known functions of “pattern” recognition receptors that both 
receptors distinguished mammalian from microbial nucleic acids, but could sense 
“self” nucleic acids if mammalian nucleic acids displayed molecular patterns 
more often associated with microbial nucleic acids.  This in vitro evidence 
suggested that autoantibodies specific for RNA, DNA and/or associated proteins 
developed in vivo following BCR engagement and sensing by TLR7 and or TLR9.  
Since B cells are essential for the pathogenesis of lupus, this meant that TLR7 
and/or TLR9 contributed via B cell activation and proliferation.  This would be 
consistent with the two-signal hypothesis but required in vivo vertias.  
 
K. Roles of TLR9 and TLR7 in autoAb production in murine lupus models 
     To determine if TLR7 and/or TLR9 contributed to the development of lupus in 
murine models, the TLR7KO, TLR9KO and TLR7/DKO alleles were bred onto the 
MRL/lpr background.  The mice were monitored for the development of 
autoantibodies and disease.  When TLR7 was inactivated, the mice did not 
develop antibodies against RNA or RNA associated autoantigens. When TLR9 
was inactivated, the mice did not develop antibodies against DNA or DNA 
associated autoantigens. When both TLR7 and TLR9 were inactivated, the mice 
did not develop any autoantibodies (107).  This demonstrated that the 
engagement of the toll like receptors selected for autoantibody specificity. The 
		
29 
development of autoantibodies required two signals, engagement of the BCR as 
well as an innate immune receptor. In the absence of a signal from an innate 
immune receptor, the autoantibodies did not develop.  This paradigm was 
repeated in several other models of autoimmunity paired with TLR7/9 deficiency 
or TLR7/9 inhibitor treatment (108-112) 
 
L. Roles of TLR9 and TLR7 in overall disease severity  
     Although the development of autoantibodies for the corresponding nucleic 
acid required TLR7 or TLR9, their role in pathogenesis was divergent.  When 
TLR9 was ablated, the mice developed autoantibodies specific for RNA and/or 
RNA associated proteins and developed more severe kidney disease and died 
faster than mice that were TLR9 sufficient. On the other hand, when TLR7 was 
ablated, the mice were largely protected from kidney disease relative to TLR7 
sufficient mice (107).  These data suggested a divergent role for TLR7 and TLR9 
engagement in lupus pathogenesis. The importance of TLR7 engagement in 
lupus pathogenesis was repeated by several other labs (67, 75 , 109, 110). It 
was suggested that in addition to TLR7 promoting lupus pathogenesis that TLR9 
might have a negative regulatory role.  Although the cell type intrinsic role was 
not elucidated, these data reinforced the original findings that TLR9 had a 
protective role in lupus (111, 112).  
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M. Role of FcγRIIB in TLR7 Mediated Disease  
     The role of TLR7 in murine models of lupus was further elucidated when 
investigators realized that the Yaa autoimmune prone mouse strain had acquired 
a spontaneous mutation that led to two-fold TLR7 overexpression and 
accelerated autoimmunity. A genomic interval including the TLR7 gene from the 
X chromosome was translocated onto the Y chromosome leading to the yaa 
mutation (113, 114). Due to X inactivation, only the males overexpressed TLR7 
and developed accelerated disease. The overexpression of TLR7 accelerated 
mortality but only in mice that were the FcγRIIB-deficient or prone to autoimmune 
disease due to other genetic risk alleles. The synergism between FcγRIIB 
inactivation and Yaa in the development of autoimmunity suggested interaction 
between innate immune sensing and adaptive signaling.  Furthermore, over 
expression of TLR7 led to a shift of autoantibody specificity from anti-chromatin 
to anti-nucleolar (i.e. DNA to RNA) (113). Subsequent studies using mixed bone 
marrow chimeras demonstrated that FcγRIIB KO B cells produced anti-DNA 
antibodies, while FcγRIIB KO Yaa B cells produced anti-RNA.  These results 
suggested a B cell intrinsic role for FcγRIIB and Yaa in the selection of 
autoreactive B cells specific for RNA (113).  However, the use of bone marrow 
chimeras cannot exclude the contribution of FcγRIIB KO Yaa myeloid cells.  
Furthermore, these studies and others using the FcγRIIB KO derived from 129 
ES cells were confounded by the presence of the sle1 locus.  That is to say, sle1 
contains FcγRIIB and the KOs made on the 129 background would retain the 
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genes around the FcγRIIB KO allele even when backcrossed to C57BL/6. This 
was significant because other genes (i.e. SLAM) within the sle1 locus contributed 
to the spontaneous development of autoimmunity (115, 116).  When FcγRIIB KO 
C57BL/6 mice in the absence of sle1 were combined with Yaa, the original result 
was recapitulated in that the two genes synergized to accelerate mortality (42).  
This study demonstrated a role for FcγRIIB in TLR7 (i.e. yaa) driven 
autoimmunity independent of the other genes in the sle1 locus.  On the other 
hand, no B cell specific role for FcγRIIB was established. Therefore, it was 
possible that in addition to B cells, myeloid cells deficient in FcγRIIB and 
overexpressing TLR7 could have contributed to disease. Nonetheless, these 
studies demonstrated a clear link between FcγRIIB inactivation and enhancement 
of TLR7 dependent immune responses in murine models of lupus. Though, 
molecular mechanisms to explain the connection between FcγRIIB ablation and 
enhanced TLR7 dependent responses remain to be elucidated.  
     An in vitro link was established when AM14 FcγRIIB KO B cells responded 
significantly better than AM14 B cells to a spontaneous RNA IC (117). On the 
other hand, the response to a DNA ICs appeared to be unaffected. This 
suggested bifurcation of TLR7 and TLR9 responses by FcγRIIB. These studies 
raised additional question regarding: 1) Were these findings confined to anti-RNA 
and anti-nucleosome or were they extendable to additional autoantibodies? 2) 
Were the responses still TLR dependent following FcγRIIB ablation?  3) Why did 
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FcγRIIB inhibit TLR7 responses but not TLR9? and 4) How did FcγRIIB attenuate 
responses that were TLR7 and or TLR9 dependent? The mechanism underlying 
this FcγRIIB dependent enhancement of autoreactive B cells responses was a 
fundamentally important question for three reasons: 1) B cells are essential 
cellular effectors of lupus pathogenesis 2) FcγRIIB inactivation or hypomorphisms 
are important susceptibility alleles in human and mice and 3) TLR7 drives 
pathogenic disease in multiple murine models.  Understanding how inactivation 
of FcγRIIB enhances BCR-TLR7 responses but not BCR-TLR9 could illuminate 
not only aspects of TLR biology but also mechanisms of autoimmune disease.  
     The AM14 B cell proliferative responses to DNA IC and RNA IC were TLR9 
and TLR7 dependent respectively.  Therefore, a response required that the 
AM14 BCR deliver RNA or DNA to an endo-lysosomal compartment containing 
TLR7 or TLR9.  As FcγRIIB seemingly attenuated RNA IC responses but not 
DNA IC responses I hypothesized that engagement of FcγRIIB inhibited 
trafficking of the RNA IC to a TLR7 containing intracellular compartment. I found 
that FcγRIIB was not differentially regulating RNA and DNA IC responses 
because DNA IC and RNA IC responses were both attenuated by FcγRIIB 
engagement.  The preferential regulation of RNA IC responses was because the 
responses were no longer TLR7 dependent and BCR responses are effectively 
attenuated by FcγRIIB.  This suggested that in the context of FcγRIIB deficiency 
agents that inhibit BCR signaling (i.e. btk, PI3Kδ inhibitors) would be effective in 
antagonizing the responses of autoreactive B cells to RNA IC.  
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     Although at first it seemed that FcγRIIB did not regulate DNA IC responses, 
this resulted from an Fc domain mutation in the antibody used to make our DNA 
IC. I found that single base pair mutation resulted in a missense codon that 
dramatically reduced binding to activating and inhibitory FcγR. In addition to 
demonstrating that DNA IC were also regulated by FcγRIIB, this finding also 
suggested a mechanism by which antibody producing cells secrete antibodies 
that do not bind FcγR. In the context of autoimmunity, antibodies with reduced 
binding to FcγR could be less pathogenic because many of the pathogenic 
mechanism of IC mediated diseases are FcγR dependent. Therefore, this could 
represent a possible explanation for the presence of autoantibodies in the 
absence of disease manifestations.  
      Since autoreactive B cell responses stimulated by DNA ICs with unmutated 
Fc regions were regulated by FcγRIIB engagement, I hypothesized that FcγRIIB 
was antagonizing BCR-TLR9 responses by modulating IC trafficking to inhibit 
sensing by TLR9. I found that FcγRIIB engagement led to residence of the IC in a 
higher pH compartment. This would antagonize sensing of DNA by TLR9 
because an acidic pH is required for optimal TLR9 function.  
     To summarize, in this dissertation, I defined why FcγRIIB differentially 
regulated RNA IC and DNA IC responses. 1) RNA ICs engaged the inhibitory Fc 
receptor better than DNA IC and 2) Autoantibodies may have Fc domain 
polymorphisms that modify FcγR engagement. One potential mechanism to 
explain the attenuation of TLR9 responses was increased pH of the IC containing 
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intracellular compartment. The tools developed to answer these biological 
questions will permit follow up studies and new directions to understand 
pathogenic mechanisms of immune complex mediated disease. 
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CHAPTER TWO 
 
II. Materials  
Mice used in this dissertation are presented in Table I 
Primers for mouse genotyping are presented in Table II 
Plasmids used for cloning or as PCR templates are presented in Table III 
Primers for antibody sequencing and cloning are presented in Table IV 
Cell lines and bacterial strains are presented in Table V 
Monoclonal antibodies are presented in Table VI  
Formation of Anti-SA SA DNA IC is presented in Table VII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
			
	
 
Table I: Mouse Strains 
Mouse Strain  Background Source of Alleles  
AM14Vκ8 BALB/c AM14 (118), Vκ8 (119) 
AM14Vκ8 FcγRIIBKO BALB/c AM14 (118), Vκ8 (119),FcγRIIBKO (120) 
AM14Vκ8 TLR9KO BALB/c AM14 (118), Vκ8 (119),TLR9KO (63) 
AM14Vκ8 TLR7KO BALB/c AM14 (118), Vκ8 (119),TLR7KO (121) 
AM14Vκ8 TLR7KO TLR9KO BALB/c AM14 (118), Vκ8 (119), TLR7KO 
(121),TLR9KO (63), FcγRIIBKO (120) 
AM14Vκ8 FcγRIIBKO TLR9KO BALB/c AM14 (118), Vκ8 (119),TLR9KO (63), 
FcγRIIBKO (120) 
AM14Vκ8 FcγRIIBKO TLR7KO BALB/c AM14 (118), Vκ8 (119), TLR7KO (121), 
FcγRIIBKO (120) 
AM14Vκ8 FcγRIIBKO TLR7KO TLR9KO BALB/c AM14 (118), Vκ8 (119), TLR9KO (63), 
TLR7KO (121), FcγRIIBKO (120) 
AM14 Vκ8 FcγRIIBKO Mixed CBA and BALB/c AM14 (118), Vκ8 (119), FcγRIIBKO (120)  
AM14 Vκ8 FcγRIIBKO Xid  Mixed CBA and BALB/c AM14 (118), Vκ8 (119), FcγRIIBKO (120), xid 
(19) 
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Table II: Primers for Mouse Genotyping   
Primer Name Sequence Genotyping Protocol 
AM14-131 ACCCGTCGTAATTATAGTAAAACCC AM14 
AM14 140 CTGCAGCAGCCTGGGAC AM14 
JH1 up-f GCCAAGGACTTACCAAGAGG Heavy Chain WT 
JH1 up-r GATGCAGGACTCACCTGA Heavy Chain WT 
Vk8F-MW133 GGTACCTGTGGGGACATTGTG Vk8 
Vk8R-MW157 AGCACCGAACGTGAGAGG Vk8 
Jk3-5' CTGTAAATCACATTCAGTGATGG Light Chain WT 
Jk4-rev CCGAGCCGAACGTGAATCACA Light Chain WT 
FcR2EC1 AAGGCTGTGGTCAAACTCGAGCC FcγRIIB 
OL4143 CTCGTGCTTTACGGTATCGCC FcγRIIB 
OL4080 TTGACTGTGGCCTTAAACGTGTAG FcγRIIB 
Tlr7XT CCAGATACATCGCCTACCTACTAGACC TLR7 
TLR7 WT ACGTGATTGTGGCGGTCAGAGGATAAC TLR7 
TLR7 Neo ATCGCCTTCTATCGCCTTCTTGACGAG TLR7 
TLR9 F-new CATGGCCTGGACTGCAA TLR9 
TLR9 R-new TGAAGAGAACGCGCAGGCTG TLR9 
TLR9 neo ATCGCCTTCTATCGCCTTCTTGACGAG TLR9 
Xid Forward CTCTACTAAGTTCCTACCTACCAC Btk 
Xid Reverse TTTACAACAGGGAGCAGG Btk 
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Table III: Plasmids Used for Cloning or as PCR Templates 
Name Promoter Selectable marker Fluorescent Marker Source 
pIRESPuro2 CMVeuk Amp prok Puro euk NA Clonetech 
pIRES2-zsGreen 1 CMVeuk Kanprok Neoeuk zsGreen1 Clonetech 
pCherrypicker2 CMVeuk Kanprok Neoeuk mCherry Clonetech 
pDisplay BirAER CMVeuk Kanprok Neoeuk NA Addgene 
pBluescriptIISK lac prok Amp prok NA Stratagene 
pLitmus29 lac prok Amp prok NA NEB 
pCDNA3.1 Puro CMVeuk Amp prok Puro euk NA ThermoFisher 
pLitmus-C11 Lacprok Amp prok NA (101) 
pUC57 KAN  Kanprok NA Genescript 
pET28a T7prok Kanprok NA Novagen 
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Table IV: Primers for Antibody Sequencing and Cloning 
 
 
 
 
 
 
 
 
 
 
Primer Name Sequence 
CH1-Reverse CTCAATTTTCTTGTCCACCTTGGTGC 
PL9-3Vh TGGGGCTGAACTGGTGAAGCCTG 
PL9-9Vh CAGGTCCAACTGCAGCAGCCTGG 
PL2-3Vh GAGGTCCAGCTGCAACAGTCTG 
1E11.1 Vh GAAGTGCAGCTGGTGGAGTC 
IgG2a CH3-3’ B6 Balb GCTGAGCTCATTTACCC 
Oligo dT(18) TTTTTTTTTTTTTTTTTT 
RACEMOG2a AGGACAGGGCTTGATTGTGGG 
RACERAG1 AGGCTTGCAATCACCTCCACA 
RACKFOR CTCATTCCTGTTGAAGCTCTTGACGAC 
B7-6 Light Chain SpeI GACTAGTATGGGCATCAGGATGGAGTCA 
CkforRat- XhoI CTCATTCCTGTTGAAGCTCTTGACGACGGG 
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Table V: Cell lines and Bacterial Strains  
Cell line Species Source  
NSO-Bcl2 Mus musculus (122) 
A20 Mus musculus (123) 
BHK-21 Mesocricetus auratus 
(124) 
HEK293T Homo sapiens 
(125) 
C57BL6/J FcγRIIBKO Macrophages Mus musculus This study 
NEB5α Escherichia coli New England Biolabs 
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Table VI: Monoclonal Antibodies Used in this Dissertation  
Clone Specificity Species Strain Isotype Source 
1E11.1 Streptavidin Mus musculus BALB/c IgG2a This study 
3A20.2 Streptavidin Mus musculus BALB/c IgG2b This study 
1D4 Biotin Mus musculus BALB/c IgG2a (101) 
PA4 dsDNA Mus musculus A.SW IgG2a (126) 
PL2-3 H2A-H2B-DNA Mus musculus MRL/+ IgG2a (89) 
PL2-8 H2A-H2B-DNA Mus musculus MRL/+ IgG2b (89)  
PL9-9 H2A-H2B-DNA Mus musculus MRL/+ IgG2a (127) 
PL9-3 H2A-H2B-DNA Mus musculus MRL/+ IgG2a (127) 
BWR4 RNA Mus musculus NZBXNZW IgG2a (128) 
HA310.2 Nucleoli Mus musculus Yaa IgG2a Generous gift of S. Bolland 
B7-6 mIgM Rattus 
norvegicus 
 Rat IgG1 (129) 
8C5.5 mCherry Mus musculus BALB/c IgG2a This study 
2.4G2 CD16/CD32B Rattus 
norvegicus 
 Rat IgG2a (130) 
M5/114 MHC-II Rattus 
norvegicus 
 Rat IgG2b (131) 
36-54 ARS Mus musculus  IgM (132) 
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Table VII: Formation of Anti-SA SA DNA IC 
Immune Complex 2-end bio C11 SA SA-AF488 SA-FITC SA-AF647 Anti-SA 
Anti-SA SA DNA IC 0.5 µg/mL 0.13 µg/mL    0.5 µg/mL 
Anti-SA SA-AF488 DNA IC 0.5 µg/mL  0.4 µg/mL   0.5 µg/mL 
Anti-SA SA-FITC/AF647 DNA IC 0.5 µg/mL   0.35 µg/mL 0.05 µg/mL 0.5 µg/mL 								
42
			
	
43 
 
A. Hybridoma production  
1. Complete DMEM: DMEM (Gibco, ThermoFisher) was supplemented by 
addition of 10% (v/v) fetal bovine serum (FBS, HyClone, GE Healthcare), 
100 U/mL penicillin, 100 µg/ml streptomycin sulfate, 10 mM HEPES pH 7.5, 
1 mM sodium pyruvate, 4.5 mg/mL glucose, 0.87 mg/mL L-glutamine 
(Gibco, ThermoFisher), 100 µM non-essential amino acids (Gibco, 
ThermoFisher), 1X Normocin (InvivoGen) and sterilized by vacuum filtration 
(0.2 µm PES membrane, Corning).  
2. PEG: 50% (w/v) polyethylene glycol (PEG) 1500 in 75 mM HEPES (Roche) 
3. HT media: Complete DMEM with the addition of HT media supplement 
(Sigma) to hypoxanthine 100 µM and 16 µM thymidine.  
4. H(2A)T media- Complete DMEM with the addition of aminopterin (Sigma)  to 
0.8 µM in complete DMEM.  
5. Serum-free DMEM: DMEM (Gibco, Thermo Fisher) containing 0.58 mg/mL 
L-glutamine.  
 
B. ELISAs 
1. ELISA Plates: Ultracruz® 96 well flat bottom (Santa Cruz) or Nunc™ 
Maxisorp™ (ThermoFisher Scientific) 
2. PBS: 1 mM KH2PO4, 155 mM NaCl, 3 mM NaHPO4 (Corning)  
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3. 1% BSA in PBS: PBS(-) with addition of 1% (w/v) BSA fraction V (Roche)  
4. ELISA wash buffer: PBS(-) with addition of 0.05% (v/v) Tween-20® (Sigma) 
5. ELISA dilution buffer: PBS(-) with addition of 0.05% (v/v) Twen-20® (Sigma) 
and 1% (w/v) BSA fraction V (Roche) 
6. TMB substrate: OptEIA™ TMB substrate (Becton, Dickinson) reagent set 
7. 2N H2SO4: 18.2 M H2SO4 in dH2O 
8. Goat anti-mouse IgG2a (Southern Biotech) 
9. Goat anti-mouse IgG2a-HRP (Southern Biotech)  
10. Goat anti-mouse Kappa LC (Southern Biotech)  
11. Goat anti-mouse IgG (H+L)-HRP (Southern Biotech) 
12. Streptavidin-HRP (Southern Biotech)  
 
C. Antibody Preparation  
1. Low IgG RPMI: complete RPMI was supplemented by addition of low IgG 
5% (v/v) fetal bovine serum (FBS, HyClone, GE Healthcare),  
2. Protein G Sepharose™ 4 Fast Flow (GE Healthcare) 
3. Protein A agarose (ThermoFisher) 
4. Protein A binding buffer (ThermoFisher) 
5. Human IgG Sepharose® 6 Fast Flow (GE Healthcare) 
6. Glycine Elution Buffer: 0.1 M glycine-HCl in dH2O adjusted to pH 2.7 
7. Sodium Acetate Elution buffer: 0.1 M C2H3NaO2 and 0.1M C2H4O2 in dH2O 
adjusted to pH 4.5 
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8. Neutralization Buffer: 1M Tris-HCl in dH2O adjusted to pH 9.0 
9. NanoDrop™ (ThermoFisher Scientific) 
10. Pristane: 2,6,10,14-Tetramethylpentadecane (Sigma)  
11. Amicon® Ultra-15 Centrifugal Filter 30k NMWCO (Millipore, Billerica, MA) 
12. Table top centrifuge 
 
D. Plasmid Vector Construction and Bacterial Protein Production  
1. Restriction Enzymes: BamHI, EcoRI, NotI, XbaI, XhoI, SpeI, HaeII, NheI and 
DpnI (New England BioLabs) 
2. Antarctic Phosphatase (New England BioLabs) 
3. QIAquick Gel Extraction Kit (QIAGEN)  
4. NEBuilder® HiFi DNA Assembly Master Mix (New England BioLabs) 
5. T4 DNA ligase (New England BioLabs) 
6. Escherichia coli NEB5α (New England BioLabs)  
7. SOC Medium: 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose in dH2O, 
sterilized by autoclaving 
8. 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (Sigma) 
9. Isopropyl β-D-1-thiogalactopyranoside (Sigma) 
10. Luria-Bertani Agar, Lennox medium: 1% (w/v) tryptone, 0.5% (w/v) NaCl, 
0.5% yeast extract, 1.5% (w/v/) agar in dH2O and sterilized by autoclaving. 
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Cool medium to 50°C, add carbenicillin or kanamycin to 100 µg/mL or 50 
µg/mL respectively prior to pouring plates.  
11. TE Buffer: 10 mM Tris-HCl, 1 mM EDTA, pH 8.0 (QIAGEN) 
12. TAE running buffer (50x): 2 M Tris base, 2 M acetate, 50 mM EDTA, pH 8.0 
13. HisPur Ni-NTA Agarose Resin (ThermoFisher) 
14. Agarose gel: dissolve 1% (w/v) Agarose (Fisher Scientific, ThermoFisher) in 
1× TAE buffer containing 0.5 µg/mL Ethidium Bromide.   
 
E. Plasmid DNA Preparation  
1. Carbenicillin (1000×): 100 mg/mL carbenicillin (Mediatech) in dH2O  
2. Kanamycin (1000x): 50 mg/mL kanamycin (Mediatech) in dH2O 
3. Luria-Bertani Broth, Lennox medium: 1% (w/v) tryptone, 0.5% (w/v) NaCl, 
0.5% yeast extract in dH2O, sterilized by autoclaving. Addition of carbenicillin 
or kanamycin to 100 µg/mL or 50 µg/mL, respectively, before inoculation 
where appropriate. 
4. QIAprep Spin Miniprep kit (QIAGEN)  
5. EndoFree® Plasmid Maxi Kit (QIAGEN)  
 
F. Cell Culture  
1. Complete RPMI: RPMI 1640  (Gibo®) with addition of 5% (v/v) heat 
inactivated FBS (HyClone, GE Healthcare), 100 U/mL penicillin, 100 µg/mL 
streptomycin sulfate, 0.29 mg/mL L-glutamine (Gibco®), 10 mM HEPES pH 
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7.5 and 22 µM β-mercaptoethanol (MP Biomedical, Santa Ana, CA), sterilized 
by filtration (0.2µm PES, Corning) 
2. IMag buffer: PBS with 0.5% (w/v) AlbuMAX  (ThermoFisher scientific) and 0.2 
mM EDTA, sterilized by filtration (0.2µm PES, Corning).  
3. Anti-mouse CD45R/B22O magnetic particles (BD Biosciences)  
4. IMagnet (BD Biosciences)  
5. 12x100mm round bottom tubes (ThermoFisher)  
6. LPS (Sigma) 
7. CLO97 (InvivoGen) 
8. ODN Bio-TEG-1826 (Eurofins) 
9. S-ODN-1826 (Coley Pharmaceuticals)  
10. Biotinylated Fab α-mIgM (Jackson Immunoresearch) 
11. Biotinylated F(ab’)2 α-mIgM (Jackson Immunoresearch)  
12. Streptavidin (Bioworld, Dublin, OH) 
13. Fluorescent streptavidin: streptavidin BV421 (Biolegend), streptavidin FITC, 
streptavidin AF647, streptavidin AF488 and streptavidin OG488 (Life 
Technologies, ThermoFisher)  
14. H-thymidine medium: Complete RPMI with 25 µCi/mL[methyl-3H]thymidine 
(PerkinElmer)  
15. Brandel Harvester (Brandel, Gaithersburg, MD) 
16. Microbeta trilux counter (PerkinElmer) 
17. Filtermat: 90x120 mm glass fibre printed filter mat A (PerkinElmer) 
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18. Filtermat sample bag (Perkin Elmer) 
19. Scintillation fluid: Ecoscint (National Diagnostics, Atlanta, GA)  
 
G. Labeling of Antibodies with Biotin or Fluorochromes 
1. DyLightTM 649 NHS Ester (ThermoFisher) 
2. DyLightTM 488 NHS Ester (ThermoFisher) 
3. 50 mM Sodium Carbonate Buffer, pH 8.5 (ThermoFisher) 
4. Borate Buffer: BupH™ Borate Buffer Pack (ThermoFisher) in dH2O 
 
H. Nucleic Acid Purification, RT-PCR and Rapid Amplification of cDNA  
Ends  
1. Extract solution  
2. Tissue prep solution  
3. Neutralization solution (Sigma) 
4. TRIzol® (ThermoFisher) 
5. TNE Buffer: 20 mM Tris-HCl (pH 7.5), 0.5 M NaCl, 1 mM EDTA 
6. TE Buffer: 20mM Tris-HCl (pH 7.5), 1mM EDTA 
7. polyA Spin™ mRNA Isolation Kit (New England BioLabs) 
8. RNeasy Mini kit (QIAGEN) 
9. Superscript®III RT PCR Kit (Life Technologies, ThermoFisher) 
10. Terminal deoxynuclteotidyl transferase (New England BioLabs) 
I. PCR  
1. EconoTaq PLUS GREEN 2X Master Mix (Lucigen, Middleton, WI) 
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2. Phusion® High-Fidelity PCR Master Mix with HF Buffer (New England 
BioLabs) 
3. 5X Green GoTaq® Reaction Buffer (Promega) 
4. 25 mM MgCl2 (Promega) 
5. dNTPs: 100 mM dATP, 100 mM dCTP, 100 mM dGTP and 100 mM dTTP 
(Roche) 
6. 100 mM biotin-16-dUTP (Roche?) 
7. GoTaq® (Promega) 
8. DNA Clean & Concentration-25™ kit (Zymoresearch, Orange CA)  
 
J. Flow Cytometry  
1. FACs buffer: PBS with 3% (v/v) FBS (Sigma) and 0.02% (w/v) NaN3 
2. Physiological saline: 0.9% (w/v) NaCl in dH2O 
3. Monensin (Sigma) 
4. Nigercin (Sigma) 
5. Indo-1-AM (ThermoFisher)  
6. Complete PR- RPMI medium: phenol red free RPMI with 5% (v/v) heat 
inactivated FBS, 22 µM β-mercaptoethanol (Sigma) and sterilized by filtration 
7. F(ab’)2 goat anti-mouse IgG2a-Alexafluor 647 (Jackson ImmunoResearch)  
8. Cluster tubes (Corning) 
9. LSRII Flow Cytometer (BD Biosciences) 
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K. Confocal Microscopy  
1. Poly-L-lysine 0.01% (w/v)  (Sigma) 
2. Gelatin type B 2% (w/v) (Sigma)  
3. #1 12 mm glass coverslips (ThermoFisher) 
4. 4% (v/v) paraformaldehyde: 39% paraformaldehyde with PBS 
5. PFA Quenching buffer: 125 mM Glycine in PBS 
6. Blocking Buffer: PBS with 5% (v/v) normal goat serum (Gibco®), 0.1% 
saponin (Sigma) and 0.02% (w/v) NaN3  
7. Superfrost™ Plus Microscope Slides (ThermoFisher)   
8. Prolong anti-fade gold (ThermoFisher)  
9. SP8 spectral confocal microscope (Leica, Exton, PA) 
 
L. Transfections and Stable Cell line Production  
1. Attractene (QIAGEN) 
2. Lipofectamine 2000 (Life Technologies, ThermoFisher)  
3. Puromycin (Sigma) 
4. G418 (Mediatech) 
5. Streptavidin magnetic particles (BD biosciences)  
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III. Methods  
 
A. Genotyping of Mice  
1. Murine Tail DNA Preparation  
     Sample of mouse tail was placed in a microfuge tube with 50 µL of extract 
solution and 12.5 µL of tissue prep solution.  The tubes were incubated at 95°C 
for 3 min, mixed by vortexing, and 50 µL of neutralization solution was added to 
each tube.  Samples were again mixed by vortexing and then centrifuged at 
13,000 RPM for 5 min.  The supernatant fluid was transferred to a clean 
microfuge tube for storage at 4°C for up to 6 months.  
 
2. AM14 Heavy Chain PCR  
     Mice were genotyped for the AM14 heavy chain by mixing 1.5 µL of primer 
AM14-131 (10 µM), 1.5 µL of primer AM14-140 (10 µM), 12.5 µL of EconoTaq 
PLUS GREEN 2X Master Mix, 7.5 µL dH2O and 2 µL of tail DNA extract in a 200 
µL thin walled PCR tube. PCR conditions were as follows: 94°C for 5 min, and 35 
cycles of 94°C for 30 sec, 55°C for 45 sec, and 72°C for 45 sec, followed by a 
final extension of 7 min at 72°C (133).  
  
3. Vκ8 Light Chain PCR 
     Mice were genotyped for the Vκ8 light chain by mixing 1 µL of primer Vk8-
MW133 (20 µM), 1 µL of primer Vk8-MW157 (20 µM), 15 µL of EconoTaq PLUS 
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GREEN 2X Master Mix, 12 µL dH2O and 1 µL of tail DNA extract in a 200 µL thin 
walled PCR tube. PCR conditions were as follows: 94°C for 5 min, and 36 cycles 
of 94°C for 20 sec, 58°C for 30 sec, and 72°C for 30 sec, followed by a final 
extension of 5 min at 72°C.  
 
4. Wild Type Heavy Chain Locus PCR 
     To determine if AM14 HC positive mice were heterozygous or homozygous 
for the allele, the mice were genotyped for the presence of the WT allele.  PCR 
reactions were prepared by mixing 0.5 µL of primer JH1 up-f (20 µM), 0.5 µL of 
primer JH1-up-r (20 µM), 12.5 µL of EconoTaq PLUS GREEN 2X Master Mix, 9.5 
µL dH2Oand 2 µL of tail DNA extract in a 200 µL thin walled PCR tube. PCR 
conditions were as follows: 94°C for 3 min, and 35 cycles of 94°C for 30 sec, 
60°C for 40 sec, and 72°C for 60 sec, followed by a final extension of 5 min at 
72°C.  
 
5. Wild Type Light Chain Locus PCR  
     To determine if Vκ8 positive mice were heterozygous or homozygous for the 
allele, the mice were genotyped for the presence of the WT Jκ3-4 locus.  PCR 
reactions were prepared by mixing 1 µL of primer Jk3-5’  (20 µM), 1 µL of primer 
Jk4-rev (20 µM), 15 µL of EconoTaq PLUS GREEN 2X Master Mix, 11 µL dH2O 
and 2 µL of tail DNA extract in a 200 µL thin walled PCR tube. PCR conditions 
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were as follows: 94°C for 5 min, and 36 cycles of 94°C for 30 sec, 58°C for 45 
sec, and 72°C for 30 sec, followed by a final extension of 5 min at 72°C. 
 
6. FcγRIIB PCR  
     Mice were genotyped for FcγRIIB by mixing 1 µL of primer FcR2EC1 (10 µM), 
1 µL of primer OL4080 (10 µM), 1 µL of primer OL4143 (10 µM), 10 µL of 
EconoTaq PLUS GREEN 2X Master Mix, 5 µL dH2O and 2 µL of tail DNA extract 
in a 200 µL thin walled PCR tube. PCR conditions were as follows: 94°C for 15 
min, and 35 cycles of 94°C for 45 sec, 55°C for 60 sec, and 72°C for 60 sec, 
followed by a final extension of 5 min at 72°C. 
 
7. TLR7 WT PCR 
     Mice were genotyped for TLR7 by mixing 1 µL of primer TLR7 XT (10 µM), 1 
µL of primer TLR7 WT (10 µM), 12.5 µL of EconoTaq PLUS GREEN 2X Master 
Mix, 8.5 µL dH2O and 2 µL of tail DNA extract in a 200 µL thin walled PCR tube. 
PCR conditions were as follows: 94°C for 3 min, and 40 cycles of 94°C for 45 
sec, 65°C for 45 sec, and 72°C for 2 min, followed by a final extension of 15 min 
at 72 °C. 
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8. TLR7 KO PCR 
     Mice were genotyped for the TLR7 knock out allele by mixing 1 µL of primer 
TLR7 XT (10 µM), 1 µL of primer TLR7 Neo (10 µM), 12.5 µL of EconoTaq PLUS 
GREEN 2X Master Mix, 8.5 µL dH2O and 2 µL of tail DNA extract in a 200 µL thin 
walled PCR tube. PCR conditions were as follows: 94°C for 3 min, and 40 cycles 
of 94°C for 45 sec, 65°C for 45 sec, and 72°C for 2 min, followed by a final 
extension of 15 min at 72°C. 
 
9. TLR9 PCR 
     Mice were genotyped for TLR9 by mixing 0.5 µL of primer TLR9-F new (10 
µM), 0.5 µL of primer TLR9-R new (10 µM), 0.5 µL of primer TLR9 neo (10 µM), 
12.5 µL of EconoTaq PLUS GREEN 2X Master Mix, 10 µL dH2O and 1 µL of tail 
DNA extract in a 200 µL thin walled PCR tube. PCR conditions were as follows: 
94°C for 15 min, and 35 cycles of 94°C for 45 sec, 55°C for 60 sec, and 72°C for 
60 sec, followed by a final extension of 5 min at 72°C. 
 
10. Xid PCR and Restriction Digest  
     The Xid mutation is a single nucleotide transition mutation in the PH domain 
of Btk leading to a missense mutation. This single base pair change leads to the 
deletion of a HaeII restriction enzyme cleavage site. To detect the Xid allele, a 
fragment harboring the deleted site was amplified by mixing 1µL of primer Xid 
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Forward (10 mM), 1 µL of Xid Reverse, 25 µL of Phusion Master Mix, 18 µL of 
dH2O, 2 µl of tail DNA extract and 2 µL DMSO in a 200 µL thin walled PCR tube.  
The PCR cycling conditions were 95°C for 5 min and then 10 cycles of 94°C for 
15 sec, 64°C -0.5°/cycle for 30 sec, 72°C for 15 sec then 30 cycles of 94°C for 15 
sec, 53 °C for 15 sec, 72°C for 10 sec, followed by a final extension of 2 min at 
72°C.   The PCR product was purified using the DNA Clean & Concentration-25 
DNA purification kit and digested with HaeII for 1 hr and separated by 
electrophoresis on a 2.5 % agarose gel. 
 
B. Analysis of Data  
1. Statistical analysis  
Statistical analyses were carried out with the aid of GraphPad Prism.  Standard 
error of the mean (SEM) was calculated by dividing the standard deviation by the 
root base two of the number of samples. Statistical significance was determined 
by two tailed t tests with statistical significance defined by p<0.05.  For multiple t 
tests of titrations, statistical significance was determined by the Holm-Sidak 
method.  Statistical significant data were indicated with asterisks as follows: 
p<0.05, *, p<0.005, **, p<0.0005, ***, and non significant data with the 
abbreviation n.s.   
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2. Calculation of IC50  
Inhibition of B cell responses by inhibitors was interrogated by interrogated by 
stimulating cells with a single concentration of The data were normalized by 
dividing each ligand by the largest value in the data set and multiplying by 100. 
The normalized values were graphed against the log base 10 of the inhibitor 
concentration and fitted via non-linear curve fit with variable curve. The IC50 was 
defined as the inhibitor concentration where 50% of the maximum proliferative 
value was achieved.			
C. Production of Monoclonal Antibodies  
 
1. Immunization of mice and fusion  
     Female BALB/cJ mice were immunized i.p. with 100 µg/mL of antigen 
emulsified in PBS. After 4-8 weeks, the mice were boosted i.v. with 100 µg of 
antigen, and 4 days later, the mice were sacrificed, and the spleens removed. A 
single cell suspension of splenocytes was mixed with the NSO-Bcl2 (122) fusion 
partner at a ratio of 1 to 5, respectively. The mixture of splenocytes and NSO-
Bcl-2 was placed in a 50 ml tube and centrifuged at 1,250 RPM for 5 min.  The 
mixed cell suspension was washed twice with serum-free DMEM.  After the final 
wash, the supernatant fluid was aspirated, and the cell pellet was gently 
disrupted by flicking the tube then warmed to 37°C in a water bath.  Next, a 1 mL 
syringe was filled with 1 mL of prewarmed PEG, and a 1.5” 18 gauge needle was 
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attached. The PEG was added to the cell suspension at a rate of one drop every 
10 sec while stirring slowly using the needle. Next, 1 mL of serum-free DMEM 
was added dropwise, followed by an additional 3 mL of serum-free DMEM and 
finally 10 mL of serum-free medium was added dropwise at a rate of one drop 
every 10 sec.  The tube was then incubated for 5 min at 37°C, and then cells 
were pelleted by centrifugation at 1,250 RPM for 5 min. The supernatant fluid 
was aspirated, and 20 mL of HT-media was added without disturbing the cell 
pellet.  The cells were incubated at 37 °C for 1 hr, then resuspended to 5x105 
NSO-Bcl2 cells/mL in HT media.  This cell suspension was plated at 100 µL per 
well into 96 well flat bottom plates and incubated overnight at 37°C with 5% CO2. 
The next day, 100 µL of H(2xA)T media was added to each well (134). The 
plates were returned to the incubator until the media changed color to orange, 
and then the hybrids supernatant fluids were screened by ELISA as described 
below.  
 
2. Cloning of Cells by Limiting Dilution.  
     Antigen specific hybrids or stable transfectants were diluted to 1.5, 0.3 and 
0.15 cells/ml in cDMEM. A 96 well flat bottom tissue culture plate was divided 
into thirds and each cell concentration plated at 200 µL into a third of a plate (32 
wells). After 2 weeks, wells with single colonies were rescreened for antigen 
reactivity by ELISA for hybridomas and for fluorescent markers for transfectants.   
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3. Biotinylation of Ovalbumin.  
     Ovalbumin was dissolved in 4 mL of PBS at a concentration of 25 mg/mL, and 
444 µL of 10 mM amine reactive biotin was added for 20-fold molar excess biotin. 
The biotinylation reaction was incubated for 30 min at room temperature with 
agitation every 10 min.  Next, the free biotin was removed by bringing the 
biotinylation reaction to 15 mL with TBS, applying to an Amicon 10K NMWCO 
centrifugal filter unit and centrifuging for 20 min at 3,000×g at 20°C.  The flow 
through was discarded, and the process repeated thrice.  The biotinylated 
ovalbumin remaining in the top of the filter unit was diluted to a concentration of 5 
mg/mL, aliqoted and stored at -20 °C for future use.  
 
4. Detection of Streptavidin Specific Antibodies 
     Ultracruz ELISA plates were coated overnight at 4°C with 50 µL of biotinylated 
ovalbumin at 5 µg/mL. After coating, the plates were washed 3× with PBST and 
blocked by adding 200 µL of ELISA blocking buffer, then incubated at RT for 2 hr.  
After blocking, the plates were washed 3× with 300 µL/well PBST, then 50 µL of 
1 µg/mL unlabeled streptavidin was added and the plate incubated at RT for 1 hr. 
Next, the plate was washed 3× with 300 µL/well PBST and 50 µL of hybridoma 
supernatant fluid (neat) or purified antibody diluted in ELISA blocking buffer was 
added to each well neat, and the plate was incubated for 1hr at RT. The plate 
was washed 3× with 300 µL/well PBST, and total murine antibody was detected 
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by the addition of HRP-conjugated goat α-mouse Ig diluted 1:5,000 in ELISA 
blocking buffer at RT for 1 hr. Alternatively IgG2a antibodies were detected by 
adding HRP-conjugated goat α-mouse IgG2a diluted to 1:3,000 in ELISA 
blocking buffer for 1 hr at RT.  The plates were then washed 4× with 300 µL/well 
PBST and developed by adding 50 µL of BD OptEIA TMB substrate to each well 
and incubating for 15-20 min in the dark. The reaction was stopped by addition of 
50 µL of 1N H2SO4 to each well, and the plates read on a microplate reader at 
450 nm.  
 
5. Detection of mCherry Specific Antibodies.  
     Ultracruz ELISA plates were coated overnight at 4°C with 50 µL per well of 
recombinant mCherry diluted to 1 µg/mL in PBS. After coating, the plates were 
washed 3X with PBST and blocked by adding 200 µL of ELISA blocking buffer 
and incubated at RT for 2 hr.  After blocking, the plates were washed 3X with 
PBST and 50 µL of hybridoma supernatant fluid or purified antibody was added 
to each well neat or diluted in ELISA blocking buffer and the plate incubated for 2 
hr at RT.   Next, the plate was washed 3X with 300 µL/ well PBST and total 
murine antibody detected by adding 50 µL of HRP conjugated goat α-mouse Ig 
diluted to 1:5,000 in ELISA blocking buffer and the plate incubated for 1 hr at RT. 
Alternatively IgG2a antibodies were detected by adding 50 µL of HRP conjugated 
goat α-mouse IgG2a diluted to 1:3,000 in ELISA blocking and the plate incubated 
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for 1 hr at RT.  After 1 hr, the plates were washed 4X with 300 µL/well PBST and 
the developed by adding 50 µL of BD OptEIA TMB substrate and incubating for 
15-20 min in the dark. The reaction was stopped by adding 50 µL of 1N H2SO4 
and the plates read on a microplate reader.  
 
6. Packing Gravity Flow Columns for Affinity Chromatography.  
     A porous polyethylene disc was firmly seated at the bottom of a Thermo 
Scientific Pierce Disposable Plastic Column and the column capped to prevent 
flow through. Next, 1-5 mL of the appropriate affinity purification resin was added 
to the column and incubated for 20 min at room temperature. A porous 
polyethylene disc was seated just about the resin bed using the large end of a 
Pasteur pipette, the cap removed, and 10 mL of PBS 0.02 % NaN3 (w/v) was 
added to the column and allowed to pass through.  The column was capped at 
the bottom, 5 ml of PBS 0.02 % NaN3 added to the column, capped at the top, 
and the edge sealed with Parafilm.  The packed column was stored at 4°C until 
use.  
 
7. Antibody Purification from Ascites by Protein A Affinity  														Chromatography 
     A column packed with protein A agarose and protein A binding buffer was 
equilibrated to room temperature.  Next, 5 mL of protein A binding buffer was 
applied to the column, the bottom cap of the column removed and the flow 
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through discarded. The ascites was diluted by adding 1 mL ascites to 9 mL of 
protein A binding buffer, and the diluted ascites filtered using a 0.45 µm PFTE 
syringe filter. The filtered solution was applied to the column in 5 mL batches, 
and then the column was washed by adding 15 mL of protein A binding buffer in 
5 mL batches.  A 15 mL conical tube with 1 mL of 1M TRIS pH 8.0 was placed 
below the column to collect the flow through, and 4 mL of elution buffer was 
applied to the column.  The collection tube was agitated frequently to facilitate 
rapidly neutralize the low pH elution buffer. The eluted antibody was buffer 
exchanged against PBS, and the column regenerated by applying 15 mL of PBS 
0.02 % NaN3 (w/v) to the column in 5 mL batches, and the flow through 
discarded.  The column was capped at the bottom, 5 ml of PBS 0.02 % NaN3 
added to the column, the top capped, the edge sealed with Parafilm.  The packed 
column was stored at 4°C until use. 
 
8. Antibody Purification from Hybridoma Supernatant Fluid by Affinity  
           Chromatography 
     A column packed with protein A agarose and protein A binding buffer was 
equilibrated to room temperature.  Next, 5 mL of protein A binding buffer was 
applied to the column, the bottom cap of the column was removed, and the 
column drained. 100 mL of hybridoma supernate was diluted with an equal 
volume of protein A binding buffer, and the diluted supernate was filtered using a 
0.45 µm PES bottle top filter. The filtered solution was applied to the column in 5 
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mL batches, and then the column was washed by applying 15 mL of protein A 
binding buffer in 5 mL batches.  A 15 mL conical tube with 1 mL of 1M TRIS pH 
8.0 was placed below the column to collect the flow through, and 4 mL of elution 
buffer was applied to the column.  The collection tube was agitated frequently to  
rapidly neutralize the low pH elution buffer. The eluted antibody was buffer 
exchanged against PBS, and the column was regenerated by applying 15 mL of 
PBS 0.02 % NaN3 (w/v) to the column in 5 mL batches, and the flow through 
discarded.  The column was capped at the bottom, 5 ml of PBS 0.02 % NaN3 
added to the column, the top capped, the edge sealed with Parafilm and the 
column stored at 4°C. 
 
9. Buffer Exchange  
     Proteins to buffer exchange were QS to 15 mL with PBS, loaded on an 
Amicon Ultra-15 centrifugal filter unit with a NMCO of 10k and centrifuged for 20 
min at 3,000xg at 20°C, the flow through was discarded and the protein sample 
was QS to 15 mL with PBS and centrifuged again for 20 min at 3,000xg at 20°C.  
The flow through was discarded, the protein sample was QS to 15 mL with PBS 
and the sample centrifuged again for 20 min at 3,000xg at 20°C. The flow 
through was discarded, and the protein sample centrifuged for 20 min. The 
concentrated protein was brought to a final concentration of 1-5 mg/mL with PBS.  
 
 
			
	
63 
10. Fluorochrome or Biotin Conjugation of Antibodies 
     Antibodies were buffer exchanged against 50 mM Sodium Borate buffer, pH 
8.5 or 50 mM Sodium Carbonate buffer, pH 8.5.  The amine reactive biotin or 
fluorochrome were diluted in H2O or DMSO and added at 20-fold molar excess 
relative to the antibody.  The tube was mixed and incubated at RT for 1 hr.  The 
conjugation reactions were QS to 15 mL with 0.1 M Tris-HCl then buffer 
exchanged against TBS.  
 
D. Assembly of Streptavidin DNA Immune Complexes  
1. PCR Amplification of Stimulatory DNA Fragments Biotinylated at  														Both Ends  
     The DNA fragment used for all studies was Clone 11 that was isolated from a 
murine library of CpG islands. It was previously shown to be stimulatory (101). A 
PCR master mix was made by combining 1.25 mL of 2X EconoTaq master mix, 
25 µL of 10 µM primer bio-3558, 25 µL of 10 µM bio-3559, 50 µL DMSO, 25 µL of 
100 ng/µL pLITMUS29-C11 and 1.125 mL of DNase free water. The master mix 
was divided amongst 25 0.2 mL PCR tubes and cycled under the following 
conditions: 94°C for 2 min then 40 cycles of 94 °C for 15 sec, 60 °C for 30 sec, 
72 °C for 45 sec. Followed by a final extension of 5 min at 72°C. 
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2. PCR Amplification of DNA Fragments Biotinylated Through out  
To synthesize a DNA fragment with biotinylated base substitution throughout, 
PCR was used as previously described (101). Briefly, a PCR reaction was made 
by combining 20 µL of promega PCR buffer, 6 µL of 25 mM MgCl2, 0.5 µL of 100 
µM primer 3558, 0.5 µL of 100 µM primer 3559, 0.6 µL of 100 mM dATP, 0.6 µL 
of 100 mM dCTP, 0.6 µL of 100 mM dGTP, 0.5 µL of 10 mM dTTP and 5µL of 
Biotin 16-dUTP 1 mM, 1 µL of GoTaq, 2 µL of 100 ng/µL of clone 11 template 
and 62.7 µL of dH2O.  The PCR reaction was cycled by heating to 94°C for 2 min 
and then 39 cycles of 94°C for 30 sec, 55 °C for 45 sec, 72°C for 1 min. Followed 
by a final extension of 5 min at 72°C. 
 
3. Purification of DNA Fragments (Qiagen) 
     Five volumes of buffer PB were added for each PCR reaction, and the sample 
mixed. Next, 10 µL of 0.1 M sodium acetate buffer pH 4.5 was added, and the 
sample was applied to a QIAquick spin column.  The column was centrifuged at 
maximum speed in a microcentrifuge for 1 min, and the column flow through was 
discarded. The spin column was washed by adding 0.75 mL of buffer PE, 
centrifuging for 30 sec at max speed, and the flow through was discarded. The 
spin column was centrifuged for 5 min at max speed to dry the spin column.  The 
spin column was transferred to a clean eppendorf tube, 50 µL of EB added to the 
column, and the tube was centrifuged for 1 min at max speed. 
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4. Optimization of anti-SA DNA IC  
     To optimize the ratios of DNA biotinylated at both ends, streptavidin and anti-
streptavidin to stimulate AM14 B cell proliferation, the reagents were titrated 
against each other.  First, streptavidin was diluted in ½ log steps across a 96 well 
plate (i.e. in columns) in biotin free medium (i.e. DMEM) from 4 µg/mL to 0.04 
µg/mL in a volume of 50 µL.  Next, DNA biotinylated at both ends was diluted to 
2 µg/mL in DEMEM and and 50 µL added to each well of a 96 well plate.  The 
plate was incubated for 5 min on ice. Anti-SA IgG2a was diluted between 5 
µg/mL to 0.015 µg/mL in complete RPMI containing 10% heat inactivated sera 
and 50 µL of each concentration was added down the plate in rows (i,e, row A 5 
µg/mL anti-SA, row B 1.5 µg/mL anti-SA). The plate was incubated on ice for 10 
min. Next, purified AM14 B cells were brought up to 8x106 cells/mL in complete 
RPMI containing 10% heat inactivated sera and 50 µL was added to each well of 
the plate. After a 24 hr incubation at 37°C under 5% CO2, proliferation was 
quantified by adding 50 µL of 25 µCi/mL 3H thymidine diluted in complete RPMI 
and incubating for an additional 6 hr.  
 
5. Formation of Non-fluorescent Anti-SA DNA IC  
Defined anti-SA DNA IC was formed from biotinylated DNA, unlabeled 
streptavidin and anti-SA (1E11.1). For the stimulation of AM14 B cells, anti-SA 
DNA IC were used at a final concentration for each components: unlabeled SA 
0.13 µg/mL, DNA biotinylated at both ends 0.5 µg/mL and anti-SA 0.5 µg/mL. 
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The components were assembled by first mixing the DNA and unlabeled SA in 
an eppendorf tube.  Care was taken to avoid buffers or solutions containing biotin 
when mixing the SA and biotinylated DNA. The tube was incubated for 5 min. 
Next, anti-SA was added, the tube mixed and incubated on ice for 10 min.  The 
complex was QS with complete medium.  
 
6. Formation Fluorescent Anti-SA DNA IC  
     Defined anti-SA DNA IC was formed from biotinylated DNA, unlabeled 
streptavidin and anti-SA (1E11.1). For the stimulation of AM14 B cells, anti-SA 
DNA IC were used at a final concentration for each components: fluorescent SA 
0.4 µg/mL, DNA biotinylated at both ends 0.5 µg/mL and anti-SA 0.5 µg/mL. The 
components were assembled by first mixing the DNA and fluorescent SA in an 
eppendorf tube.  When mixing the SA and biotinylated DNA, care was taken to 
avoid buffers or solutions containing biotin. The tube was incubated for 5 min. 
Next, anti-SA was added, the tube mixed and incubated on ice for 10 min.  The 
complex was QS with complete medium.  
 
7. Formation pH Sensing Anti-SA DNA IC  
     Defined anti-SA DNA IC was formed from biotinylated DNA, unlabeled 
streptavidin and anti-SA (1E11.1). For the stimulation of AM14 B cells, anti-SA 
DNA IC were used at a final concentration for each components: pH sensing SA 
(i.e. FITC or OG488) 0.35 µg/mL, pH insensitive SA (i.e. AF647 or BV421) DNA 
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biotinylated at both ends 0.5 µg/mL and anti-SA 0.5 µg/mL. The components 
were assembled by first mixing the DNA and fluorescent SA in an eppendorf 
tube.  When mixing the SA and biotinylated DNA, care was taken to avoid buffers 
or solutions containing biotin. The tube was incubated for 5 min. Next, anti-SA 
was added, the tube mixed and incubated on ice for 10 min.  The complex was 
QS with complete medium.  
 
8. Optimization of Bio-Fab Streptavidin Bio DNA Fragment Complexes  
     To optimize the ratios of DNA biotinylated at both ends, streptavidin and bio-
Fab α-IgM to stimulate B cell proliferation, the reagents were titrated against 
each other.  The biotinylated DNA fragment alone was not stimulatory therefore a 
constant concentration of the DNA fragment was added to titrations of 
streptavidin and bio-Fab α-IgM fragment.  First, streptavidin was diluted to 13 
and 4.1 µg/mL in DMEM and 50 µL was of each concentration was added to 
separate columns of a 96 well plate.  Next, bio-Fab α-IgM was diluted in ½ log 
steps between 2 and 0.002 µg/mL in DMEM and 50 µL of each dilution was 
added to separate rows containing streptavidin (i.e. each row was a different 
concentration of bio-Fab-α-IgM. The plate was incubated on ice for 5 min. Next, 
100 µL of AM14 or AM14 TLR9KO B cells diluted in RPMI containing 10% heat 
inactivated serum at 8x106 cells/mL were added to each well. After a 24 hr 
incubation at 37°C under 5% CO2, proliferation was quantified by adding 50 µL 
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of 25 µCi/mL 3H thymidine diluted in complete RPMI and incubating for an 
additional 6 hr.  
   
9. Optimization of Bio-F(ab’)2 α-IgM Streptavidin Bio-Oligo Complexes 
     To optimize the ratios of biotinylated oligo, streptavidin and bio-F(ab’)2 anti-
IgM to stimulate B cell proliferation, the reagents were titrated against each other.  
As the biotinylated oligo alone was stimulatory, a concentration of streptavidin 
was required that would prevent the oligo alone from being stimulatory. First, 
streptavidin was diluted to 4.8 µg/mL, 1.6 µg/mL, 0.48 µg/mL and 0.016 µg/mL in 
DMEM and 50 µL was of each concentration was added to separate wells of a 96 
well plate.  Next, bio-1826 was diluted to 120 nM in DMEM and 50 µL was added 
to each well containing streptavidin. The plate was incubated on ice for 5 min. 
Next, 100 µL of AM14 or AM14 TLR9KO B cells diluted in RPMI containing 10% 
heat inactivated serum at 4x106 cells/mL were added to each well. After a 24 hr 
incubation at 37°C under 5% CO2, proliferation was quantified by adding 50 µL 
of 25 µCi/mL 3H thymidine diluted in complete RPMI and incubating for an 
additional 6 hr.  
     The optimal concentration of streptavidin to block B cell stimulation by 30 nM 
bio-1826 was 100 nM (1.6 µg/mL) streptavidin. Streptavidin and bio-1826 were 
mixed to final concentrations of 400 nM and 120 nM respectively in DMEM and 
incubated on ice for 5 min. The streptavidin/bio-1826 complex was added to a 96 
well plate at 50 µL/well. Next, bio-F(ab)’2 α-IgM was diluted in 2-fold steps 
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between 8 µg/mL and 0.125 µg/mL in DMEM. The bio-F(ab)’2 α-IgM  dilution 
were added to separate well containing the streptavidin/bio-1826 complexes in a 
volume of 50 µL.  To the tripartite complexes was added, either 100 µL of AM14 
or AM14 TLR9KO B cells. After a 24 hr incubation at 37°C under 5% CO2, 
proliferation was quantified by adding 50 µL of 25 µCi/mL 3H thymidine diluted in 
complete RPMI and incubating for an additional 6 hr.  
 
E. Antibody Gene Sequencing   
1. RNA Isolation using TRIzol 
    Approximately 1-3×107 hybridoma cells were collected in 15 ml polycarbonate 
tube by centrifugation, and 1.5 ml of TRIzol® added to the pellet. The sample was 
pipetted up and down several times to homogenize the pellet, and the tube was 
incubated at room temperature for 5 min.  Next, 0.3 mL of chloroform was added, 
and the tube was shaken by hand for 10 sec, then incubated at RT for 3 min. The 
sample was divided into 2 eppendorf tubes and centrifuged at 12,000×g for 15 
min at 4°C.  The supernatant fluid was transferred to clean eppendorf tubes, and 
0.25 mL of 100% isopropanol was added to each tube.  The tubes were 
centrifuged 12,000×g for 15 min at 4°C, the supernatant fluid was discarded, and 
0.75 ml of 75%(v/v) ethanol was added to wash the RNA pellets.  The tubes were 
vortexed and centrifuged at 7500×g for 5 minutes at 4°C. The supernatant fluid 
was discarded, and the pellet dried by opening the eppendorf tubes and placing 
the tubes in a laminar flow hood for approximately 1 hr.  
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2. Poly A RNA Purification  
    Cloning of antibody genes from hybridoma B7-6 was performed by 5’ RACE 
using poly A RNA purified from total hybridoma RNA (135). Oligo (dT)25 –
cellulose beads were collected in a centrifuge tube by centrifugation at 5,000×g 
for 20 sec.  The supernatant fluid was discarded, and the beads were 
resuspended in 0.2 ml of TNE Buffer. The purified total RNA pellet from TriZOL 
purification above was resuspended in 450 µL of TNE Buffer and incubated at 
65°C for 5 min to denature the RNA, then immediately placed on the ice.  The 
RNA was added to the beads, mixed and placed horizontally on an orbital shaker 
for 5 min at RT to allow binding.  The tube was centrifuged at 2,000×g for 10 sec 
to collect the beads, and the supernate was transferred to a clean eppendorf 
tube again incubated at 65°C for 5 min then snap cooled on ice.  The RNA was 
added back to the beads, shaken and placed horizontally on an orbital shaker for 
5 min at RT. Then the beads were collected by centrifugation at 2,000×g for 10 
sec, the supernate was discarded, and the beads were resuspended in 0. 4 ml of 
TNE Buffer.  The resuspended beads were mixed, transferred to a spin column, 
capped and placed horizontally on an orbital shaker for 2 min at room 
temperature. Then the tube was centrifuged at 2,000×g for 10 sec, and the 
column flow through was discarded. An additional 0.4 ml of TNE Buffer was 
added to the column and the tube placed horizontally on an orbital shaker for 2 
min at room temperature. Then the column was centrifuged at 2,000 x g for 10 
sec, the column flow through discarded and the column placed in a clean 
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eppendorf tube.  To elute the RNA, 200 µL of TE Buffer prewarmed to 70°C was 
added, the column shaken manually and then incubated for 2 min on an orbital 
shaker at RT. Then the column was centrifuged 2,000×g for 10 sec and the flow 
through transferred to a clean tube. This process was repeated, and the flow 
through combined with the first elution. The poly A RNA was precipitated by 
adding 44 µL of 3 M Sodium Acetate, 20 µL of Glycogen Carrier and 1.0 ml of 
cold 95% ethanol and incubating the tube at -20°C for 30 min.  The tube was 
centrifuged at 12,000×g for 15 min at 4°C, and the supernate was discarded. 
Next, the RNA pellet was washed with 75%(v/v) ethanol, and the tube was 
vortexed and centrifuged at 7500×g for 5 minutes at 4°C. The ethanol was 
discarded, and the pellet dried by opening the eppendorf tubes and placing them 
in a laminar flow hood for approximately 1 hr.  
 
3. RNA Purification Using RNeasy  
     Approximately 107 cells were pelleted by centrifugation at 1,250 RPM for 5 
min at 8°C, the supernatant fluid was removed and washed twice with 10mL of 
PBS. After washing, the cell pellet was resuspended in 600 µL RLT buffer 
containing 6 µL β-Mercaptoethanol in a 2 mL eppendorf tube. Samples were 
homogenized by aspirating in and out of a 3 mL Luer-lock affixed syringe with an 
18 gauge needle 10 times. The lysate was cleared by centrifugation for 3 min at 
maximum in speed in a microcentrifuge.  The supernatant fluid was transferred to 
a clean 2 mL eppendorf tube and 600 µL of 70%(v/v) ethanol was added, the 
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sample was mixed and then added to a RNeasy spin column.  The column was 
centrifuged at 8,000×g for 30 sec at RT, the flow through discarded and washed 
with 700 µL of buffer RW1 followed by two washes with 500 µL of buffer RPE.  
Following each addition, the column was centrifuged at 8,000×g for 30 sec at RT 
and the flow through discarded.  Following the final wash, the column was 
centrifuged for an additional 5 min at 8,000×g at RT. The column was transferred 
to a clean eppendorf tube, 75 µL of RNase-free water was added to the center of 
the column, and the eppendorf tube was centrifuged for 1 min at 8,000×g.  The 
eluted RNA was quantified using the Nanodrop, according to the manufacturer’s 
instructions.  
 
4. cDNA Synthesis and Tailing of vH and vK from B7-6.   
     In a thin walled 0.2 mL tube, cDNA was synthesized by mixing 1 µL of 10 µM 
RACERAG1 for the heavy chain or 1 µL of 10 µM RACKFOR with 1 µg of poly A 
mRNA, QS to 10 µL with RNase free water and heated to 65°C for 5 min, then 
placed on ice. In a separate thin walled 0.2 mL tube, 2 µL of 10X RT buffer, 4 µL 
of 25 mM MgCl2, 2 µL of 0.1M DTT and 1 µL of RNase OUT were mixed and 
then added to the cDNA synthesis primer and poly A RNA tube on ice. Next, the 
mixture was centrifuged to collect the liquid at the bottom of the tube and then 
heated to 42°C for 2 min. Then 1 µL of SuperScript II RT was added, the tube 
mixed and incubated at 42 °C for 60 min.  The tube was then heated to 70°C for 
15 min to inactivate RT, and the cDNA was purified as described below.  
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To tail the cDNA, 1 µg of cDNA was mixed with 5.0 µL 10X TdT Buffer, 5.0 
µL 2.5 mM CoCl2 solution, 5.0 µL 10 mM dATP and 0.5 µL Terminal Transferase 
(20 units/µL), then QS to a final volume of 50 µL with DNase free water.  The 
tailing reaction was incubated for 30 min at 37°C and stopped by incubating at 
70°C for 10 min and QS to 500 µL with DNase free water.  
 
5. cDNA Synthesis for Sequencing of Full Length IgG2a Heavy Chains  
     In a thin walled 0.2 mL tube, cDNA was synthesized by mixing 1 µL of 50 µM 
OligodT (18) for the heavy chain, with 1 µg of poly A mRNA, QS to 10 µL with 
RNase free water and heated to 65°C for 5 min, then placed on ice. In a separate 
thin walled 0.2 mL tube, 2 µL of 10X RT buffer, 4 µL of 25 mM MgCl2, 2 µL of 
0.1M DTT and 1 µL of RNase OUT were mixed and then added to the cDNA 
synthesis primer and poly A RNA tube on ice. Next, the mixture was centrifuged 
to collect the liquid at the bottom of the tube and heated to 42°C for 2 min. Then 
1 µL of SuperScript III RT was added, the tube mixed and incubated at 50 °C for 
50 min.  The tube was then heated to 70°C for 15 min to inactivate the reverse 
transcriptase.  Next, 1 µL of RNase H was added, and the tube was incubated at 
37°C for 20 min.  
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6. cDNA Purification 
     To the 20 µL, cDNA synthesis reaction, 140 µL of DNA Binding Buffer was 
added, the tube was mixed, and the contents transferred to a DNA Clean & 
Concentration-25™ Column.  The tube was centrifuged at maximum speed for 1 
min, and the column flow through was discarded.  The column was washed twice 
with 0.2 mL of DNA wash buffer by addition to the spin column and centrifugation 
at maximum speed for 1 min. The column flow through was discarded and the 
spin column was dried by centrifugation at maximum speed for 5 min. The spin 
column was placed in a clean eppendorf tube, and 25-50 µL of DNA elution 
buffer was added to the center of the spin column followed by centrifugation for 1 
min at maximum speed to elute the DNA from the column.  
 
7. PCR Amplification and cloning of the vH and vK from B7-6 
     To amplify the heavy and light chains from B7-6, 10 µL of the tailed cDNA was 
mixed with 1 µL of 10 µM primer XSCTnTag and 1 µL of 10 µM of either primer 
MOCG12FOR for the vH or CKRAsp for the light chain, 25 µL 2X Phusion master 
mix, 2 µL of DMSO and 11 µL of water. The reactions were mixed, placed in the 
thermocycler and heated to 95°C for 5 min, then 40 cycles of 95°C for 30 sec, 
60°C for 30 sec, 72°C for 30 sec.  After the 40th cycle, there was a final extension 
of 72°C for 1 min. The amplified vH and vK from B7-6 were separated by 
fractionation on a 1% agarose gel, stained with EtBr, and the appropriate sized 
band was excised using a UV transilluminator. The vH and vK PCR fragments 
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were gel purified and ligated into EcoRV linearized pBluescript II as described 
above.   Plasmid minipreps were digested with NotI/XhoI to confirm the 
appropriate insert size and then sequenced with M13R and M13F for the 
absence of premature stop codons.  
 
8. PCR Amplification of Full Length IgG2a Heavy Chains  
     To a 200 µL PCR tube was added 2 µL of the cDNA for PL2-3, PL9-9, PL9-3, 
or 1E11.1, 1 µL of IgG2a primer CH3-3’ B6 Balb (10 µM) and 1 µL of primer PL2-
3 Vh, PL9-3 Vh, PL9-9 Vh or 1E11.1 Vh (10 µM), 10 µL of Phusion Master mix, 
1µL of DMSO and 5 µL of dH2O.  The PCR cycling conditions were 95°C for 5 
min and then 10 cycles of 94°C for 30 sec, 65°C -1°/cycle for 30 sec, 72°C for 30 
sec then 25 cycles of 95°C for 30 sec, 50 °C for 30 sec, 72°C for 30 sec. 
Followed by a final extension of 5 min at 72°C. 
 
9. Gel Purification of DNA Fragments  
     DNA fragments excised from agarose gel were placed in an eppendorf tube 
and 0.3 mL of ADB buffer added to the tube and the tube incubated at 55°C for 5 
min, mixed by vortexing and incubated at 55°C until the gel slice was solubilized. 
The solubilized gel slice was loaded onto a Zymo-Spin Column and centrifuged 
at maximum speed in a microcentrifuge for 1 min.  The flow through was 
discarded, and the column washed twice with 0.2 mL of DNA wash buffer by 
centrifugation at maximum speed for 1 min. The spin column was dried by 
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centrifugation at maximum speed for 5 min then transferred to a clean eppendorf 
tube.  DNA fragments were eluted with 25-50 µL of DNA elution buffer added to 
the center of the filter and passed through the column by centrifugation for 1 min 
at maximum speed.  
 
10. Transformation of E. coli with plasmid DNA and Screening for  
           Inserts.  
     Ligation reactions were heat inactivated by incubating for 10 min at 65°C and 
the tube placed on ice. A tube of chemically-competent NEB5α cells were 
thawed on ice for 15-20 min, and then 2 µL of the ligation or assembly reaction 
added. The cells were incubated on ice for 30 min, and then moved to 42 °C for 
45 sec and returned to ice for 2 min.  Next, 1 mL of  SOC media was added, the 
tube incubated on an orbital shaker (125 RPM) for 1 hr, and plated onto LB 
plates with the appropriate antibiotic for the corresponding plasmid backbone.   
 
11. Small Scale Plasmid Purification 
     An overnight culture of the E. coli strain harboring the plasmid was prepared 
by inoculating 10 mL of LB Miller broth supplemented with the appropriate 
antibiotic with a single isolated colony from a bacterial plate.  The culture was 
incubated at 37°C overnight with shaking at 200 RPM. Approximately 1.5 mL of 
the culture was transferred to an eppendorf tube and pelleted by centrifugation at 
max speed for 5 min at room temperature. The supernatant fluid was removed 
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and the cells resuspended in 0.25 mL of P1.  Next, 0.25 mL of buffer P2 was 
added to lyse the bacteria, the tube inverted 5-10 times to mix and incubated at 
room temperature for 5 min. The bacterial lysate was neutralized by adding 0.35 
mL of buffer N3, inverted 5-10 times to mix thoroughly and centrifuged at max 
speed for 10 min at room temperature. The supernate was decanted into a 
QAIprep mini spin column and centrifuged at max speed for 30 sec and the flow 
through discarded. The spin column was washed with 0.75 mL of buffer PE by 
centrifuging for 30 sec at max speed. The spin column was centrifuged for 5 min 
at max speed to dry the spin column and transferred to a clean eppendorf tube.  
DNA was eluted with 50 µL of EB added to the column and passed through the 
column by centrifugation for 1 min at max speed. 
 
12. Large Scale Plasmid Purification (Endo Free)  
      A starter culture of the E. coli strain harboring the plasmid was prepared by 
inoculating 10 mL of LB broth supplemented with the appropriate antibiotic and 
incubating at 37°C overnight on an orbital shaker.  The starter culture was used 
to inoculate a larger culture by adding 100 µL to a 1L Erlenmeyer flask containing 
500 mL of LB Miller broth supplemented with the appropriate antibiotic.  The 
culture was incubated overnight at 37°C.  After 18-24h, the tube culture was 
harvested by centrifugation at 6,000xg for 20 min at 4 °C. The supernatant fluid 
was discarded, and the bacterial pellet resuspended in 10 mL of buffer P1 and 10 
mL of buffer P2 was added to lyse the bacteria.  The tube was incubated for 5 
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min at room temperature, and 10 ml of buffer P3 was added to the bacterial 
lysate.  The tube was inverted 5-10 times, added to a QIAfilter cartridge and then 
incubated for 10 min at room temperature to allow binding. The plunger was used 
with a QIAfilter cartridge to filter the lysate. Next, 2.5 mL of buffer ER was added, 
the lysate mixed by inversion 5-10 times and incubated on ice for 30 min. A 
QIAGEN-tip 500 was prepared by adding 10 mL of buffer QBT and allowing the 
column to evacuate by gravity. Next, the lysate was applied to the QIAGEN-tip 
500 and allowed to pass through the column. The column was washed twice with 
30 mL of buffer QC.  Plasmid DNA was eluted by adding 15 mL of buffer QN and 
collecting the flow through in a clean 50 mL conical tube.  The eluted DNA was 
precipitated with 10.5 mL of isopropanol and pelleted by centrifugation at 
5,000×g for 60 min at 4°C. The supernatant fluid was removed by decanting, and 
the pellet washed with 1ml of room temperature 70% ethanol to remove salts and 
pelleted by centrifugation at 12,000×g for 20 min at 4°C in an eppendorf tube. 
The ethanol was carefully removed, and the pellet allowed to air dry in an open 
eppendorf tube in a laminar flow hood for approximately 1 hr. 
 
13. Restriction Enzyme Digestion and Ligation of DNA Fragment and  
           Plasmids 
     Purified plasmid or DNA fragments (5-10 µL) were mixed with 2 µL of the 
appropriate restriction enzyme buffer in a 1.5 mL eppendorf tube and then QS to 
18 µL with water. Next 1-2 µL of restriction enzymes was added, and the tubes 
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were incubated at the appropriate temperature for 1 hr (plasmid DNA) or 
overnight (DNA fragments). The digested DNA was isolated by gel purification 
and used in a ligation reaction with complementary DNA at a molar ratio of 1:3 to 
1:10 (plasmid to DNA fragment).  DNA was mixed with 2 µL of 10× T4 DNA 
ligase buffer, the sample was Q.S. to 19 µL with water, and 1 µL T4 DNA ligase 
was added. Sticky end ligation reactions were incubated for 1 hr at room 
temperature, and blunt end ligations were incubated overnight at room 
temperature.  
 
14. Transient Transfections  
      HEK293T cells were plated in 6 well plates in complete DMEM to be 60-70% 
confluent the following day and incubated at 37°C with 5% CO2 overnight. 
Transfection complexes were formed by diluting 14 µg of the appropriate plasmid 
in 150 µL of serum free DMEM.  Lipofectamine2000 was diluted by adding 12.5 
µL to 150 mL of serum free medium. The diluted DNA and lipofectamine™2000 
were mixed, vortexed and incubated at room temperature for 5 min to form 
transfection complexes. The transfection complexes were added to plates 
dropwise, and the plates were mixed by rocking and incubated at 37°C with 5% 
CO2 overnight. The following morning, the media containing the complexes was 
aspirated and fresh, prewarmed complete DMEM was added to the cells, and the 
plates were returned to the incubator for 48 hrs. After 48hrs, the supernatant 
fluids were harvested to test for recombinant protein production.  
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F. Transfections to Produce BCRAM  
1. Cloning the B7-6 Light Chain into an Expression Vector   
     The light chain of B7-6 was PCR amplified from pBluescript II-B7-6LC plasmid 
using primers B7-6 Light Chain SpeI and CkforRat XhoI.  The PCR product was 
digested with the restriction enzymes SpeI and XhoI overnight.  The destination 
vector pIRES2-zsGreen1 was digested with the restriction enzymes XbaI and 
XhoI overnight.  The restriction digests were purified using the DNA Clean & 
Concentration-25 kit, and the B7-6 light chain DNA fragment was ligated with 
pIRE2-ZsGreen1 and transformed into NEB5α cells to make vector pIRES2-
zsGreen1-B7-6LC.  
 
2. Subcloning of BCRAM Heavy Chain 
     The BCRAM heavy chain was synthesized by Genescript and provided in 
vector pUC57.  The gene was excised from pUC57 by restriction enzyme 
digestion with XbaI and BamHI.  The restriction enzyme digestion was 
fractionated on an agarose gel and the DNA fragment encoding the BCRAM was 
excised and purified as described above.  The XbaI/BamHI fragment was ligated 
to pCherrypicker2 digested with NheI and BamHI, and the resultant 
clone/construct named pCherrypicker2-B7-6HC ZZ. 
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3. Isolation of Stable BCRAM Secreting Cell Line 
     To isolate a cell line secreting biotinylated BCRAM, the heavy chain, light 
chain and BirA ER genes were contransfected into BHK-21 cells (136). Prior to 
transfection, the plasmids were linearized. The plasmids pCherrypicker2-B7-6ZZ 
and pIRES2-zsGreen1 were digested with BsaI while plasmid pIRES2-BirAER 
was digested with XhoI.  The linearized plasmids were purified using the 
QIAquick spin column and transfected into BHK-21 cells using Attractene 
transfection reagent. Approximately 16 hrs later, the transfection reagent was 
removed, and the media was replaced with complete DMEM.  After 48 hrs, 1 
mg/mL G418 and 2 µg/mL puromycin was added to the cells, and they were 
expanded.  Resistant cells were single cell sorted for mCherryHi and ZsGreen1Hi 
population into 96 well plates 14-21 days after transfection.  Positive clones were 
screened for specific activity and biotinylation by IgM binding ELISA and 
subcloned by limiting dilution. Subcloned cells were screened for mCherry 
expression by FACS staining with the mCherry specific monoclonal 8C5.5 that 
was conjugated to Dy650. Specific activity and biotinylation were confirmed by 
IgM binding ELISA. A single clone 4C6.1C11 was chosen for future studies.  
 
4. Purification of BCRAM 
     A gravity flow column was prepared containing 3 mL human IgG Sepharose® 
6 Fast Flow.  The column was equilibrated to room temperature.  Supernatant 
fluid from BCRAM secreting cell line grown in serum-free medium was 
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equilibrated to room temperature and combined at 1:1 to 1:2 with protein A 
binding buffer.  The BCRAM containing supernatant fluids was added to the 
column and allowed to pass through the column.  The column was washed 2 
times with 10 mL of protein A binding buffer.  A 15 mL conical tube with 1 mL of 
1M TRIS pH 8.0 was placed below the column to collect the flow through, and 4 
mL of elution buffer was applied to the column.  The collection tube was agitated 
frequently to facilitate rapidly neutralize the low pH elution buffer. The eluted 
BCRAM was buffer exchanged against PBS, and the column regenerated by 
applying 15 mL of PBS 0.02 % NaN3 (w/v) to the column in 5 mL batches, and 
the flow through discarded.  The column was capped at the bottom, 5 ml of PBS 
0.02 % NaN3 added to the column, the top capped, the edge sealed with 
Parafilm.  The packed column was stored at 4°C until use. 
 
5. Serial Dilutions   
     Serial dilutions were performed as two-fold, ½ log and full log dilutions.  
Samples were serially diluted by transferring a fixed volume of sample into a well 
that contained a fixed volume of diluent, the sample mixed, the pipette tip 
discarded and a fresh pipette tip used to transfer the diluted sample to the next 
well. Transfer volumes were calculated according to the following formula: 
Transfer volume = (D/(F-1) where D= diluent volume and F= dilution factor. For 
two-fold, ½ log and full log dilutions, F= 2, 3.16 and 10 respectively.  
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6. IgM Binding ELISA 
      Ultracruz ELISA plates were coated overnight at 4°C with 100 µL of 36-54 at 
10 µg/mL.  After coating, the plates were washed 3× with PBST and blocked by 
adding 200 µL of ELISA blocking buffer, then incubated at RT for 2 hr.  After 2 hr, 
the plates were washed 3× with 300 µL/well of PBST. For quantitation of 
BCRAM, a standard curve of purified whole molecule B7-6 was added to the 
plate in duplicate.  B7-6 was diluted in ELISA blocking buffer at 80, 40, 20, 10, 5, 
2.5 and 1.25 ng/mL. Unknown samples were added to the plate in a volume of 
100 µL undiluted and diluted up to 1:1,000 in ½ log steps.  The plate was 
incubated for 1 hr at RT. After 1 hr, the plate was washed 3× with 300 µL/ well of 
PBST.  To detect binding, HRP-conjugated F(ab’)2 goat α-Rat LC was diluted 
1:3,000 in ELISA blocking buffer, 100 µL was added to each well, and the plate 
was incubated for 1 hr at RT. Alternatively, biotinylated molecules bound to 
murine IgM were detected by diluting HRP-conjugated streptavidin 1:10,000 in 
blocking buffer and adding 100 µL to each well incubating the plate for 1 hr at 
RT. After 1 hr, the plates were washed 4× with PBST and then developed by 
adding 100 µL of BD OptEIA TMB substrate and incubating for 15-20 min in the 
dark. The reaction was stopped by adding 100 µL of 1N H2SO4, and the plates 
read on a microplate reader at 450 nm. 
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G. B cell and Macrophage Interactions with Immune Complexes 
1. Production of Cell Suspension from Spleens 
      To make a cell suspension, spleens were placed in a 60 mm Petri dish 
containing 5 ml of PBS and perfused by injecting 3 ml of IMag buffer into the 
spleen using a 25 gauge needle attached to a 3 mL syringe. Next, the spleen 
was gently rubbed between the textured sides of two glass microscope slides 
while partially submerged in PBS.  The cell suspension was transferred to a 15 
ml conical tube placed on ice for 5 min to allow large tissue fragments and debris 
to settle to the bottom of the tube.  The cell suspension was transferred to a fresh 
tube, and the cells pelleted by centrifugation at 1,250×g for 5 min. The cell pellet 
was resuspended with 10 ml of IMag buffer, and 10 µL of the cell suspension 
was added to 90 µL of trypan blue counting buffer and enumerated using a 
hemocytometer.  
 
2. Purification of B cells  
     Splenic cell suspensions were centrifuged at 1,250 RPM for 5 min at 4°C, the 
supernatant fluid was aspirated and the pellet resuspended in Anti-mouse 
CD45R/B22O magnetic particles at 25 µL of particles per 107 B cells. The cells 
were incubated on ice for 20 min with agitation every 10 min. After 20 min, the 
cells were QS to 8 mL and transferred to a 17x100mm round bottom tubes then 
placed on the IMagnet.  After 10 min, the fluid was carefully aspirated, the cell 
resuspended in 8 mL of IMag buffer, and the cells were returned to the IMagnet 
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for 4 min.  The fluid was carefully aspirated, and the cells were resuspended in 8 
mL of IMag buffer then placed on the IMagnet for 4 min.  The fluid was carefully 
aspirated, and the cells were resuspended in complete RPMI and enumerated 
using a hemocytometer (101).  
 
3. Quantification of IC Binding to AM14 B cells  
    Dilutions of defined ICs or antibodies were added to a 96 well plate on ice in a 
volume of 100 µL of complete RPMI 1640.  Next, 4×105 cells were added to each 
well of the plate in a volume of 100 µL in complete RPMI 1640.  The plate was 
incubated on ice for 1 hr, and then centrifuged at 1,250 RPM for 5 min at 4 °C 
and washed twice with 200 µL of ice cold IMag buffer by centrifuging again at 
1,250 RPM for 5 min at 4 °C.  The final wash buffer was removed, and 100 µL of 
AF647 conjugated F(ab’)2 goat anti-mIgG2a was added diluted to 1:3,000 in ice 
cold IMag buffer.  The plate was incubated on ice for 1 hr, and then centrifuged 
at 1,250 RPM for 5 min at 4 °C and washed twice with 200 µL of ice cold IMag 
buffer by centrifuging again at 1,250 RPM for 5 min at 4 °C.  The final wash 
buffer was removed, 200 µL of ice cold IMag buffer was added to each well, and 
the cells were transferred to cluster tubes for analysis (101). 
 
4. Labeling of Cells for Calcium Flux 
     A stock solution of the calcium indicator fluorophore Indo-1-AM was prepared 
by adding 6 µL of 1 mM Indo-1-AM to 1 mL of phenol red free RPMI1640 5% 
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FCS and mixing by vortexing.   Purified B cells were resuspended to a 
concentration of 6x106 cells/mL in 5 mL of phenol red free RPMI1640 5%FCS 
and 1 mL of 6 µM Indo-1-AM added to 5 mL of cells to give a final concentration 
of 1 µM Indo-1-AM.  The tube was inverted 5 times to mix then incubated at 37°C 
for 1 hr.  The cells were centrifuged for 5 min at 1,250 RPM and 4°C, then 
washed once with 10 mL phenol red free RPMI1640 5% FCS.  After washing, the 
cells were resuspended in 10 mL of phenol red free RPMI 5% FCS and 
incubated for 30 min at RT in the dark to rest.  The cells were then stored on ice 
for up to 2 hrs prior to calcium flux analysis (137).  
 
5. Configuration of LSRII for Calcium Flux 
    Prior to calcium flux the optical and fluidic configurations of an LSRII flow 
cytometer equipped with a 355 nm line were modified to accommodate Indo-1-
AM fluorescence detection and the tube warmer, respectively. The UV trigon ‘A’ 
detector optical configuration was a 450LP dichroic mirror followed by a 485/22 
band pass filer. The UV trigon ‘B’ detector optical configuration was no mirror 
followed by a 405/20 band pass filter. The black tube holder and spring were 
removed from the sipper arm and replaced with the modified tube holder 
assembly to accommodate for the tube warmer. 
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6. Measurement of Calcium Flux 
     A 450 µL aliquot of rested, Indo-1AM labeled cells was added to a FACS tube 
and warmed to 37 °C in a water bath for 1 min. The FACS tube was place inside 
the tube warmer and place on the sipper. Events were recorded for 1 min, and 
then 50 µL of the appropriate stimulus was added to the FACS tube.  The tube 
was vortexed, placed back inside the tube warmer, back onto the sipper, and 
events were acquired for approximately 5 min.  
 
7. Quantification of PL2-3 Binding to Macrophages 
     Immortalized C57BL6 R2KO macrophages grown in T75 flasks were 
disassociated.  Briefly, the media was aspirated and the cells were incubated 
with 10 mL of PBS containing 10 mM EDTA for 20 min. The cells were pipetted 
to dislodge from the cell culture surface and pelleted by centrifugation at 1,250 
RPM for 5 min. The supernatant fluid was aspirated and the cells resuspended in 
IMag buffer and placed on ice. Either PL2-3298S or PL2-3298N were diluted in the 
supernatant fluid from overgrown A20 cells and incubated on ice for 30 min. The 
C57BL6 R2KO macrophages were plated at 100 µL/ well to a 96 well plate at 
1x106 cell/mL. To block FcγRIIIA binding, 50 µL/well of 2.4G2 at 40 µg/mL in 
IMag buffer was added to each well and the plate incubated on ice for 30 min. 
Since 2.4G2 recognizes both FcγRIIB and FcγRIIIA, it would only block FcγRIIIA 
on R2KO macrophages.  As a control, only IMag was added to some cells. After 
blocking. Next, PL2-3298S and PL2-3298N were diluted in IMag buffer between 20 
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µg/mL to 0.006 µg/mL in ½ log steps. The diluted antibodies were added at 50 
µL/well of separate wells of the 96 well plate containing cells. The plate was 
incubated on ice for 1 hr and then centrifuged at 1,250 RPM for 5 min at 4°C.  
The supernatant fluid was carefully removed from each well and 200 µL of ice 
cold IMag buffer was added to each well. The plate was centrifuged at 1,250 
RPM for 5 min at 4°C, the supernatant fluid was carefully removed from each 
well and 200 µL of ice cold IMag buffer was added to each well.  The plate was 
centrifuged at 1,250 RPM for 5 min at 4°C, the supernatant fluid was carefully 
removed from each well and 100 µL of AF647 conjugated F(ab’)2 goat anti-
mIgG2a diluted to 1:3,000 in ice cold IMag was added to each well. The plate 
was incubated for 20 min on ice.  Next, the plate was centrifuged 1,250 RPM for 
5 min at 4°C. The supernatant fluid was carefully removed from each well and 
200 µL of ice cold IMag buffer was added to each well. The plate was centrifuged 
at 1,250 RPM for 5 min at 4°C, the supernatant fluid was carefully removed from 
each well and 200 µL of ice cold IMag buffer was added to each well.  The plate 
was centrifuged at 1,250 RPM for 5 min at 4°C, the supernatant fluid was 
carefully removed from each well and 200 µL of ice cold IMag buffer was added 
to each well and binding quantified by flow cytometry.  
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8. Internalization of Defined DNA IC  
     AM14 and AM14 FcγRIIB B cells were resuspended to 2×106/mL in separate 
15 mL conical tubes and incubated on ice until cold. Fluorescently-labeled 
streptavidin DNA IC was added to the cells at a final concentration of 0.13 µg/mL 
fluorochrome labeled streptavidin, 0.166 µg/ml 2-end bio C11 and 0.166 µg/ml.  
The tubes were incubated on ice for 1 hr and centrifuged at 1,250 RPM for 5 min 
at 8°C, then the supernatant fluid was aspirated, and the cell were washed twice 
with 10 mL of ice cold complete RPMI by centrifuging at 1,250 RPM for 5 min at 
8°C and aspirating the supernatant fluid.  After the final wash, the cells were 
resuspended to the original volume in ice cold complete RPMI. A reverse time 
course was performed by adding 200 µL in duplicate from each tube to a 96 well 
plate incubated at 37°C.  The IC labeled cell aliquots were incubated at for 3 hr, 
90 min, 60 min, 30 min or 15 min. Following the incubation, the 96 well plate was 
placed on ice for 5 min, and then 200 µL of cell suspension was added to the ice 
cold plate for the 0 min time point. The plates were centrifuged at 1,250 RPM for 
5 min at 4°C and the washed twice by centrifugation with 200 µL of ice cold 
FACS buffer. After the final wash, the supernatant fluid was removed, and the 
cell were resuspended in 200 µL of ice cold FACS buffer containing Dy649-
conjugated 3A20.2 and incubated on ice for 20 min. The plates were centrifuged 
at 1,250 RPM for 5 min at 4°C and the washed twice by centrifugation with 200 
µL of ice cold FACS buffer. After the final wash, the supernatant fluid was 
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removed and the cells were resuspended in 200 µL of ice cold FACS buffer and 
transferred to cluster tubes.  Internalization of IC was quantified by flow 
cytometry.  
9. pH Assay on Primary Murine B cells  
     Dual fluorescent immune complexes were formed by replacing a single 
fluorescent streptavidin with a mixture of streptavidin-FITC (7 parts) with 
streptavidin-AF647 (1 part).  AM14 or AM14 R2KO B cells were incubated with 
the dual fluorescent IC for 24 hr at 37 °C in a 96 well plate.  The plates were 
centrifuged at 1,250 RPM for 5 min at 4°C and the washed twice by 
centrifugation with 200 µL of 0.9% (physiological) saline.  After the final wash, the 
supernatant fluid was removed and the cells were resuspended in 200 µL of 
0.9% saline.  To construct a standard curve, cells were resuspended in citric Acid 
– Na2HPO4 Buffer Solutions at pH 4-7.6 containing 4mM KCl, 4 µM monensin 
and 20 µM nigericin.  Experimental samples were resuspended in FACS buffer. 
pH was quantified by flow cytometry using a ratio of the FITC Fluorescence to 
the AF647 fluorescence (138).   
 
H. Confocal Microscopy  
1. Coating of Cover Slips 
     Gelatin type B was prewarmed by placing it in a 37°C water bath for 1 hr.  
Next, cover slips were added to each well of a 24 well plate and 0.25 ml of  poly-
L-lysine was added to each cover slip and incubated for 5 min at RT. The poly-L-
			
	
 
lysine was aspirated, and 0.5 mL of gelatin type B was added to the top of each 
cover slip, and the plate was incubated for 10-20 min at 37 °C.  The gelatin was 
aspirated and the plate left ajar at the back of a laminar flow cabinet for the cover 
slips to dry overnight. 
 
2. IF of Primary Murine B cells  
     Primary murine B cells were plated into 24 well plates containing gelatin 
coated coverslips at 2.5×106 cells/well and treated with stimuli as described for 
24 hrs.  Next, the media was aspirated, and 1 mL of PBS containing 4% 
paraformaldehyde was added to each well, and the plate was incubated for 20 
min at RT. To quench the fixative, 200 µL of 120 mM glycine in PBS was added 
to each well, and the plate was incubated for 20 min at RT.  Next, the liquid from 
each well was aspirated and was gently replaced with 1 mL/well of IF 
permeabilization buffer, and the plate was incubated overnight at 4-10°C. The IF 
permeabilization buffer was aspirated, and 0.5 mL of directly-conjugated 
antibodies were added at 1:100 to 1:1,000 diluted in IF permeabilization buffer, 
and the plate was incubated for 1-2 hr at RT in the dark.  The conjugated 
antibody solution was aspirated, and 1 mL of IF permeabilizaion buffer was 
gently added to each well, incubated for 5 min and aspirated. This wash process 
was repeated three more times with IF permeabilization buffer with dwell times of 
10, 15 and 20 min. After the final wash, 1 mL of PBS was added to each well, 
and the coverslips mounted.  A 1.5” 18 gauge needle was bent to 90° together 
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with forceps were used to extract the coverslips from the wells. The cover slips 
were placed cell side down on a 10 µL drop of ProLong Anti Fade Gold in the 
middle of a glass slide and seated by gently depressing with the large end of a 
P100 pipette tip.  The mounted cover slips were incubated overnight in the dark 
at RT and then sealed by applying a clear nail polish to the edge of the cover 
slips.  
 
3. IF of Immortalized Cell Lines 
Immortalized cell lines were plated onto gelatin coated coverslips at 2.5×105 to 
1x106 cells/well and allowed to attach overnight. After attachment, the media was 
aspirated and each well was washed with 1 mL of PBS.  Then 1 mL of cooled 
95% Ethanol, 5% Glacial acetic acid was added to each well, and the plate was 
incubated for 5 min on ice. The ethanol solution was aspirated, and 1 mL of PBS 
was added to each well and incubated for 5 min at RT.  Next, the PBS was 
aspirated, and 1 mL of PBS, 5% normal goat serum, 0.02% NaN3 was added and 
incubated for 2 hr at RT in the dark. The buffer was aspirated and 0.5 mL of 
unconjugated primary antibodies were added at 1:100 to 1:1,000 diluted in 1 mL 
of PBS, 5% normal goat serum, 0.02% NaN3 ,and the plate was incubated for 1-2 
hr at RT in the dark.  One coverslip was incubated only with buffer to serve as 
the secondary only control.  The primary antibody solution was aspirated and 1 
mL of PBS, 5% Normal goat serum, 0.02% NaN3 was gently added to each well, 
incubated for 5 min and aspirated. This wash process was repeated three more 
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with forceps were used to extract the coverslips from the wells. The cover slips 
were placed cell side down on a 10 µL drop of ProLong Anti Fade Gold in the 
middle of a glass slide and seated by gently depressing with the large end of a 
P100 pipette tip.  The mounted cover slips were incubated overnight in the dark 
at RT and then sealed by applying a clear nail polish to the edge of the cover 
slips.  
 
3. IF of Immortalized Cell Lines 
Immortalized cell lines were plated onto gelatin coated coverslips at 2.5×105 to 
1x106 cells/well and allowed to attach overnight. After attachment, the media was 
aspirated and each well was washed with 1 mL of PBS.  Then 1 mL of cooled 
95% Ethanol, 5% Glacial acetic acid was added to each well, and the plate was 
incubated for 5 min on ice. The ethanol solution was aspirated, and 1 mL of PBS 
was added to each well and incubated for 5 min at RT.  Next, the PBS was 
aspirated, and 1 mL of PBS, 5% normal goat serum, 0.02% NaN3 was added and 
incubated for 2 hr at RT in the dark. The buffer was aspirated and 0.5 mL of 
unconjugated primary antibodies were added at 1:100 to 1:1,000 diluted in 1 mL 
of PBS, 5% normal goat serum, 0.02% NaN3 ,and the plate was incubated for 1-2 
hr at RT in the dark.  One coverslip was incubated only with buffer to serve as 
the secondary only control.  The primary antibody solution was aspirated and 1 
mL of PBS, 5% Normal goat serum, 0.02% NaN3 was gently added to each well, 
incubated for 5 min and aspirated. This wash process was repeated three more 
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times with buffer dwell times of 10, 15 and 20 min.  After the final wash, 1 mL of 
fluorophore-conjugated, species-specific detection antibody diluted 1:100 to 
1:1,000 in PBS, 5% normal goat serum, 0.02% NaN3 was added to each well, 
and the plate was incubated for 1-2 hr at RT in the dark. The secondary detection 
reagent was aspirated, and 1 mL of PBS, 5% Normal goat serum, 0.02% NaN3 
was gently added to each well, incubated for 5 min and aspirated. This wash 
process was repeated three additional times with buffer dwell times of 10, 15 and 
20 min.  A 1.5” 18 gauge needle bent to 90° and forceps were used to extract the 
coverslips from the wells. The cover slips were placed cell side down on a 10 µL 
drop of ProLong Anti Fade Gold containing DAPI in the middle of a glass slide 
and seated by gently depressing the top of the coverslip with the large end of a 
P100 pipette tip.  The mounted cover slips were incubated overnight in the dark 
at room temperature and then sealed by applying a clear nail polish to the edge 
of the cover slips.  	  
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CHAPTER THREE 
 
IV. Strategies for the delivery of nucleic acid-associated ligands to the B 
cell receptor 
 
A. Introduction  
It is now well established that dual engagement of the B cell receptor and 
either endosomal TLR7 or TLR9 by nucleic acid or nucleic acid-associated 
antigen is required for the efficient activation of autoreactive B cells in murine 
models of autoimmune disease.  These findings were initially surprising because 
i) the endosomal TLRs were thought to distinguish between microbial and 
mammalian nucleic acids and ii) FcγRIIB was thought to efficiently inhibit BCR 
driven responses.  Our initial studies involved low affinity IgG2a-reactive 
rheumatoid factor (RF) B cells and IgG2a autoantibodies that bound undefined 
cell debris and no bacterial products.  These autoantibody complexes failed to 
activate RF B cell that were deficient in endosomal TLR function, thereby 
implicating self nucleic acids.  Although it was obvious from the genetic ablation 
of MyD88 or the relevant TLRs that self nucleic acid was being sensed, the 
undefined nature of exactly what the autoantibodies bound made it impossible to 
discern the properties of the DNA involved in activation.   
     To better define the properties of immunostimulatory DNA, we used defined 
DNA IC composed of an IgG2a anti-hapten (e.g. TNP, biotin) antibody combined 
with haptenated DNA fragments of defined sequence.  This strategy was refined 
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by using the same DNA fragments end-labeled with biotinylated bases and 
IgG2a anti-biotin antibodies. (101).   An analogous approach using haptenated 
RNA as the nucleic acid helped illuminate the self-RNA properties that govern 
the TLR7 dependent B cell response to self RNA (106).  
     Despite the utility of the defined anti-bio bio-DNA IC in delivering DNA via the 
BCR, they had three major limitations as far as the range of scientific questions 
that could be addressed: 1) We were unable to form fluorescent IC sufficiently 
bright for tracking their internalization and fate; 2) we could not determine 
whether our complexes went to high or low pH compartments.; and 3) our 
analysis was limited to B cells expressing the heavy and light chain for the 
IgG2a-specific BCR.    
     Sensing of RNA and DNA by TLRs 7 and 9, respectively, requires 
endocytosis of the nucleic acid ligand via the BCR and TLR sensing in an 
endolysosomal compartment. TLR7 and TLR9 traffic from the Golgi to the 
surface and then to an acidic endolysosomal compartment (73, 74).  In addition, 
it was demonstrated that depending on the intracellular localization, TLR7 and 
TLR9 engagement can have divergent effects. In one compartment, engagement 
led to IFN-α production whereas in separate compartment, it led to pro-
inflammatory cytokine production (85). Nonetheless, the endosomal TLRs 
required an acidic milieu to function. The acidic milieu is key to TLR function 
because proteolytic cleavage by acid active proteases is required for receptor 
activation and ligand degradation by acid active nucleases is required for ligand 
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sensing (75-77, 80, 81).  The central importance of endolysosomal milieu to 
TLR9 activity led me to hypothesize that FcγRIIB attenuates BCR-TLR responses 
by modulating trafficking to the optimal TLR sensing compartments.  To 
approach this question, we needed a means to interrogate the intracellular 
trafficking of IC of known composition. 
     Despite the limitations of the spontaneous IC, they proved immensely useful 
for elucidating the mechanisms of BCR-TLR activation in the context of nucleic 
acid IC in our RF B cells.  Follow up studies examining the role of possible 
downstream effectors were limited by the requirement to breed the RF BCR onto 
each possible knock out.  To more rapidly examine BCR TLR synergy, we 
required a system to deliver spontaneous nucleic acid IC to non-Tg murine B 
cells without having to breed the AM14 receptor onto that background.  
     The complexes described in this chapter can be categorized based on the 
surface receptor they bind and the cargo they deliver. The complexes that will be 
described include the following: 1) Complexes formed with IgG2a anti-
streptavidin streptavidin, DNA biotinylated at both ends, 2) Complexes formed 
with IgG2a anti-streptavidin SA-FITC, SA-AF647 and DNA biotinylated at both 
ends, 3) Complexes formed between biotinylated Fab α-mIgM, DNA biotinylated 
at both n bind to IgM positive B cells and deliver biotinylated DNA. 4) Complexes 
formed between F(ab’)2 α-mIgM, SA and DNA biotinylated at both ends. 5) 
Complexes formed with BCR adaptor IgM bind to IgM positive B cells and can 
deliver an immune complex formed with any protein A binding antibody.  The 
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complexes formed with the DVD-IgTM bind to IgM positive B cells with one arm 
and deliver molecules bound by their second arm.  
 
B. Creation of Multifunctional Streptavidin Immune Complexes 
     The high affinity and specificity of the streptavidin-biotin interaction makes it 
widely adopted.  Therefore, companies offer newly discovered small molecule 
ligands mono biotinylated. Previously, we were unable to deliver these 
monobiotinylated molecules exclusively as an IC because our anti-biotin mAb 
could not form stable IC with monobiotinylated macromolecules. The ability to 
deliver monobiotinylated ligands as fluorescent IC permits us to deliver and track 
not only DNA, RNA oligonucleotides or DNA oligonucleotides but also any 
commercially available biotinylated DAMP (e.g. poly(I:C), LPS, and MDP) ligand 
as IC.  The ligand poly(I:C) engages TLR3 which is located in a series of endo-
lysosomal compartments. Delivering this ligand as an IC could mimic what 
occurs when a B cell endocytoses an autoantigens bound to dsRNA or a dsRNA 
virus. For LPS delivery via the BCR would be informative because engagement 
of TLR4 intracellular leads to a different signaling cascade (i.e. TRIF versus 
MyD88) than cell surface engagement. Delivering this ligand as an IC could 
mimic what occurs when a Gram-negative bacteria is endocytosed via the BCR. 
The ligand MDP is endocytosed into acidic vesicles and engages NOD2, which is 
located in the cytosol. Delivering this ligand as an IC would mimic what occurs 
when a bacteria with a peptidoglycan cell wall is endocytosed via the BCR.  
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1. Method to Track the Endocytosis and Trafficking of ICs 
     Studying the activation of B cells by nucleic acid IC required the ability to track 
the uptake and subsequent fate of endocytosed IC because sensing of nucleic 
acid ligands by TLRs 7 and 9 occurs in a series of endo-lysosomal 
compartments.  High resolution imaging of the uptake and location of immune 
complexes requires brightly fluorescent defined immune complexes.  dsDNA 
fragments of defined sequence, in which approximately 10% of the incorporated 
U’s are biotinylated, can be generated by PCR.  These Bio-DNA fragments can 
be combined with an IgG2a anti-biotin mAb to form defined DNA immune 
complexes (ICs) that induce TLR9 dependent proliferation of IgG2a-reactive 
AM14 B cells (101).  To form defined DNA ICs that are fluorescently labeled and 
deliver small molecules as IC, I used an approach based on the widely 
implemented concept of interchangeable parts where readily available 
components are used to assemble a more complex final product. In my case, I 
developed a high affinity IgG2a antibody specific for streptavidin to gain access 
to two readily available components 1) Any commercially available biotinylated 
molecule and 2) magnetic, fluorescent or bead conjugated streptavidin.    
     Biotin is a small molecule (M.W. 244) that is a vitamin essential for the 
function of carboxylases important for a wide variety of metabolic processes.  
Given the evolution of antibiotics as a means of competition between bacterial 
species, it is not surprising that a genus known for antibiotic production, the 
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Streptomyces, produces streptavidin that deprives its competitors of an essential 
enzymatic cofactor.  This strategy is highly conserved with fungi and birds 
expressing high affinity biotin binding proteins as a means of host defense (139). 
Streptavidin is a tetrameric protein of approximately 60kDa produced by 
Streptomyces avidinii that has four biotin binding domains with an affinity on the 
order of 1015 for biotin making the interaction essentially covalent and extremely 
resistant to dissociation by pH requiring extreme temperature or harsh chemical 
denaturants (i.e. 8 M Guanidine HCl, pH 1.6) to break the interaction (140). The 
affinity and stability of the biotin-streptavidin interaction make it an ideal 
foundation for a system to study the uptake of defined DNA immune complexes 
into the acidic and degradative milieu of the endolysosomal system.  
  To make a brightly fluorescent defined DNA IC, rather than the 
biotinylated DNA and anti-biotin immune complex, I devised a strategy for 
making ICs by adding fluorochrome-conjugated streptavidin (SA) to the Bio-
dsDNA, and then forming an anti-streptavidin IC. Due to the wide adoption of 
streptavidin as a flow cytometry reagent, it is commercially available in nearly any 
fluorescent color.  By purchasing a different fluorochrome conjugated 
streptavidin, the IC color can be changed obviating the need to make different 
antibody conjugates or using secondary staining reagents to track the IC. 
Therefore the incorporation of streptavidin into ICs introduced a quasi covalent 
bond between streptavidin and the biotinylated ligands. The anti-SA SA defined 
IC, facilitated fluorescent tracking and permitted the use of a wide range of 
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expanding biotinylated reagents enabling the system to keep pace with the 
changing science and marketplace.  
 
2. Gel Shifts to Interrogate IC Stoichiometry  
     Our previous method for forming defined DNA IC involved replacing a fraction 
of a single dNTP, dTTP in a PCR reaction with biotinylated dUTP to achieve 
varying levels of substitution based on the proportion of dTTP replaced by 
biotinylated dUTP in the reaction mix (101).   However, the extent of 
incorporation varied from preparation to preparation, and this variability, together 
with the tetravalent nature of SA, rendered this particular methodology unsuitable 
for the preparation of ICs of comparable size and structure.   To more 
consistently form biotinylated DNA fragments, I used two, 5’ mono biotinylated 
primers to amplify a 570 bp DNA fragment called clone 11 by PCR resulting in a 
fragment with one biotin at each end (2-end bio DNA). The binding stoichiometry 
of streptavidin:2-end bio DNA complexes was directly interrogated by mixing 1.3 
pmol 2-end bio DNA (2.6 pmol bio-DNA ends) with increasing concentrations of 
streptavidin, incubating briefly and fractionating the different mixtures on an 
agarose gel.  Due to the tetravalent binding sites of streptavidin, the predicted 
complexes formed between 2-end bio DNA (~366 kDa) and streptavidin (~60 
kDa) at a close to 1:1 molar ratio of DNA ends to streptavidin would be large 
cross-linked structures where each SA biotin binding site was occupied by a 
biotinylated DNA end that would fractionate as smear on an agarose gel and not 
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separate as distinct species.  At SA in 10-100 fold molar excess relative to 2-end 
bio DNA, the expected complexes would be a single 2-end bio DNA bound to 
one or two streptavidin molecules with approximate molecular weights of 426 
kDa and 486 kDa. However, unexpectedly the gel shift at a ratio of 3 pmol of 
streptavidin to 1.3 pmol of 2-end bio DNA (2.6 pmol bio DNA ends) was a series 
of distinct bands of increasing molecular weight. This suggested the formation of 
complexes where each streptavidin tetramer bound a maximum of two DNA ends 
the two other binding sites were inaccessible. Therefore, streptavidin was 
behaving as a bivalent molecule (Figure 1).   At 30 pmol and 10 pmol streptavidin 
to 1.3 pmol 2-end bio DNA, the major species were a single DNA fragment 
bound to either one (band A) or two streptavidin (band B).  The predicted 
molecular weights for unshifted DNA, one streptavidin bound and two 
streptavidin bound DNA were 366 kDa, 427 kDa and 487 kDa respectively.   The 
calculated molecular weight from the gel was 399 kDa for the unshifted DNA  
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Figure 1. Streptavidin bound to DNA biotinylated at both ends forms distinct bands. 
DNA biotinylated at both ends was treated with increasing concentrations of SA and 
fractionated on a 1.5% agarose gel prestained with EtBr. Molecular weights were calculated 
from a standard curve by graphing migration distances against the molecular weight of 
standard bands and performing non-linear regression.  
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(band D), 482 kDa (band A) and 551 kDa (band B). Although there was a 
significant deviation from the predicted values, the shifts between one bound 
streptavidin and two bound streptavidins were proportional.  Specifically, the 
difference between unshifted DNA (band D) and band A was ~83 kDa and the 
shift between band A and B was ~69 kDa.  
     The discrepancy between the predicated and calculated molecular weight by 
agarose gel electrophoresis cannot be attributed to charge because streptavidin 
has a pI of 6 and would therefore have a net negative charge at the pH of TAE 
electrophoresis buffer (pH~8), which would lead to faster migration in the 
electrical field.  Another possibility is that the shape of streptavidin complexed 
with 2-end bio DNA contributed to the shape dependent retardation of the 
complex in the electric field. 
     This observation of non-tetravalent binding was consistent with published 
work where end biotinylated DNA captured by streptavidin bound to the opposite 
biotin binding site with one or two occupied sites observed per streptavidin 
molecule.  Furthermore, streptavidin bound to three or four biotinylated DNA 
molecules was a rare species (141-143).   
     Nonetheless, these data demonstrated a deviation from the commonly cited 
tetravalent binding properties of streptavidin and could be attributed to steric 
hindrance by the bound DNA fragments occluding the adjacent biotin binding site 
or electrostatic repulsion between two DNA fragments at adjacent sites.  
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     Although the non-tetravalent binding of DNA oligonucleotides was previously 
demonstrated, it was not performed with larger DNA fragments.  Furthermore, 
the vagaries (e.g. protein charge, shape) of native agarose gel electrophoresis 
made it difficult to identify the higher molecular weight species formed between 
streptavidin and DNA biotinylated at both ends. Therefore, I could not exclude 
the possibility that the species <900 kDa did not represent a single streptavidin 
tetramer binding three or four DNA fragments.  On way to restrict the possible 
combinations of streptavidin to biotinylated DNA would be to use DNA 
biotinylated at one end. This would limit the theoretical stoichiometric ratios of 
streptavidin tetramer: DNA biotinylated at one end to 1:1:,1:2, 1:3 and 1:4.  
     To confirm that streptavidin was binding a maximum of two DNA fragments 
biotinylated at one end, increasing concentrations of streptavidin were mixed with 
DNA biotinylated at one end.  The mixtures were briefly incubated and 
fractionated on an agarose gel. I expected that only two reaction products would 
be observed representing 1:1 and 1:2 streptavidin:DNA binding. As expected, the 
major products at saturating concentrations of streptavidin (<10:1) were 1:1(band 
A) and 1:2 streptavidin to DNA (band B) complexes (Figure 2). Interestingly, 
below a ratio of 1:1, there was an intermediate band (band C) and unshifted DNA 
(band D).  Band C could be either a partial tetramer of streptavidin  
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Figure 2. Streptavidin tetramers bound less than three DNA molecules biotiny lated at 
one end.  DNA biotinylated at one end was treated with increasing concentrations of SA and 
fractionated on a 1.5% agarose gel prestained with EtBr. Molecular weights were calculated 
from a standard curve constructed by plotting migration distances against the molecular 
weight of standard bands and performing non -linear regression.  
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and one DNA molecule.  Another possibility is that band C represented DNA 
bound to streptavidin at a different angle than band B (Figure 2). More 
specifically band B and band C could represent obtuse angle or acute angles 
between streptavidin and DNA. Nonetheless, these data demonstrated that there 
were no higher molecular weight complexes representing three and four DNA 
molecules per streptavidin.  Thus, when binding these biotinylated DNA 
fragments, streptavidin was likely restricted to binding two DNA fragments in the 
para configuration. For IC formation, 3 moles of streptavidin per mole of DNA 
fragment biotinylated at both ends would give a relatively homogenous mixture of 
DNA fragments bound to one or two streptavidins with limited chain formation.  
 
3. Confirmation of Desired Activity by Proliferation  
     To determine the optimal ratios of end-biotinylated DNA (at both ends) to 
streptavidin and anti- streptavidin that can stimulate AM14 B cell proliferation, a 
constant concentration of DNA complexed with streptavidin AF488, was mixed 
with decreasing concentrations of anti-streptavidin.  These SA ICs were 
compared to a single concentration of the same DNA fragment biotinylated 
throughout mixed with a titration of anti-biotin.  By 3H-thymidine incorporation, it 
was evident that anti-streptavidin-streptavidin-bio-DNA-bio complexes (anti-SA 
SA DNA IC) more efficiently stimulated proliferation of AM14R2KO cells than 
anti-bio DNA IC (Figure 3B). More succinctly stated, anti-SA stimulated 
proliferation at lower concentrations of antibodies than anti- bio. 
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Figure 3. Anti-SA SA DNA IC stimulated proliferation more efficiently than Anti-bio DNA.  
A) AM14 or B) AM14 R2KO B cells were stimulated with, blue circles, 0.4 mg/mL SA-AF488, 
0.5 mg/mL C11 DNA biotinylated at both ends and a titration of anti-SA.  Red squares, 0.5 
mg/mL 20% biotinylated DNA and a titration of anti-bio. Proliferation was quantified by 3H 
thymidine incorporation from 24 hr to 30 hr post stimulation. Representative of n=2 
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This was paradoxical because both IC incorporated the same DNA fragment. 
Although the anti-bio DNA IC and the anti-SA SA DNA IC incorporated the same  
sequenced DNA fragment, there were differences in the biotin density in the DNA 
molecules and antibodies used to form the ICs. From a purely theoretical 
standpoint, the anti- bio DNA IC should have more antibody binding sites than 
the anti-SA-SA DNA IC. The DNA fragment used for the anti-bio DNA IC was 
biotinylated at a substitution rate of 20% of its thymidine residues. There would 
be 30 biotin residues and therefore 30 antibody binding sites in this DNA 
fragment.  The fragment used for the anti-SA SA DNA IC incorporated 2 biotins 
at each end of the DNA fragment. Incorporation of streptavidin into the IC 
resulted in a maximum of 8 (1 SA tetramer per biotin on each DNA fragment) 
antibody-binding sites on each DNA molecule.  Therefore, the anti-bio DNA IC 
should engage FcγRIIB better than anti-SA SA DNA IC because the anti-bio DNA 
IC would have 30 antibodies per DNA molecule whereas the anti-SA SA DNA IC 
would have 8. The stoichiometric rationale for anti-bio DNA IC engaging FcγRIIB 
better than anti-SA SA DNA IC was not supported by the empirical data (Figure 
3A). The deviation from the expected result suggested that the antibodies 
differed in their affinity and/or stability of their interactions with their antigens.  
I concluded, that an in depth study of the differences between the 
streptavidin bio-DNA-bio IC and anti-bio Bio DNA IC would be ill advised. It would 
be impossible to control for the variables of epitope spacing and antibody affinity 
between the anti-bio DNA IC and anti-SA SA DNA IC. Nonetheless, these data 
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suggested that FcγRIIB regulated BCR-TLR9 responses, which contradicted 
previous work with the spontaneous IC, PL2-3 and defined anti-bio DNA IC 
(117). This warranted a more careful analysis of DNA IC and RNA IC regulation 
by FcγRIIB.  
 
4. Development of pH Sensor Immune Complexes  
Material taken up by receptor-mediated endocytosis can have a variety of 
fates based on a variety of factors including, but not limited to, the specific 
receptor, physical properties of the cargo, and ensuing signaling events. One 
common aspect of endocytosis is that the pH of the endocytic compartment 
decreases as the endosome matures, and the function of many endosomal 
enzymes and receptors is pH dependent.  Therefore a useful methodology to 
study endosomal maturation is to track the pH of the endocytosed cargo by 
making it a pH sensor of its milieu (138).  This was accomplished by capitalizing 
on the differential pH sensitivity of the “green” as opposed to “red” fluorochromes. 
The fluorescence of FITC and its halogenated derivative, Oregon Green, 
decrease with pH while the fluorescence of AF647 or TRITC are insensitive to pH 
changes.  Thus a pH sensor IC can be made by incorporating two different 
fluorochrome conjugated SAs into the IC.  This dual labeled fluorescent pH 
sensor can give a relative measure of pH by simply using a ratio of the FITC 
fluorescent as the numerator and the AF647 as the denominator so the ratio 
decreases with pH because the FITC fluorescence decreases with pH whereas 
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the AF647 remains constant. A quantitative measure of IC pH can be 
accomplished by measuring the ratio of FITC/AF647 fluorescence at known pH 
values, constructing a standard curve and calculating experimental pH values 
from ratios using the standard curve.  
  
5. Application of pH sensing ICs. 
To make a defined a DNA IC that could sense the pH of its environment, I 
first mixed the streptavidin-FITC and streptavidin-AF647 fluorophores, then 
added 2-end bio DNA. The dual fluorophore labeled 2-end bio DNA was mixed 
with our anti-streptavidin mAb to form a dual fluorophore labeled IC. The 
formation of fluorophore labeled ICs required balancing the relative fluorescence 
intensity of both fluorophores.  More directly stated, AF647 is 2x as bright as 
FITC. Therefore, more streptavidin-FITC was used in the complex relative to 
streptavidin-AF647.   AM14 B cells were stimulated for 24 hr at 37 °C. A pH 
curve was constructed by washing the cells twice with physiological saline and 
then resuspending the cells in pH buffers between pH 4-8 containing monensin 
and nigericin. The ionophores monensin and nigericin collapse the proton 
gradient equilibrating the pH of the intracellular milieu with the extracellular 
milieu.  Thus the pH of the IC in the cell is effectively the pH of the buffer used to 
resuspend the cells. A standard curve can then be constructed by graphing the 
changes in the MFI ratio against pH of the buffer (Figure 4A and B).  
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Figure 4. Fluorescent anti-SA SA DNA IC function as pH sensors and can be tracked by 
confocal microscopy. A) AM14 B cells treated with anti-SA SA FITC/AF647 DNA IC for 24 
hr, washed thrice with 0.9% NaCl and then treated with monensin and nigericin in pH buffers 
(7.7-4.1) and the ratio of FITC to AF647 fluorescence quantified by flow cytometry. B) A 
standard curve was constructed by graphing pH against the geometric mean fluorescent 
intensity and performing non-linear regression.C) AM14 B cells were treated with Anti-SA SA 
AF488 DNA IC (green) for 24 hr, washed thrice with PBS and then fixed with 4% PFA in PBS 
for 15 min. The cells were stained with DAPI (blue) and M5/114-AF647 (red) in blocking buffer 
with 0.1% saponin. The cells were imaged on an Leica SP8 mutlispectral microscope.  
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This methodology could be used to ask how coengagement of FcγRIIB 
modulated the pH of ICs taken up by the BCR by comparing the pH of the IC as 
a function of time in RF B cells that did or did not express FcγRIIB.  Presumably 
the MFI ratio of the complex reflected the pH of the compartment in which the IC 
was localized. 
     In addition to tracking the internalization and trafficking of IC by flow 
cytometry, microscopy is also used to assess intracellular compartment 
localization. To validate anti-SA SA DNA IC internalization and trafficking by 
confocal microscopy, AM14 B cells were treated with anti-SA SA-AF488 DNA IC 
for 24 hr.  The cells were fixed, permeabilized and stained with M5/114-AF647 
and DAPI.  The cells were imaged by confocal microscopy. It was apparent that 
the immune complexes were highly fluorescent and internalization in an 
intracellular compartmental localization could be observed (Figure 4C).  
 
6. Limitation of the Defined Immune Complex Methodology 
     Despite the broad applications of SA ICs, our study of IC dependent activation 
of B cells was still restricted to the AM14 B cell transgenic. The AM14 B cell 
transgenic proved instrumental in dissecting the mechanisms of BCR-TLR 
activation of low affinity autoreactive B cells (100, 102, 104). The AM14 BCR is a 
membrane bound receptor composed of a heavy chain, AM14 and a light chain, 
Vk8, and when paired, the AM14 BCR is a low affinity receptor that binding 
murine IgG2a of the ‘a’ or ‘j’ allotypes with µM affinity (99).  To activate AM14 B  
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cells, the low affinity of the receptor is overcome by IgG2a crosslinking its antigen 
and delivery of the nucleic acid cargo for sensing by the endosomal TLRs 7 
and/or 9 (100, 104).  Formal demonstration of the dual BCR-TLR dependent 
activation of AM14 B cells required crossing the genetic elements (i.e. AM14 and 
Vk8) for the receptor with knockouts that abrogate TLR7/9 activity.   Despite the 
benefit of allelic exclusion, that allows for AM14 receptor expression even in mice 
heterozygous for the AM14 and Vk8 genes, the need for both the heavy and light 
chain loci means that breeding the AM14 receptor genes onto a homozygous KO 
background is a time and resource intensive process.  
    To illustrate the time required to interrogate pathways downstream of BCR-
TLR engagement consider the following breeding strategy to determine the role 
of MyD88 in the response of B cell to nucleic acid delivered through the BCR 
using the AM14 receptor (Figure 5).  For the first generation, an AM14 +/+ Vk8 
+/+ mouse would be bred to a MyD88 -/- to a give F1 offspring that are 
heterozygous for all alleles born 3 weeks after the breeding pair was setup. The 
resulting F1 would be backcrossed to MyD88 -/- 6 weeks later and the offspring 
born in 3 weeks would be genotyped for AM14, VK8 and MyD88. The probability 
of a mouse that expresses the AM14 receptor and is a MyD88 -/- would be 
approximately ½ x ½ x ½ because the AM14 VK8 genes only need to be 
heterozygotes and could be used for an experiment at 8 weeks of age.  
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Figure 5. Breeding of AM14 heavy chain and Vk8 light chain onto a KO is time and 
resource intensive Expression of the AM14 BCR specific for IgG2aa/j required that the mice 
were heterozygous for the AM14 heavy chain and the Vk8 light chain.  At least three 
generations was required to breed the AM14 BCR onto a KO background.   
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With the most sanguine Mendelian assumptions and breeding projections, it 
would take 26 weeks from initiation of the F1 cross to an experimental mouse 
that expresses the AM14 receptor and is MyD88-/- (Figure 5).  A more realistic 
assumption is an additional cross of the AM14 +/-, Vk8 +/-, MyD88 -/- mouse 
back to an F1 mouse and aging the experimental mice 8 weeks.  This would give 
37 weeks from the initial cross to an experiment mouse that expresses the AM14 
receptor and is MyD88 -/-.  The time and costs associated with completing these 
crosses significantly impeded the capability to rapidly interrogate the role of other 
factors in B cell activation by BCR-TLR engagement. To avoid this inefficiency, a 
method was required to recapitulate the results of BCR-TLR engagement 
observed in the AM14 system with out breeding the AM14 receptor onto each 
knock out background.   
 
C. Bio-Fab α-IgM-Bio-DNA-Streptavidin Complex 
     A strategy capable of recapitulating the response of AM14 B cells to nucleic 
acid IC but in polyclonal B cell populations required 3 conditions be met 1) 
Targeting a nucleic acid ligand to the BCR of polyclonal B cells, 2) BCR 
dependent endocytosis and sensing of the nucleic acid by TLR7 and/or TLR9 
and 3) Proliferation of the B cells dependent on sensing by the appropriate 
endosomal TLR.    
     Most naïve splenic B cells are IgM positive which means they have a 
membrane antibody molecule with the antigenic determinant for IgM.        
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Although the majority of B cells in a normal mouse are IgM positive, the 
specificities of their B cell receptors is quite diverse (i.e polyclonal), which made 
IgM a natural means to circumvent BCR specificity for BCR-mediated 
endocytosis of nucleic acid ligands. To target a nucleic acid ligand to the BCR of 
polyclonal B cells and induce TLR dependent proliferation a tripartite complex 
was conceived: 1) biotinylated Fab fragment of α-IgM to target the BCR, 2) a 
DNA fragment biotinylated at both ends to engage TLR9 and 3) streptavidin to 
form a stable complex between the DNA and biotinylated Fab fragment.  
     This tripartite complex was optimized by titrating the biotinylated Fab fragment 
against two different concentrations of SA complexed with bio-DNA-bio The 
objective was to determine the optimal molar ratios of the different components 
to stimulate TLR9 dependent proliferation but not so large so as to stimulate 
TLR9 independent proliferation.  The tripartite complexes stimulated TLR9 
dependent proliferation independent of the AM14 BCR and were sufficient to 
interrogate pathways downstream of BCR-TLR9 in polyclonal B cell populations 
and recapitulated some aspects of PL2-3 activation of AM14 B cells, such as 
TLR9 dependent proliferation (Figure 6A).   
     Furthermore, the information gleaned from their development was used to 
develop a complex incorporating biotinylated RNA in the place of the 2-end bio 
DNA.  
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.		Figure 6. Stimulation of B cells via the BCR and TLR9 by IgM targeted complexes 
incorporating TLR9 ligands. A) AM14 (triangles) or AM14 TLR9 KO (diamonds) B cells were 
treated with a constant concentration of: open symbols, 0.5 µg/mL of DNA biotinylated at both 
ends complexed with 13 µg/mL streptavidin or closed symbols, 0.5 µg/mL DNA biotinylated at 
both ends complexed with 4.1 µg/mL streptavidin and a titration of biotinylated Fab fragment 
α-IgM. B) AM14 (triangles) or AM14 TLR9 KO (diamonds) B cells were treated with a 
decreasing concentration of Bio-1826. C) AM14 (triangles) or AM14 TLR9 KO (diamonds) B 
cells were treated with a constant concentration of bio-1826 (30 nM) premixed with decreasing 
concentrations of streptavidin. D) AM14 (triangles) or AM14 TLR9 KO (diamonds) B cells were 
treated with a constant concentration of premixed bio-1826 (30 nM) and streptavidin (316 nM) 
and a titration of F(ab’)2 α-IgM. For A, B, C and D, proliferation was quantified by 3H thymidine 
incorporation from 24 hr to 30 hr post stimulation. A, B and C representative of two 
independent experiments 
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This Bio-Fab α-IgM-Bio-RNA-Streptavidin complex was used to determine the 
roles of TLR3 and TLR7 in the responses of B cells to endogenous RNA ligands 
(106).  The one downside of these complexes was that they induced significant 
UNC93B1 independent proliferation, likely due to BCR crosslinking.  
     Despite their utility in recapitulating BCR-TLR9 responses the complexes 
were not without their drawbacks (Figure 6A). The first is readily apparent by the 
very narrow concentration ranges for both streptavidin and the biotinylated Fab 
fragment required to construct the optimal stoichiometry and simulate BCR-TLR9 
dependent proliferation (Figure 6A). The second draw back was lot-to-lot 
variation in the biotinylated Fab fragment activity, most likely due to different 
levels of biotinylation.  
 
D. Bio-F(ab’)2 α-IgM-bio DNA oligo IC  
      To form an IC with a more widely used TLR9 ligand, a different strategy was 
employed using a phosphorothioate oligonucleotide.  Rather than ICs, most 
studies utilize a phosphorothioate (PTO) oligonucleotide to stimulate B cells. The 
advantages include that the ligands are stabilized against nuclease degradation 
via the PTO linkages. The PTO oligonucleotides are widely available 
commercially and widely adopted by other laboratories (144, 145). This simplifies 
the comparison of studies. 
  As before, the parameters were the same, BCR dependent delivery of a 
TLR9 ligand leading to TLR9 dependent proliferation. The only modification from 
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the previous strategy would be the use a conventional TLR9 ligand, the PTO 
oligo 1826, biotinylated at the 5’ end and polyclonal B cell populations whose 
BCR targeted was targeted using a biotinylated F(ab’)2 α-IgM.  One concern I 
had before testing this approach was that PTO oligos can be endocytosed 
independently of the BCR and stimulate TLR9 dependent proliferation of murine 
B cells.    
 However, the molecular weight of the canonical CpG-B ODN, oligo 1826, 
is 6 kDa and the molecular weight of tetramer streptavidin is 60 kDa, we 
reasoned that the quasi-covalent complex between streptavidin and bio-1826 
would be sufficiently large to prevent BCR independent endocytosis and 
stimulation via TLR9.  To determine the optimal ratio of streptavidin to bio-1826 
to abrogate BCR independent endocytosis and stimulation via TLR9, a constant 
concentration of the biotinylated Bio-1826 was mixed with a titration of 
streptavidin in biotin free media and the complexes added to cells.   At a ½ log 
molar excess of streptavidin, the TLR9 dependent proliferation stimulated by bio-
1826 was abrogated (Figure 6B and C).  This meant that complexing the 
stimulatory oligo with streptavidin prevented sensing by TLR9 likely by inhibiting 
endocytosis.  
     TLR9 dependent proliferation was recovered via BCR dependent delivery of 
30 nM bio-1826 complexed with 316 nM streptavidin and mixed with a titration of 
biotinylated F(ab’)2 α-IgM (Figure 6D).  
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1. Limitations of Bio-F(ab’)2 α-IgM Complexes 
Despite the improvements of the bio-1826-streptavidin-bio-F(ab’)2 α-IgM 
complexes, there were three problems with these complexes that did not allow 
me to efficiently recapitulate all aspects of the AM14 response to our 
spontaneous and defined IC. 1) There is considerable lot-to-lot variability in the 
anti-IgM targeting reagents with regard to endotoxin contamination and the biotin 
density. 2) Relying on streptavidin coupling limited delivery to just biotinylated 
ligands not our spontaneous and defined IC. 3) Using Fab and F(ab’)2 anti-IgM 
targeting modalities prevented me from interrogating the role of BCR-FcγRIIB 
coengagement in attenuating the response to BCR-TLR engagement because 
these antibodies lack an Fc region.
 
E. Development of BCR Adapter IgM 
     The ideal method to delivery IC to polyclonal B cells and recapitulate the 
AM14 receptor would: 1) Become independent of commercial vendors for IgM 
targeting, 2) Permit delivery of spontaneous IC and defined IC to polyclonal B 
cells as if they were AM14 B cells and 3) Engage pathways physiologically 
relevant to B cell responses to immune complexes (e.g. FcγRIIB).  
  A molecule that could target an autoantibody to polyclonal IgM+ B cells, 
would bind both the surface of the B cell and the antibody. To achieve this goal I 
decided to create a molecule with two domains, one specific for the BCR and the 
other capable of binding IgG mAbs of any specificity.  
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The murine IgM binding Vh and Vκ pair were cloned from the rat anti-mIgM 
hybridoma, B7-6 to have a monoclonal mIgM binding domain and thus avoid 
dependence on commercial suppliers (129).  For the Fc binding domain, an 
engineered dual domain from SpA was used because it binds most murine and 
human antibodies with high affinity.  In its native state, SpA is a cell wall 
anchored pathogenic effector from Staphylococcus aureus that interferes with 
opsonization and phagocytosis by binding the Fc portion of antibodies via five 
high affinity Ig binding domains. One domain, Z, was engineered into a bivalent 
ZZ dual domain that is a high affinity IgG binding moiety commonly used as a 
part of a tandem affinity purification (TAP) tag or for affinity chromatography 
protein using IgG resin (146, 147).  Additional properties beyond IgM binding and 
Fc binding were added to the final protein to permit expansion in the future to 
other aspects of BCR-TLR coengagement: (1) an OVA peptide was incorporated 
so that targeted cells could be evaluated for antigen presentation using well 
characterized TCR transgenics; and (2) a biotin acceptor site was added to 
permit labeling with streptavidin and (3) a tobacco etch virus protease cleavage 
site so that the monobiotinylated fragment can be separated from the ZZ domain.  
The IgM and Fc binding protein was called BCR adapter IgM (BCRAM). It 
is a dual chained fusion protein with 5 functional units (Figure 7A). 1) The N 
terminus is a disulfide paired B7-6 Vh and Vk that binds murine IgM (129).  
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Figure 7. Design and Function BCR Adapter IgM. A) The Fab fragment heavy chain of rat 
anti-mIgM monoclonal B7-6 was amplified by 5’ RACE. A gene was synthesized fusing the 
heavy chain Vh-CH1 fragment to ovalbumin a.a. 230-359, biotin acceptor peptide, TEV site 
and the IgG Fc binding ZZ domain from SpA.  The light chain fragment of B7-6 was amplified 
by 5’RACE. Coexpression of the light chain, synthetic heavy chain and biotin ligase resulted in 
secreted protein that bound IgM, streptavidin and IgG. B) Primary splenic B cells from A) 
AM14 (blue circles), AM14 R2KO (red squares) or AM14 TLR7/9 KO (purple triangles) were 
stimulated with decreasing concentrations of BCRAM and a constant concentration of PL2-8. 
Proliferation was measure by 3H thymidine incorporation from 24 hr to 30 hr post stimulation. 
Data representative of n=2.     	
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2) To the C terminus of CH1, a.a. 230-359 from ovalbumin were fused 
incorporating the peptides SIINFEKL and ISQAVHAAHAEINEAGR, recognized 
by the OT-1, OT-II and DO11 TCR transgenics respectively to permit 
interrogation of antigen presentations (148). 3) To the C terminus was then fused 
the biotin ligase (BirA) acceptor peptide (BAP) to allow biotinylation when 
coexpressed with ER localized BirA (136, 149). 4) For purification of 
monobiotinylated α-IgM, a tobaccoetch virus (TEV) protease cleavage site to 
permit separation of the subsequent ZZ domain from the rest of the construct 
(150). 5) The ZZ domain was fused to the C terminus of the TEV cleavage site 
resulted in a molecule that binds murine IgM via the N terminus and most IgG 
molecules via the C terminus effectively permitting polyclonal IgM positive murine 
B cells ex vivo into IgG binding B cells (Figure 7A)  
In addition to targeting autoantibodies to IgM+ B cells, BCRAM also 
needed to stimulate TLR dependent proliferation and engage pathways 
physiologically relevant to B cell responses to immune complexes (i.e. FcγRIIB).  
A control used in previous publications to demonstrate the specificity of the AM14 
BCR for IgG2a was the IgG2b anti-chromatin antibody PL2-8 that does not 
induce AM14 proliferation as IgG2b molecules are not recognized by the AM14 
BCR (89, 100).  In the absence of BCRAM, the IgG2b antibody was unable to 
stimulate AM14 B cell proliferation. When BCRAM was titrated against a single 
concentration of PL2-8 it induced TLR7/9 dependent proliferation (Figure 7B).  
		
125
 
  
	 Figure 8. BCRAM binds murine B cells, streptavidin and hIgG1. Primary splenic B cells 
from an AM14 mouse were purified by B220 bead selection and treated with A) BCRAM 
alone, B) BCRAM and SA-AF488, C) BCRAM and hIgG1 or D) BCRAM, SA-AF488 and 
hIgG1. The cells were stained with Anti-hIgG-AF647 and binding quantified by flow cytometry. 
Data represent a single experiment.  
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Furthermore, the BCRAM/PL2-8 complex demonstrated FcγRIIB dependent 
attenuation of BCR-TLR responses.  This meant that this reagent could be used 
to interrogate the mechanisms of this attenuation in non-Tg B cells (Chapter 4).  
To demonstrate that BCRAM could permit murine B cells to bind hIgG1 and 
streptavidin, purified AM14 B cells were treated with BCRAM alone (Figure 8A), 
BCRAM with SA-AF488 (Figure 8B), and BCRAM with hIgG1 (Figure 8C) and 
BCRAM with hIgG1 and SA-AF488 (Figure 8D) and the binding quantified by flow 
cytometry.  BCRAM was able to bind streptavidin and convert AM14 B cells 
specific for IgG2a into B cells that bound hIgG1.   
 
1. Limitations of BCRAM Complexes  
     As an adapter BCRAM accomplished the goals of 1) targeting an 
autoantibody IC to non-Tg B cells, independent of BCR specificity 2) Inducing 
TLR dependent proliferation and 3) Targeting IgM independently of commercially 
available reagents.  One limitation of BCRAM was that fetal bovine sera used to 
make our B cell growth media contained protein A binding bovine IgG. 
Furthermore, the concentration of bovine IgG in FBS are orders of magnitude 
higher than the concentration of stimulatory antibody used in our assays.  This 
required the use of IgG depleted medium in our proliferation assays (151).  An 
additional limitation of BCRAM was that there were two sources of variation.   
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Although we were no longer subject to lot-to-lot variation of commercial IgM 
targeting reagents, there was still the possibility of variation in preparation of 
BCRAM and the antibodies used to stimulate B cells.  
 
F. Development of Dual Variable Domain Antibodies  
 The polyclonal B cell stimulating reagents discussed above are all dual 
specificity molecules.  One specificity is murine IgM and second is any 
biotinylated molecule via streptavidin or any protein A binding antibody.  Although 
the non-covalent interactions between streptavidin-biotin and protein A-Fc are 
both sub nanomolar Kd interactions, there is no way to ensure the identical 
complex is formed between experiments.  An alternative strategy would be to 
construct, covalently bound dual specificity molecules where one specificity 
would bind IgM and the other would bind nucleic acid.   
     Several pharmaceutical and biotechnology companies have dual specificity 
molecules in clinical trials or approved for clinical use (152, 153). AbbVie’s 
approach to dual specificity targeting was striking similar to an antibody in 
structure except that instead of one, each antibody arm has two covalently linked 
antigen recognition domains and the Fc domain is human IgG1 (Figure 9A).  The 
dual variable domain Ig  (DVD-IgTM) arms are arrayed in parallel where the 
internal domains recognize one antigen and external domains recognize another.  
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     To construct DVD-Igs that were capable of binding murine B cells and DNA or 
RNA, the B7-6 α-mIgM and PA4, anti-DNA domains were combined in a single 
molecule for DNA delivery. The B7-6 anti-IgM and BWR4 were combined in a 
single molecule for RNA delivery.  The DVD-IgTM was produced by transient 
transfection and their activity confirmed in IgM binding assays and ANAs.  The 
DNA-DVD-IgTM and RNA-DVD-IgTM were used to stimulated AM14, AM14 
TLR9KO or AM14TLR7KO. I expected that the AM14 B cells would proliferate to 
both DVD-Igs. The AM14 TLR9KO would not proliferate to the DNA-DVD-Ig and 
the AM14 TLR7KO would not proliferate to the RNA-DVD-Ig.  As expected, the 
AM14 B cells proliferated when stimulated with the DNA-DvD-IgTM and the AM14 
TLR9 KO B cells did not.  This demonstrated that the DNA-DVD-IgTM 
recapitulated the TLR9 dependent proliferation observed when AM14 B cells 
were stimulated with PA4, an anti-DNA IgG2a monoclonal antibody (Figure 9B).  
On the other hand the both the AM14 and AM14 TLR7 KO proliferated when 
stimulated with the RNA-DVD-IgTM (Figure 9C). This demonstrated that the RNA-
DvD-IgTM did not recapitulate the TLR7 dependent proliferation observed when 
AM14 B cells were stimulated with BWR4. It was previously shown that ablation 
of FcγRIIB enhanced the response to BWR4.  Furthermore, the RNA-DvD-IgTM 
has a human IgG1 constant domain. Interestingly, hIgG1 (Ka = ~2x105) has ½ the 
affinity for murine FcγRIIB as IgG2a (Ka= ~4x105) (154).  
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Figure 9. DNA-DVD-Ig stimulated TLR7/9 dependent proliferation but RNA-DVD-Ig 
stimulated TLR7 independent proliferation. A) DVD-Ig were constructed by coexpressing 
light chains and heavy chains specific for mIgM and RNA or DNA. Primary splenic B cells from 
B) AM14 (blue bar) or AM14 TLR9KO (red bar) were treated with DNA-DVD-Ig or C) AM14 
(blue bar) or AM14 TLR7KO (green bar) were treated with RNA-DVD-Ig. Proliferation was 
measure by 3H thymidine incorporation from 24 hr to 30 hr post stimulation. A) Created by A 
Marshak-Rothstein. B) Representative of n=2 and C) n=1 
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Therefore it was possible that TLR7 independent proliferation induced by RNA-
DVD-IgTM resulted from extensive BCR crosslinking in the absence of FcγRIIB 
coengagement (Figure 9C).  Perhaps, when FcγRIIB was ablated the AM14 
proliferative response to BWR4 was TLR7 independent.  
 
A. Discussion   
The development and validation of the tools presented in this chapter 
represent additional methods to interrogate mechanisms of BCR-TLR and or 
FcγR-TLR responses in B cells and macrophage. The DNA-DVD-IgTM was used 
to demonstrate that DNaseII was required for TLR9 recognition of self-DNA (80).  
The anti-SA SA DNA IC recapitulated the cell death observed following 
engagement of BCR-TLR9 spontaneous IC (i.e. PL2-3) and the proliferative 
response was TLR9 dependent (84).  
In addition, comparing the proliferative response of AM14 and AM14 
R2KO B cells to anti-SA SA DNA IC suggested that BCR-TLR9 responses were 
also attenuated by FcγRIIB engagement.  This was in contrast to previous work 
where BCR-TLR9 were not regulated by FcγRIIB engagement but BCR-TLR7 
responses were regulated by FcγRIIB (117). Comparing the proliferative 
responses of AM14 and AM14 TLR7KO B cells to RNA-DVD-Ig suggested that 
the response was partially TLR7 independent. The different targeting mechanism 
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to B cells and Fc region made a direct comparison to BWR4 difficult. 
Nonetheless, this required a more careful examination of the attenuation of BCR-
TLR responses by FcγRIIB engagement. This is the subject of chapter 4.   
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CHAPTER FOUR 
 
V. Role of FcγRIIB in the regulation of BCR/TLR-dependent responses 
to autoantibody-associated nucleic acid associated ligands.  
 
A. Introduction 
 
 In lupus and other autoimmune diseases, patients develop antibodies 
against nucleic acids or nucleic acid associated ligands.   One important negative 
regulator of humoral immune responses (i.e. antibodies) is FcγRIIB, the only 
inhibitory Fcγ receptor.  FcγRIIB attenuates antibody-mediated inflammation by 
interfering with signaling. An antigen coated with antibody is able to bind both the 
BCR and FcγRIIB, called coengagement.  Coengagement leads to 
phosphorylation of the ITIM motif of FcγRIIB and activation of SHIP-1, which 
attenuates BCR signaling by degrading PIP3 (155).  This represents a negative 
feedback mechanism where existing antigen-specific IgG attenuates the 
production of additional IgG against the same antigen.  Not surprisingly, 
hypomorphisms in FcγRIIB are known risk factors for the development of 
autoimmunity (41, 156, 157).  
 To interrogate the role of FcγRIIB in the activation of autoreactive B cells, 
the response of IgG2a-specific AM14 B cells to nucleic acid containing immune 
complexes was investigated.   AM14 FcγRIIB-/- (R2KO) mice were previously 
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generated by intercrossing C57BL/6 R2KO mice to BALB/c AM14 mice (117) and 
then B cells from these mice were activated by either spontaneous or defined IC.  
In the initial studies, IgG2a monoclonal autoantibodies PL2-3 and BWR4 were 
used as spontaneous ICs.   It was assumed that both of these autoantibodies 
bound to cell debris present in the B cell cultures and formed ICs that were then 
bound by the AM14 receptor and transported to compartments where the IC-
associated nucleic acids engaged TLR9 or TLR7.  At the time, PL2-3 was 
considered an anti-nucleosome antibody (89) that bound a TLR9 ligand, and 
BWR4 was considered an anti-RNA antibody that bound a TLR7 ligand (128).  
Defined IC was made by combining an IgG2a anti-biotin mAb with an  ~600bp 
CpG-rich dsDNA fragment, clone 11, that incorporated biotinylated bases (101, 
117). 
 AM14 and AM14 R2KO B cells were stimulated with both spontaneous 
and defined IgG2a ICs and proliferation was assessed by 3H-thymidine 
incorporation 24 hr post stimulation.  FcγRIIB and AM14 bind to IgG2a antibodies 
with comparably low affinities (49, 99), and therefore, it was expected that the 
AM14 R2KO would respond better than cells expressing this inhibitory receptor.  
Unexpectedly, PL2-3 activated AM14 and AM14 R2KO B cells responded to a 
comparable extent. Similar results were obtained with the defined anti-
biotin/biotin-clone 11 complex. By contrast, expression of FcγRIIB reduced the 
response of AM14 B cells to the BWR4 RNA containing ICs.   
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Since the RNA IC responses and DNA IC responses of AM14 B cells are 
dependent on TLR7 and TLR9 respectively, it was hypothesized that FcγRIIB 
inhibits TLR7 but not TLR9 dependent responses.  
     However, this simple interpretation was limited by certain caveats.  In the first 
place, it is difficult to compare the size and valency of spontaneous ICs and 
therefore difficult to estimate the relative extent to which PL2-3 and BWR4 
crosslink the B cell receptor.  Secondly, further characterization of the PL2-3 
response revealed that PL2-3 also binds a TLR7 ligand but the TLR7-response is 
delayed relative to the TLR9 response and is more evident after approximately 
48 hr of stimulation (84). Together these data demonstrate that the role of 
FcγRIIB in the regulation of AM14 B cell responses to IC warrants further 
investigation, including (a) analysis of additional monoclonal autoantibodies; (b) 
measurement of BCR engagement; and (c) a careful comparison of FcγRIIB+ 
WT, TLR7-/-, TLR9-/-, TLR79-/- and R2KO, WT, TLR7-/-,TLR9-/-, TLR79-/- 
AM14 B cell responses.  The results of this analysis are the topic of this chapter. 
 
B. RESULTS  
1. AM14 R2KO Responses to TLR Ligands  
     The AM14 R2KO strains were created by breeding BALB/c R2KO mice to 
homozygosity for the AM14 heavy chain and Vκ8 light chain, and then crossing 
to the corresponding TLR-deficient strains.  Keeping the AM14 BCR transgenic  
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on the BALB/c background was relevant because: (1) the BALB/c background 
limits inheritance of other potential autoimmune promoting genes; and (2) AM14 
B cells undergo receptor editing or are anergic on the C57BL/6 background or a 
mixed BALB/c x C57BL/6 background (Nundel et al., manuscript in preparation). 
To measure the B cell response to IC, B cells were purified with B220 magnetic 
beads from spleen cell suspensions obtained from AM14, AM14 TLR7/9 DKO, 
AM14 R2KO or AM14 R2KO TLR7/9 DKO.  To determine if ablation of FcγRIIB 
had any effect on TLR7 and/or TLR9-dependent responses, B cells were 
stimulated with the small molecule ligands CLO97 (TLR7 ligand) or 1826 (TLR9 
ligand), respectively.  The TLR4 ligand LPS was also included in this analysis.  
Since these ligands do not engage either the BCR or FcγRIIB, I expected AM14 
and AM14 R2KO B cells to respond comparably. Consistent with expectations, 
the proliferative responses to CLO97 and 1826 were identical between the AM14 
and AM14 R2KO B cells and abrogated in the AM14 TLR7/9 DKO and AM14 
R2KO TLR7/9 DKO B cells (Figure 10A and Figure 10B). Furthermore, 
inactivation of FcγRIIB, TLR7 or TLR9 did not impair responses to LPS (Figure 
10C).  These data demonstrated that inactivation of FcγRIIB, TLR7 and TLR9 did 
not result in off target defects that could confound the interpretation of the 
response to DNA or RNA containing immune complexes.  
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Figure 10. Ablation of FcγRIIB does not affect the response to small molecule toll Like 
receptor agonists. AM14 (black triangles), AM14 R2KO (black squares), AM14 TLR7/9 DKO 
(red triangles) and AM14 R2KO TLR7/9 DKO (red squares) B cells were stimulated with A) 
CLO97, B) 1826 and C) LPS. Proliferation of B cells to the ligands was measured by 
incorporation of [3H]-Thymidine for 6 h at 24 h after stimulation. For each treatment condition, 
the y-axis represents the percentage of the max value for each genotype.  Error bars 
represent SEM, n=3.  
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2. Role of FcγRIIB in Attenuating BCR-TLR Responses 
In lupus, autoantibodies specific for nucleic acids and nucleic acid 
associated proteins bind a diverse array of cellular structures. For example, an 
autoantibody that binds RNA or an autoantibody that targets ribonucleoproteins 
both represent RNA ICs. Analogously, an autoantibody that binds DNA or an 
autoantibody that binds nucleosomes-dsDNA, both represent DNA IC. Due to the 
diversity in autoantibody targets, I tested the B cell proliferation response to a 
panel of autoantibodies to examine the role of FcγRIIB in attenuating BCR-TLR 
responses. The DNA ICs were represented by PL2-3, which binds nucleosomes-
dsDNA and PA4 that binds dsDNA (89, 126). The RNA ICs were represented by 
BWR4, which binds RNA (128) and HA310.2, which binds nucleoli (kindly 
provided by Dr. S. Bolland).  
 B cells were purified with B220 magnetic beads from splenic cell 
suspensions obtained from AM14, AM14 TLR7/9 DKO, AM14 R2KO or AM14 
R2KO TLR7/9 DKO and stimulated with PL2-3, PA4, BWR4, or HA310.2.  Based 
on previous studies demonstrating that the activation of AM14 B cells by RNA or 
DNA IC was TLR dependent, I expected that AM14 and AM14 FcγRIIB B cells to 
respond to these spontaneous ICs, and AM14 TLR7/9KO and AM14 TLR7/9KO 
R2KO B cells not to respond to these ICs (100, 104).  Since previous results 
demonstrated that the TLR7-dependent BWR4 proliferative response was 
significantly enhanced by FcγRIIB ablation and the TLR9-dependent PL2-3 
response was unaffected, I expected the proliferative response to HA310.2 to be  
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significantly enhanced and the proliferative response to PA4 to be unaffected by 
FcγRIIB ablation.   
 As previously demonstrated, the proliferative responses to PL2-3 were 
unaffected by FcγRIIB ablation, and completely dependent on TLR expression, 
even in the absence of FcγRIIB expression (Figure 11A and B).  Although the 
proliferation response to PA4 was similarly completely dependent on TLR 
expression, even in the absence of FcγRIIB expression, I unexpectedly found 
that FcγRIIB ablation enhanced the response to the DNA IC, PA4 (Figure 11C 
and D).  These results demonstrate that a TLR9-dependent response can be 
regulated by the inhibitory receptor.   
The outcome of the RNA IC responses further diverged from the expected 
result.  Consistent with previous results, BWR4 and HA310.2 responses were 
enhanced by FcγRIIB-deficiency (Figures 11E and G).  However, in the absence 
of FcγRIIB, the responses to BWR4 and HA310.2 were completely unaffected by 
the loss of TLR7 (Figure 11F and H).  These data suggested that BWR4 and 
HA310.2 crosslinked the BCR sufficiently well to drive a proliferative response 
that was TLR7 independent under conditions where the BCR signal was not 
attenuated by FcγRIIB, or that an additional RNA sensing TLR is involved (106).  
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Figure 11. Enhancement of RNA IC responses by FcγRIIB ablation is independent of 
TLR7 and TLR9.  AM14 and AM14 R2KO (A, C, E and G) or AM14 TLR7/9 DKO and AM14 
R2KO TLR7/9 DKO (B, D, F and H) B cells were stimulated with increasing amounts of PL2-3 
(A and B), PA4 (C and D), BWR4 (E and F) and HA310.2 (G and H). The response of B cells 
to the ligands was measured by incorporation of [3H]-Thymidine between 24 to 30 hrs of after 
initial stimulation. R2KO shown as squares; wild-type shown as triangles.  Error bars 
represent SEM; the average of n=3 is shown, except G and H where n=2.  
		
140
 
3. Binding of Spontaneous IC to AM14 B cells  
     Taken together these data suggest that enhancement of BCR-TLR responses 
by FcγRIIB ablation is not dependent on the nucleic acid content of the IC but 
rather on other IC properties. Since the AM14 receptor and FcγRIIB bind the 
same ligand, an IC that engages FcγRIIB (i.e. whose proliferation is significantly 
enhanced by FcγRIIB ablation) would engage the BCR similarly well. The AM14 
BCR and FcγRIIB are low affinity receptors for IgG2a (49, 99).  The low affinity of 
the AM14 receptor (Kd~2.5x10-6) and FcγRIIB (Kd~2.39x10-6) are overcome by 
the multivalency of ICs. If the TLR7 independence of RNA IC stimulated 
proliferation in the context of FcγRIIB ablation resulted from increased BCR 
engagement, then it follows that RNA IC should be able to bind the BCR better 
than DNA IC. I hypothesized that RNA IC would bind better than DNA IC to 
AM14 B cells due to enhanced avidity of the AM14 BCR for RNA IC. 
     The affinity between an antibody and antigen describes the strength of the 1 
to 1 molar interaction between one arm of the antibody and a single epitope.  By 
contrast, avidity describes strength of the interaction between multiple antibody 
arms and epitopes in a macromolecular complex.  The strength of a high avidity 
interaction is not simply the sum of the 1 to 1 interactions but rather involves a 
relationship between size, shape and valency in addition to the affinity of the 1 to 
1 interactions.  Valency can vary as a function of antigen size and or affinity of 
the antibody. For example, a high affinity antibody could form larger complexes 
because it would crosslink antigen more efficiently. A larger antigen with many 
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epitopes could have a higher valency because the surface area would 
accommodate more antibody binding.  Therefore, avidity is the result of the 
complex interaction between size, valency and affinity that affects receptor-ligand 
binding.  It was demonstrated that an IC formed between a 570 bp biotinylated 
DNA fragment and anti-biotin antibody bound better to AM14 B cells at higher 
levels of DNA fragment biotinylation (101). However at over 30 biotins per 570 bp 
DNA fragment, no increased enhancement in IC binding to AM14 B cells was 
seen. This could have been due to close proximity of additional biotin molecules 
to others (closer than 6 nm) preventing optimal binding of both antibody arms 
and thus limiting the ability of antibody to bind additional biotin (101).  
     To determine if RNA IC and DNA IC differ as far as their capacity to bind the 
AM14 receptor as a measure of relative avidity, I compared the ability of the DNA 
IC PA4, PL23 and the RNA ICs BWR4 and HA310.2 to bind to AM14 and AM14 
R2 KO B cells by flow cytometry.  The expected results for the binding data were 
based on the premise that enhanced BCR engagement and proliferation would 
result in more binding to B cells. Based on the TLR7/9 independent proliferative 
response of the AM14 R2KO B cells, I expected the RNA IC to bind better to 
AM14 B cells than the DNA IC.  Since PA4 but not PL2-3 stimulated proliferation 
was enhanced by FcγRIIB ablation, I also expected that PA4 would bind better to 
AM14 B cells than PL2-3.  AM14 is a low affinity receptor, and FcγRIIB 
represents an additional receptor for IC on AM14 B cells.  I expected this 
additional receptor would enhance binding of all four IC to AM14 B cells.  
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     As expected, the RNA ICs BWR4 and HA310.2 bound better to AM14 B cells 
or AM14 R2KO B cells than the DNA ICs, PL2-3 and PA4 (Figure 12). However, 
PL2-3 bound significantly better than PA4 to AM14 B cells. In all cases, FcγRIIB 
expression did not significantly enhance binding. The minimal FcγRIIB enhanced 
binding could be due to the performance of the experiment on ice.  
These data demonstrated that AM14 B cells bound RNA IC more avidly than 
DNA IC.  This difference could depend on many factors of the IC, such as size, 
valency, or frequency of the autoantigen in cultures. Perhaps, RNA IC crosslinks 
the AM14 receptor more effectively than DNA IC because of the density of the 
antibody in the IC complex.  The spontaneous ICs were formed from debris in B 
cell cultures and antibodies added to the culture or are preformed by 
copurification with antigen from hybridoma cell cultures.  Perhaps, RNA IC bound 
better to AM14 B cells than DNA IC because there were more complexes. This 
could also account for why PA4 bound worse than PL2-3 to AM14 B cells.  
Perhaps there was less debris for PA4 to bind than PL2-3 in AM14 B cell cultures 
or PL2-3 was copurified with antigen. 
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Figure 12. RNA IC bind better than DNA IC to AM14 B cells. A) AM14 or AM14 R2KO B 
cells were incubated with increasing amounts of BWR4 (blue line), HA310.2 (light blue), PL2-3 
(red line), or PA4 (green line) on ice for 1 hr in RPMI complete media.The gray tinted 
histogram represents cells that were not treated with antibody.  After incubation, the cells were 
washed 3x with ice cold FACS buffer.  Bound immune complex was detected by staining for 
IgG2a and detected by flow cytometry. B) Geometric mean fluorescent intensities for each 
sample were calculated using FlowJo.    Data is representative of two independent 
experiments. 
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 Further understanding of the differences between these IC will help elucidate the 
specific properties of IC that affect the B cell response. 
  
4. Induction of Calcium Flux by Spontaneous IC  
     Binding assays were an effective means to assess the initial interaction 
between the BCR, FcγRIIB and IC under static conditions.  However, the binding 
assays were performed on ice, which does not interrogate the dynamic 
processes of BCR crosslinking such as receptor clustering and signal 
transduction.  Ca++ flux is a dynamic measure of BCR engagement that is known 
to be inhibited by coengagement of BCR-FcγRIIB.  Changes in intracellular 
concentrations of Ca++ were measured by labeling AM14 and AM14 R2KO B 
cells with indo-1-AM. The fluorescent emission wavelength for indo-1-AM shifts 
when the dye binds Ca++.  A ratio of Ca++ bound to unbound indo-1-AM 
fluorescence is a relative measure of intracellular Ca++.  The intracellular Ca++ 
concentrations of labeled AM14 or AM14 R2KO B cells were measured for 1 min 
at 37°C, then the stimuli were added, and Ca++ efflux was monitored over a 5 
minute period at 37°C.  ICs are formed when an antibody binds its antigen. An 
IgG2a antibody without an antigen to bind would be monomeric in solution.  In 
response to monomeric IgG2a, neither the AM14 WT nor AM14 R2KO B cells 
induced Ca++ flux (Figure 13A).   
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Figure 13. Ca++ flux response to IgG2a and F(ab)’2 is similar between AM14 R2KO and 
AM14 WT. AM14 (solid line) or AM14 R2KO (dotted line) B cells were loaded with Indo-1-AM, 
and intracellular flux of Ca++ was monitored by flow cytometry at 37°C. After 60 sec, 1E11.1 
(A) or F(ab)’2 α-IgM (B) was added and intracellular Ca++ monitored for an additional 300 sec 
at 37°C. Data are representative of two independent experiments. 	
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This observation was consistent with the low affinity AM14 requiring an immune 
complex to crosslink the receptor.  To determine if AM14 R2KO B cells were 
hyperesponsive to BCR crosslinking, AM14 and AM14 R2KO B cells were 
stimulated with F(ab’)2 α-IgM, a commercial ligand known to crosslink the BCR 
but not engage FcγRIIB because the Fc portion of a F(ab’)2 has been removed 
by pepsin digestion. Stimulation with F(ab’)2 α-IgM led to comparable Ca++ flux in 
the AM14 WT and AM14 R2KO. This suggests that there was likely no 
dysregulation of Ca++ flux due to loss of FcγRIIB (Figure 13B).  
     Stimulation of cell proliferation by BWR4 and PA4 was enhanced by FcγRIIB 
ablation (Figure 11D and F). Therefore, I expected the BWR4 and PA4-induced 
Ca++ flux to be similarly enhanced by FcγRIIB ablation.  On the other hand, I 
expected the PL2-3 induced Ca++ flux to be unaffected by FcγRIIB ablation. 
Consistent with the proliferation assays, PA4 elicited a stronger Ca++ flux in the 
FcγRIIB insufficient cells than B cells with FcγRIIB, and PL2-3 showed no 
significant difference with or without FcγRIIB.  An explanation to account for 
these differences was not apparent based on the binding data. In response to 
BWR4, the Ca++ flux was significantly enhanced by ablation of FcγRIIB (Figure 
14A).  This was consistent with the proliferation data where ablation enhanced 
proliferation and the binding data where BWR4 bound well to the AM14 receptor.   
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Figure 14. Ca++ flux to BWR4 and PA4 but not PL2-3 was inhibited by FcγRIIB 
engagement. AM14 (solid line) or AM14 R2KO (dotted line) B cells were loaded with Indo-1-
AM and intracellular concentrations of Ca++ were monitored by flow cytometry for 60 sec at 
37°C. After 60 sec, A) BWR4 (3 µg/mL), B) PA4 (0.3 µg/mL) or C) PL2-3 (1 µg/mL) was added 
and intracellular Ca++ monitored for 240 sec at 37 °C. Data are representative of three 
independent experiments. 
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     In response to PA4, the Ca++ flux was also significantly enhanced by ablation 
of FcγRIIB, which was consistent with the proliferation data where ablation 
enhanced the proliferation (Figure 14B). Consistent with the correlation between 
proliferation and Ca++ flux, there was no difference between AM14 and AM14 
FcγRIIB KO B cells stimulated with PL2-3 (Figure 14C).  Together these data 
suggested that the attenuation of BCR-TLR responses by BCR-FcγRIIB 
engagement is not affected by the kind of nucleic acid in the complex – both 
BWR4 and PA4 responses appeared to be comparably regulated by FcγRIIB 
engagement. However the lack of regulation by FcγRIIB of the B cell response to 
PL2-3 responses remains unclear.  
 
5. Role of Antibody Isotype in BCR-TLR Response Attenuation by  
             FcγRIIB 
     Two possible explanations for why PL2-3 (α-nucleosome) differed from PA4 
(α-DNA) were the antibody specificity (interaction with the antigen) or changes in 
the FcγRIIB binding site within the Fc domain of the antibody (interaction with the 
cell).  One way to begin to address these possibilities would be to use antibodies 
specific for nucleosomes with different isotypes. In lupus prone mice, the 
autoantibodies specific for nucleic acids or nucleic acid associated proteins are 
primarily of the IgG2a and IgG2b isotypes (89, 90, 127). The Fc receptor effector 
functions of antibody isotypes were found to be regulated by the strength of their 
		
149
 
interaction with activating receptors versus the inhibitory receptors or the ratio of 
activating to inhibitory receptor binding. For example, IgG2a is more 
inflammatory than IgG2b because it binds FcγRIIB with lower affinity (49). The 
AM14 receptor recognizes IgG2a and therefore does not bind IgG2b.  This 
property was clearly demonstrated by comparing the proliferative response of 
AM14 B cell to PL2-3 (IgG2a) and the clonally related hybridoma PL2-8 (IgG2b). 
Both antibodies have been reported to bind to nucleosomes (89). AM14 B cells 
do not proliferate in response to PL2-8 (100).  Since PL2-8 and PL2-3 are 
clonally related and purportedly bind similar target autoantigen, there is minimal 
variation in the Vh domain relative to a non-clonally related antibody.  Therefore, 
a comparison of PL2-8 and PL2-3 is able to distinguish the role of specificity from 
Fc region binding by FcγRIIB.  If FcγRIIB dependent attenuation of BCR-TLR 
responses was related in some way to antibody specificity, then similar to PL2-3, 
PL2-8 would be unaffected by FcγRIIB engagement. 
     However, since the AM14 receptor does not recognize IgG2b, a method was 
required to deliver both IgG2a and IgG2b to non-Tg B cells. One way to deliver 
autoantigens to non-Tg B cells would be to use an adaptor that binds both the 
IgM on the B cell surface and autoantibody/autoantigen IC. The adaptor BCRAM 
binds murine IgM and most IgG isotypes (see Chapter 3).  BCRAM-bound PL2-8 
and BCRAM-bound PL2-3 were used to stimulate BALB/c WT or BALB/c R2KO 
B cells. Murine IgG2a and murine IgG2b have similar affinity for protein A 
because they were eluted at similar pH or chaotrope concentration (158, 159).  
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     The response to BCRAM/PL2-3 was comparable in WT and R2KO B cells, 
similar to the PL2-3 response of WT and R2KO AM14 B cells (Figure 15A).  
Unlike BCRAM/PL2-3, the proliferative response to BCRAM/PL2-8 was 
attenuated by FcγRIIB engagement (Figure 15B). These data demonstrate that 
ICs that incorporate nucleosomes can be regulated by FcγRIIB and suggest that 
something specific to the PL2-3 monoclonal antibody as far as its apparent 
failure to engage FcγRIIB.  Interestingly, BCRAM/PL2-3 was more stimulatory 
than BCRAM/PL2-8 independent of FcγRIIB engagement. It was previously 
demonstrated that PL2-3 had a higher avidity for nucleosomes than PL2-8, which 
may explain the difference (89).  These results led me to consider the possibility 
that unique changes in either the germ line MRL mouse strain IgG2a constant 
domain or PL2-3 IgG2a constant region domains might preclude binding to 
FcγRIIB.  
 
6. Role of the PL2-3 Fc Domains in FcgRIIB Interactions 
     Inbred laboratory strains have IgG2a Fc polymorphisms that result in 
serologically distinct allotypes. In general, allotypic differences are not thought to  
have an effect on FcγR associated functions.  However, PL2-3 and PA4 were 
generated from different mouse strains.  PL2-3 was isolated from the spleen of 
an MRL/+ while PA4 was isolated from an A.SW mouse with drug induced 
autoimmunity (89, 126). I hypothesized that MRL lines have a mutation in their 
constant domain that abrogates FcγRIIB binding.   
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Figure 15. Isotype dependent inhibition by FcγRIIB engagement in non-Tg B cells. 
BALB/c (triangles) or BALB/c R2KO (squares) B cells were stimulated with increasing 
concentrations of BCRAM along with PL2-3 (A) or PL2-8 (B). Proliferation of B cells to the 
ligands was measured by incorporation of [3H]-Thymidine between 24 to 30hrs after initial 
stimulation.  Error bars represent SEM of three independent experiments, n=3.  
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The IgG2a (Igh-1) constant domain sequences of these strains have not been 
published and therefore one possible explanation for my data was that that MRL 
lines have a mutation in their constant domain that abrogates FcγRIIB binding.  
The residues responsible for the interaction between the Fc region of antibodies 
and Fc receptors have been mapped (160).  Interestingly, the residues in the Fc 
region required for FcγR interaction are highly conserved between rodents, non-
human primates and humans (161).   The 297N residue within the constant 
domain was found to be crucial for Fc receptor binding for human IgG1 and 
murine IgG2a (49, 160). The 297N is the glycosylated residue within a conserved 
sequon.  Antibody glycosylation at 297N maintains the quaternary structure of 
the Fc portion of antibody that is essential for FcγR binding. In addition, residues 
234L and 235L were also found to be essential for IgG2a binding to Fc receptors, 
as murine IgG2a binding to Fc receptors was abrogated by Fc mutations 
L234A/L235A or N297A (162).  The sequence determinants for human IgG1 
binding to Fc receptors have been studied extensively (160, 161).   Scanning 
mutagenesis of the human IgG1 Fc region identified residues that modified the 
binding to some receptors but not others.  
     To determine if PL2-3 and other MRL-derived antibodies had an Fc mutation, 
additional hybridoma lines were collected to compare to PL2-3.  The Fc regions 
were sequenced for PL2-3, PL9-9, PL9-3, and 1E11.1.  The anti-chromatin 
IgG2a antibodies PL2-3, PL9-9 and PL9-3 antibodies were isolated from the 
fusion of MRL /+ spleens (89, 127). The IgG2a antibody 1E11.1 was isolated  
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from the fusion of BALB/c (Igh-1a) B cells. RNA was isolated from these 
hybridomas and cDNA was synthesized using a poly A primer.  Using the cDNA 
as template, the full length hybridoma heavy chains were amplified using a Vh 
specific primer and a 3’ CH3 primer. A Vh specific primer ensured that that 
amplified heavy chain was the same as the translated antibody and not an 
aberrant transcript.  I expected PL2-3, PL9-3, and PL9-9 to have Fc region 
mutations that abrogate binding to FcγR because they were derived from the 
same autoimmune prone strain, MRL, as PL2-3.  On the other hand, I expected 
1E11.1 to have an unmutated Fc region because it was derived from a 
nonautoimmune-prone BALB/c mouse.  
     The sequencing results demonstrated that PL2-3 but not PL9-3, PL9-9 or 
1E11.1 had a single nucleotide transition mutation in the CH2 domain.  The 
mutation was a G to A transition at position 2 of serine codon AGT resulting in an 
asparagine codon AAT (Figure 16).  This mutation occurred in the critical Fc 
binding motif  “NST” spanning amino acid 297 to 299 that is conserved within all 
isotypes of mouse IgG.  Furthermore, the DNA sequence for the NST motif was 
also conserved between murine IgG2a and IgG2b (163). Interestingly, the hIgG1 
DNA sequence is identical except that the serine codon is AGC instead of AGT. 
Despite this codon usage difference, a G to A transition at position 2 in the 
human sequence would also result in an asparagine codon, AAC.  
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Figure 16. PL2-3 but not PL9-3, PL9-9 or 1E11.1 has a mutation in a highly 
conserved region. Total RNA was isolated from the MRL/+ IgG2a anti-nucleosome 
hybridomas, PL23, PL9-3 and PL9-9 and the BALB/cJ IgG2a anti-streptavidin 1E11.1. 
cDNA was synthesized from the RNA using a Oligod(T) primer. The IgG2a heavy 
chains were amplified from the cDNA template by PCR using a 3’ CH3 primer, the 
appropriate Vh specific primer.  PCR products were purified and submitted for Sanger 
DNA sequencing by Genewiz. DNA Sequences were aligned against BALB/c IgG2a, 
BALB/cJ IgG2b and hIgG1 or translated and aligned.  	
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      Interestingly, most targeted mutations in the NST motif abrogated binding of 
hIgG1 to all FcγR not just FcγRIIB. The NST motif represents a sequon for N 
linked glycosylation and mutation of N297A was known to abrogate both 
glycosylation and FcγRIIB binding for mouse IgG2a and human IgG1 (160, 162).  
In human IgG1, the S298N mutation was induced and found to abrogate binding 
to hFcγRIIB, hFcγRIIA and hFcγRIIIC by surface plasmon resonance but did not 
affect glycosylation (160). 
  
7. Comparison of Anti-Nucleosome Antibodies  
     Although previous studies demonstrated that the S298N mutation of hIgG1 
abrogated FcγR binding, they may not be predictive of the function of the S298N 
mutation in mouse IgG2a (160). The other anti-chromatin antibodies PL9-3 and 
PL9-9 are murine IgG2a antibodies and do not harbor the S298N mutation.  If the 
lack of attenuation by FcγRIIB resulted from specificity then PL9-3 and PL9-9 
should not be attenuated by FcγRIIB engagement in proliferation and Ca++ 
assays.  On the other hand, if it was the IgG2a Fc region that regulated FcγRIIB 
mediated inhibition then PL9-9 and PL9-3 but not PL2-3 should be attenuated by 
FcγRIIB engagement.  
     AM14 and AM14 R2KO B cells were purified by B220 magnetic bead positive 
selection and stimulated with PL2-3, PL9-3 or PL9-9.  Using proliferation as a 
metric, I observed that PL9-9 engaged FcγRIIB because the proliferative 
response was enhanced in the AM14 R2KO (Figure 17).  Conversely, PL9-3 did 
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not appear to engage FcγRIIB by proliferation. Furthermore, it stimulated 
significantly less proliferation than PL2-3 or PL9-9 and never achieved a plateau 
within the optimal antibody concentration range for PL2-3 or PL9-9.  This was 
possibly a result of PL9-3 displaying a lower avidity than either PL9-9 or PL2-3 
for nucleosomes (89).  Perhaps at orders of magnitude higher concentrations of 
PL9-3, there would be higher levels of proliferation and FcγRIIB dependent 
attenuation of the proliferative response.  
     The divergent effect of FcγRIIB engagement on PL2-3 versus PL9-9 
stimulated proliferation suggested that the S298N mutation in the PL2-3 Fc 
region resulted in reduced FcγRIIB dependent attenuation of the response.  On 
the other hand, proliferation was measured over a 30 hr time period and is 
indicative of both BCR and TLR stimulation. Ca++ flux is a dynamic measure of 
BCR crosslinking and demonstrated FcγRIIB dependent attenuation.  Thus, it is a 
proximal measure of FcγRIIB engagement.  Based on the proliferation data, I 
expected PL9-9 stimulated Ca++ flux would be attenuated by FcγRIIB 
engagement and PL2-3 would not be inhibited. I expected the magnitude of Ca++ 
on AM14 FcγRIIB KO would be similar for PL2-3 and PL9-9.  Furthermore, PL9-3 
would stimulate reduced Ca++ flux relative to PL2-3 and PL9-9, similar to the 
reduced proliferation described above. Despite comparable proliferative 
responses as determined by the maximum proliferative value reached (Figure 8), 
PL2-3 and PL9-9 gave dramatically different magnitudes and kinetics of Ca++ 
flux. 
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Figure 17. Proliferation to PL9-9 but not PL9-3 or PL2-3 was inhibited by FcγRIIB 
engagement.  AM14 (circles) or AM14 R2KO (squares) B cells were stimulated with 
increasing concentrations of PL2-3 (A), PL9-3 (B) and PL9-3 (C). Proliferation of B 
cells to the ligands was measured by incorporation of [3H]-Thymidine for 6 h at 24 h 
after stimulation. Data are representative of two independent experiments. 	
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PL2-3 stimulated rapid Ca++ that was consistent with the kinetics for BWR4 and 
PA4.  On the other hand, PL9-9 stimulated Ca++ flux with delayed kinetics that 
started at 5 min but did not reach the same magnitude as PL2-3 during the time 
course (Figure 9).  In light of the reduced PL9-3 stimulated proliferation it was not 
surprising that PL9-3 stimulation resulted in little to no Ca++ flux. The decreased 
kinetics and magnitude of Ca++ flux made it difficult to compare the FcγRIIB 
dependent attenuation of BCR crosslinking by PL9-9 versus PL9-3.  
     According to the proliferation data and previous publications, PL9-9 and PL2-
3 were both IgG2a antibodies specific for nucleosomes by ANA staining and 
ELISA (89, 127). More succinctly stated, PL9-9 and PL2-3 had similar 
specificities but differed at amino acid 298.  The proliferation data and 
sequencing data were consistent with this statement because PL9-9 but not PL2-
3 stimulated proliferation was attenuated by FcγRIIB engagement.  The Ca++ flux 
data clearly demonstrated that PL9-9 and PL2-3 were not equivalent and there 
existed additional differences in IC formed with these antibodies in addition to the 
S298N mutation. Comparing the proliferative responses between the IgG2a anti-
nucleosome antibodies, there was a clear difference between PL9-3 and the 
other antibodies. The reduced proliferative response to PL9-3 was likely the 
result of reduced affinity relative to the other antibodies. As PL9-3 and PL9-9 
came from the same fusion, their comparative affinity was assessed by ELISA 
using plate bound nucleosome DNA complexes. It was found that PL9-9 was of 
significantly higher affinity (127). The relative affinity of PL9-9 and PL2-3 was not 
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known because they were never directly compared.  Therefore it was possible 
that, PL9-9 had a lower affinity than PL2-3. Alternatively, there might be less 
antigen bound by PL9-9 than PL2-3 in primary B cell cultures.  
     IgG2a autoantibodies can be used to stimulate AM14 B cells to proliferate by 
forming ICs with antigen in the B cell culture or by using preformed by virtue of 
copurification of antibody and antigen. In the context of AM14 B cells with these 
antibodies in culture, Ca++ flux is also a measure of the rate of IC formation. 
Broadly, the equation for IC formation would be [Ab] + [Ag] → [Ab•Ag].  The rate 
of forward reaction would be retarded by reduced concentration of the reactants. 
As the concentration of PL9-9 and PL2-3 were the same, perhaps the 
concentration of [Ag] for PL9-9 was lower in AM14 B culture than [Ag] for PL2-3. 
This would result in retarded kinetics of IC formation and therefore Ca++ flux.  
 To assess IC formation in the context of primary B cell cultures, PL2-3 and 
PL9-9 were compared for their ability to bind debris in BALB/c B cell cultures.  
Splenic B cells were purified by magnetic bead B220 selection and plated onto 
gelatin coated coverslips. The cells were stimulated with 1826 for 24 hr.  After 24 
hr, the cells were fixed with 4% PFA in PBS and stained with PL2-3 or PL9-9.  As 
the cells were not permeabilized, only [Ag] that was antibody accessible (i.e. 
outside the cell membrane or released from dead cells) would be detected.  The 
expected result was that the [Ag] for PL9-9 would be less abundant than the [Ag] 
for PL2-3.   
 
		
160
 
  
 
 
 
Figure 18. PL2-3, PL9-9 and PL2-3 stimulated different kinetics and magnitude of Ca++ 
flux. AM14 (A) or AM14 R2KO (B) B cells were loaded with Indo-1-AM, and intracellular flux of 
Ca++ was monitored by flow cytometry for 1 min at 37°C. After 1 min, PL2-3 (black line), PL9-
3 (grey dotted line) or PL9-3 (grey dashed line) was added and intracellular Ca++ monitored for 
an additional 4 min at 37° C. Data are representative of two independent experiments. 
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The confocal microscopy images showed that PL9-9 bound to less debris in B 
cell cultures than PL2-3 (Figure 19).  Furthermore, PL2-3 bound debris that was 
largely devoid of membrane staining.  Furthermore, the PL2-3 bound debris 
largely colocalized with DNA.  The B cells were not permeabilized so the staining 
pattern resembled more of what would be available for binding in an 
autoantibody stimulated B cell culture. In light of IC induced Ca++ by PL2-3 and 
PL9-9, these data suggested that the reduced Ca++ flux induced by PL9-9 
relative to PL2-3 was due to the reduced abundance of [Ag] to form an IC with 
PL9-9.   
The B cell staining for PL2-3 and PL9-9 suggested that retarded Ca++ flux 
stimulated by PL9-9 was due to reduced [Ag] abundance.  In addition to 
illuminating a possible mechanism for retarded Ca++ between two antibodies with 
identical specificity by ANA, these data suggested a more nuanced approach to 
autoantibody specificity.  In that spirit, these data should be taken with the caveat 
that the autoantibody target [Ag] in vivo may not be from a B cell or hepatocyte 
(i.e. ANA stain) and so antigen distribution and availability may differ from what 
was seen here.  
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Figure 19. PL2-3 Binding Antigens are more abundant than PL9-9 in primary B cell cultures. Balb/c B cells were 
treated with 1826 (1 ug/mL) for 24 hr. The cells were fixed with 4% PFA and stained with DAPI (Red), MHC-II (Blue), and 
A)PL2-3 or B)PL9-9. Binding of murine IgG2a antibodies was detected by AF488-protein A (Green). Images represent data 
from a single experiment.  	
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8. Role of Fc Domain Mutation in FcγRIIB Mediated Inhibition  
     Comparing the different anti-nucleosome antibodies by Ca++ and B cell 
staining it was apparent that despite being IgG2a anti-nucleosome antibodies, 
PL9-9 and PL2-3 were not equivalent. To assess the role of the 298S mutation in 
abrogating PL2-3 regulation by FcγRIIB, PL2-3 capable of engaging FcγRIIB was 
constructed by fusing the PL2-3 variable domains with a standard BALB/c 
derived heavy chain constant domain that lacked the 298N mutation (kind gift of 
C.H. Choi, AbbVie Pharmaceuticals). Therefore, PL2-3298S and PL2-3298S have 
identical constant domain sequences except for position 298. This FcγRIIB 
engaging form of PL2-3 is henceforth referred to as PL2-3298S.  The proliferative 
response elicited by PL2-3298N is TLR and has both TLR7- and TLR9-associated 
autoantigen components (84). When TLR7 was inactivated, the proliferative 
response to PL2-3 was TLR9 dependent.  When TLR9 was inactivated, the 
proliferative response to PL2-3 was TLR7 dependent.  PL2-3 represents a 
means to dissect the role of FcγRIIB in regulating TLR9 dependent responses 
simply by using the PL2-3298S revertant.  
     To assess the role of FcγRIIB in regulating TLR9 dependent AM14 
proliferation, AM14, AM14 TLR7 KO, AM14 TLR7 KO R2KO, AM14 TLR7/9 
DKO, and  AM14 TLR7/9 DKO R2KO were treated with PL2-3298N and PL2-3298S 
for 24 hr.  To quantify proliferation, the stimulated cells were pulsed from 24 hr to 
30 hr post stimulation with 3H-thymidine. Due to the conservation of the NST 
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motif, I expected that the PL2-3298S stimulated proliferation but not PL2-3298N 
would be regulated by FcγRIIB and I expected the proliferative response to be 
completely TLR7/9 dependent.  
   As expected, the TLR9 (AM14 TLR7KO vs AM14 TLR7KO R2KO) dependent 
proliferative response to PL2-3298N was only modestly enhanced by R2KO while 
the proliferative response to PL2-3298S was significantly enhanced by R2KO 
(Figure 20A and B). In addition, the proliferative responses were completely TLR 
dependent for both PL2-3298S and PL2-3298N.  These data demonstrate that the 
N298S substitution in the conserved residue of the Fc region of PL2-3 affects the 
ability of FcγRIIB to attenuate the B cell response to IC.  The data with the IgG2a 
PL2-3 were confirmed with PL2-3 DVD that had a hIgG1 Fc region. It is important 
to highlight that hIgG1 has approximately ½ the affinity for mFcγRIIB as IgG2a 
(154).  Nonetheless, the TLR9 dependent response to PL2-3 DVD was enhanced 
by FcγRIIB ablation (Figure 20C).  On the other hand, there was someTLR7/9 
independent proliferation elicited by PL2-3 DVD.  This could have been the result 
of a different mechanism of delivery. The PL2-3 DVD relied on a high affinity arm 
specific for mIgM to bind B cells.  By contrast, an IgG2a antibody binding to 
AM14 relied on the low affinity of AM14 for IgG2aa/j. 
    In addition to proliferation, an additional measure of FcγRIIB attenuation of 
BCR dependent response was Ca++. I previously demonstrated that the Ca++ flux 
stimulated by PL2-3298N was unaffected by engagement of FcγRIIB.   
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Figure 20. Amino acid substitution N298S restores inhibition by FcγRIIB. 
The effect FcγRIIB on the response to 298N and 298S PL2-3 was measured using AM14 
TLR7KO (Blue triangles), AM14 TLR7KO R2KO (Blue squares), AM14 TLR7/9DKO (Red 
triangles) and AM14 TLR7/9 DKO R2KO (Red squares) B cells were stimulated with 
increasing concentrations of A) PL2-3 298N, B) PL2-3 298N or C) PL2-3 DVD Proliferation 
was measured by incorporation of [3H]-Thymidine for 6 hr at 24 hr after stimulation. Data 
shown is representative of three independent experiments. Error bars represent standard error 
of the mean.  
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To assess the role of the 298N mutation in abrogating FcγRIIB engagement, I 
compared Ca++ stimulated by PL2-3298S and PL2-3298N.  AM14 TLR7/9DKO or 
AM14 TLR7/9DKO R2KO B cells were labeled with indo-1-AM to monitor 
intracellular concentrations by flow cytometry. I expected that Ca++ stimulated by 
PL2-3298S would be attenuated by FcγRIIB engagement whereas PL2-3298N would 
be unaffected.  
     As expected, the Ca++ flux stimulated by PL2-3298S was attenuated by FcγRIIB 
engagement.  In agreement with previous data, the Ca++ flux stimulated by PL2-
3298N was minimally affected by FcγRIIB engagement (Figure 21A). The 
proliferation and Ca++ data demonstrated that 298N mutation in the IgG2a PL2-3 
Fc region significantly diminished FcγRIIB engagement. These demonstrated that 
inhibition of BCR-TLR responses by FcγRIIB was dependent on engagement of 
FcγRIIB not the nucleic acid content of the IC.    
 
9. Role of Fc Domain Mutation in FcγRIIIA Binding   
 The S298N mutation of hIgG1 abrogated binding to activating FcγRIIB, 
FcγRIIIA and FcγRIIA (160). In previous studies, PL2-3 activated bone marrow 
derived dendritic cells via engagement of FcγRIIIA (CD16) (52). This suggested 
that PL2-3 was still able to engage activating FcγRs.   This was paradoxical 
because the NST motif is highly conserved yet had divergent effects on 
activating receptor engagement in murine and human cells (i.e. no FcγR 
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engagement).    To determine if the S298N mutation also affected binding to 
murine activating FcγR, I compared the binding of PL2-3298N and PL2-3298S to 
C57BL/6 R2KO bone marrow derived macrophages.  
     R2KO BMDMs were incubated with an increasing concentrations of PL2-3298N 
or PL2-3298S for 1 hr on ice, and the role of CD16 (FcγRIIIA) was interrogated by 
the presence or absence of 2.4G2, a blocking antibody for CD16 and FcγRIIB. As 
the BMDM were R2KO, 2.4G2 could only block binding to CD16.  Binding of PL2-
3298N or PL2-3298S was quantified by staining for IgG2a and flow cytometry.  The 
298N mutation significantly reduced binding to activating FcγRs when compared 
to PL2-3298S. This binding was likely dependent on CD16 because it was 
abrogated by 2.4G2 (Figure 21B). These data demonstrated that the 298S 
mutation in PL2-3 reduces binding to both activating and inhibitory FcγR. This still 
left unresolved the role of downstream signaling effectors in the attenuation of 
BCR-TLR responses.  
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Figure 21. Ca++ flux to PL2-3 298S but not PL2-3 298N was Inhibited by FcγRIIB 
Engagement. A) AM14 TLR7/9DKO (blue) or AM14 TRL7/DKO (red) R2KO B cells were 
loaded with Indo-1-AM, and intracellular flux of Ca++ was monitored by flow cytometry for 60 
seconds at 37°C. Then 1 µg/mL of PL2-3 298S (top panel) or PL2-3 298N (bottom) was 
added, and intracellular Ca++ was monitored for an additional 240 sec at 37° C. B) C57BL6 
R2KO macrophages were treated with PL2-3 298N (blue triangles) or PL2-3 298N (red 
squares) for 1 hr on ice. Excess antibody was washed and antibody quantified by FACS. The 
CD16/FcγRIIB blocking antibody 2.4G2 (10 mg/mL) was used to block binding (open 
symbols). Data shown are representative of two independent experiments. 
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10. Downstream Signaling Effectors in BCR-TLR Mediated Inhibition  
Having shown that engagement of FcγRIIB is needed for attenuation of the 
BCR response and that the nucleic acid content of the complex did not influence 
the ability of FcγRIIB to inhibit TLR-dependent stimulation, I now sought to 
understand the downstream signaling effects of FcγRIIB engagement.  The role 
of downstream signaling in the inhibition of BCR responses by FcγRIIB was 
thought to result from the recruitment of SHIP-1. It was discovered that 
abolishing SHIP-1 recruitment only partially ablated FcγRIIB mediated inhibition 
of BCR responses (164). Therefore, the mechanisms of FcγRIIB mediated 
inhibition of spontaneous IC responses could be independent of signaling. 
Therefore, it was important to understand if FcγRIIB attenuated spontaneous IC 
responses by recruiting SHIP-1 and inhibiting Btk recruitment.  
     In response to BCR crosslinking, PI3K is activated leading to production of 
PIP3, which is required to recruit the signaling effector Btk as well as the 
production of DAG and IP3.  In the absence of functional Btk, AM14 B cells did 
not respond to BCR crosslinking (165). One mechanism that FcγRIIB could use 
to inhibit BCR-TLR9 response could be by antagonizing BCR signaling.  The 
proliferative responses to PL2-3 were completely TLR9 dependent but this did 
not preclude a role for BCR dependent signaling.  Coengagement of FcγRIIB 
attenuates PI3K signaling by 1) disrupting BCR clustering in lipid rafts and 2) 
recruitment and activation of SHIP-1 that dephosphorylates PIP3 to PIP2(3’,4’).  
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Dephosphorylation of PIP3 inhibits the recruitment of Btk because its PH domain 
does not bind PIP2(3’,4’).  Therefore, ablation of FcγRIIB would lead to enhanced 
Btk recruitment and BCR signaling.  Although the roles of Btk and SHIP-1 in the 
regulation of BCR responses were well characterized, their role in BCR-TLR 
responses was not well characterized.  
 Previous data from our lab using xid AM14 Vκ8 mice, demonstrated that 
BCR-TLR responses were attenuated, but not eliminated, by the xid mutation 
(165).  The muted response of xid to BCR-TLR9 engagement was associated 
with more cell death. Interestingly, the response of xid B cells to BWR4 was only 
modestly attenuated.  Furthermore, the response to engagement of TLR9 alone 
was unaffected by the xid mutation, and the response to TLR7 engagement 
alone was only modestly attenuated.  One possible interpretation of these data 
was that engagement of TLR7 and/or TLR9 rescued the defect of the xid 
mutation.  This publication did not address the role of Btk in the context of 
FcγRIIB dependent attenuation of BCR-TLR responses because FcγRIIB 
engagement would antagonize Btk recruitment. Testing the response to 
spontaneous IC in the context of Btk ablation would address several questions: i) 
Did FcγRIIB ablation enhance BCR-TLR responses by promoting Btk 
recruitment?, ii) Was Btk recruitment enhancing BCR-TLR synergy? iii) Were 
BWR4 and HA310.2 responses dependent on Btk when FcγRIIB was ablated? 
The enhancement of BCR-TLR9 responses by FcγRIIB engagement was still 
TLR9 dependent. Therefore, ablation of FcγRIIB led to enhanced BCR-TLR 
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synergy.  One possible mechanism for enhanced BCR-TLR TLR synergy was via 
enhanced Btk recruitment. In the context of FcγRIIB deficiency, the response to 
anti-RNA IC was TLR7/9 independent, which suggested that the anti-RNA IC 
response was driven by the BCR.  On the other hand, TLR7/9 independent does 
not remove the possibility that the response to RNA IC was dependent on 
another RNA-sensing TLR (e.g. TLR13) (166, 167).  An alternative means to 
address these issues was to examine the role of Btk in the enhancement of RNA 
IC responses by FcγRIIB ablation.  If the RNA IC response was driven by BCR 
engagement, then it would be efficiently attenuated by Btk inhibition. If the RNA 
IC responses were driven by engagement of a TLR then it was unlikely they 
would be sensitive to Btk inhibition.  
PCI-32765 (Imbruvica®) is a specific, irreversible inhibitor of Btk that is 
FDA approved for the treatment of chronic lymphocytic leukemia (168). To 
assess the role of Btk in BCR-TLR response enhancement by FcγRIIB ablation, 
AM14 R2KO B cells were stimulated with a constant concentration of CLO97, 
RNA IC (BWR4) or F(ab’)2 α-IgM and a titration of PCI-32765.  I expected that 
for nucleic acid IC, the magnitude of inhibition would be inversely proportional to 
the magnitude of enhancement by FcγRIIB ablation.   
The response to F(ab’)2 α-IgM was efficiently inhibited by PCI-32765, which was 
consistent with the abrogated response to BCR crosslinking by AM14 xid B cells 
(165).  
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Figure 22. The proliferative responses to BWR4 and α -IgM were inhibited by the Btk 
inhibitor, PCI-32765. A) AM14 R2KO B cells were treated with a single concentration of 
BWR4 (blue squares), F(ab’)2 α-IgM (green triangles) or CLO97 (purple inverted triangles) 
and increasing concentrations of PCI-32765. Proliferation was measured by incorporation of 
[3H]-Thymidine for 6 h at 24 h after stimulation. Data was normalized using the signal with no 
PCI-32765 treatment for each ligand and is representative of two independent experiments. B) 
IC50 values were calculated for BWR4 (blue bar) and F(ab’)2 α-IgM (green bar) from 3 
independent experiments, n=3.  
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The response to BWR4 was also efficiently inhibited by PCI-32765, which was 
consistent with previous data demonstrating that the response to the RNA IC in 
the FcγRIIB KO was TLR7 independent (Figure 22). The response to TLR7 
engagement alone was modestly inhibited at higher concentrations of the 
inhibitor. The inhibition of CLO97 was consistent with the xid mice where it was 
modestly inhibited. These data suggested that the RNA IC response in the 
context FcγRIIB deficiency was nearly entirely dependent on Btk. This was 
similar to F(ab’)2 α-IgM crosslinking of the BCR.  
     However, the Btk inhibitor has equal molar affinity for another B cell signaling 
molecule, Blk and inhibited other RTKs at higher concentrations (169). It was 
possible that the inhibition of RNA IC was due to off target effects. To address 
this caveat of off target effects, the role of Btk in the context of FcγRIIB deficiency 
was interrogated by comparing BCR-TLR dependent proliferation of AM14 R2KO 
and AM14 R2KO xid B cells.  B cells were stimulated with IC: HA310.2, BWR4, 
PA4, PL2-3, 1826, CLO97 and F(ab’)2 α-IgM.  The expected result was that the 
anti-RNA ICs HA310.2 and BWR4 would be significantly attenuated by the xid 
mutation because they were driven by BCR crosslinking. The response to PA4 
and PL2-3 would be modestly attenuated by the xid mutation. The stimuli that do 
not require the BCR to stimulate, 1826 and CLO97, would not be attenuated by 
the xid mutation.  Finally, the response to F(ab’)2 α-IgM would be completely 
abrogated by the xid mutation.  
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     As expected the proliferative responses to HA310.2 and BWR4 were 
significantly abrogated by the xid mutation. This was consistent with the Btk 
inhibitor data and the idea that in the context of FcγRIIB deficiency the anti-RNA 
responses were BCR dependent (Figure 23A and B). Interestingly, the responses 
to PA4 and PL2-3 were attenuated by the xid mutation (Figure 23C and D).  This 
suggested that despite a proliferative response that was completely TLR9 
dependent, there was a role for xid in the response of B cells to nucleic acids 
delivered via the BCR. Although the proliferative response was TLR9 dependent, 
perhaps Btk was required for BCR-TLR synergy.  The response to a TLR9 ligand 
delivered independent of the BCR was unaffected by the xid mutation (Figure 
23E).  Consistent with previous publication and the complete BCR dependence 
of the F(ab’)2 α-IgM response, it was abrogated by the xid mutation (Figure 23F).  
     It was previously demonstrated that the xid mutation reduced the AM14 
proliferative response to BWR4 and this was associated with increased cell 
death. This was also the case for the media control where the cells also exhibited 
increased cell death in the absence of any stimuli. The proliferative response to 
BCR engagement alone, F(ab’)2 α-IgM, was completely abrogated. On the other 
hand, stimulation with a TLR9 ligand alone was unaffected by the xid mutation 
(165). This suggested that engagement of TLR7 or TLR9 was required to 
stimulate a proliferative response by xid mutant AM14 B cells. 
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Figure 23. Xid Mutation inhibits proliferation to RNA IC more than DNA IC. AM14 
R2KO (squares) or AM14 R2KO Xid- (triangles) B cells were treated with increasing 
concentrations of HA310.2 (A), BWR4 (B), PA4 (C), PL2-3 (D), 1826 (E) or F(ab’)2 
anti-IgM (F).  Proliferation was measured by incorporation of [3H]-Thymidine for 6 h at 
24 h after stimulation.  Results from a single experiment are shown. 
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     These findings together support the statement that BCR-TLR responses were 
attenuated by the xid mutation whereas BCR responses were abrogated. 
Therefore, it was likely that the response of AM14 R2KO B cells to the RNA ICs, 
HA310.2 and BWR4 were BCR dependent because they were abrogated in the 
xid mice. 
     The xid mutation results in a Btk protein with a nonfunctional PH domain that 
cannot bind PIP3 and therefore it is not recruited to the plasma membrane. 
Degradation of PIP3 to PIP2 (3,4) by SHIP-1 would have a similar consequence 
for PH domain functional Btk recruitment. It was not known if SHIP-1 acts 
downstream of FcγRIIB to attenuate BCR-TLR responses.  The intermediate 
effect of FcγRIIB lacking an ITIM domain suggested that FcγRIIB inhibited BCR-
TLR responses by other mechanisms (164). To determine the role of SHIP-1 in 
FcγRIIB mediated attenuation of BCR-TLR responses, MB1-CRE SHIP-1 fl/fl (i.e. 
SHIP-1 KO) were compared to SHIP-1fl/fl B cells for proliferation to BCR-TLR 
stimulation with BCRAM/PL2-3 and BCRAM/PL2-8.  
    The expected result was the response to BCRAM-PL2-3 would be unaffected 
by SHIP-1 ablation because the proliferative response to PL2-3 and 
BCRAM/PL2-3 were not inhibited by FcγRIIB engagement; therefore, this 
stimulus should not activate SHIP-1 downstream. On the other hand, the 
response to BCRAM/PL2-8 should be enhanced by SHIP-1 ablation because the 
proliferative response to BCRAM/PL2-8 was inhibited by FcγRIIB engagement 
and therefore this stimulus should activate SHIP-1 downstream.  BCRAM/PL2-3 
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and BCRAM/PL2-8 engaged the BCR and TLR signaling pathways. To ensure 
that the MB1-CRE SHIP-1 fl/fl and SHIP-1fl/fl responded normally to BCR and TLR 
ligation, they were treated with F(ab’)2 α-IgM, goat α-mIg (GAMIG) or 1826.  
GAMIG is an intact IgG molecule and will therefore coengage BCR-FcγRIIB. 
Ablation of SHIP-1 enhanced the response to F(ab’)2  α-IgM, which is consistent 
with previously published work showing that MB1-CRE SHIP-1 fl/fl were 
hyperresponsive to F(ab’)2  α-IgM stimulation (Figure 24A)(170). Furthermore, 
the response to GAMIG was enhanced in the MB1-CRE SHIP-1 fl/fl, which was 
consistent with FcγRIIB acting via SHIP-1 to inhibit BCR responses (Figure 24B). 
On the other hand, the response to 1826 was unaffected by SHIP-1 ablation 
(Figure 24C).  
     The response of the MB1-CRE SHIP-1fl/fl  B cells to BCRAM/PL2-3 was 
paradoxical because they proliferated less than the SHIP-1fl/fl (Figure 25A).  This 
was unexpected because the MB1-CRE SHIP-1fl/fl B cells were hyperresponsive 
to BCR stimulation and responded normally to TLR9 engagement. In response to 
BCRAM/PL2-8 that engages FcγRIIB better than PL2-3, the MB1-CRE SHIP-1 fl/fl  
B cells and SHIP-1 fl/fl B cells had the same response.  This was unexpected 
because SHIP-1 acts downstream of FcγRIIB and therefore inactivation of SHIP-
1 would ablate the downstream signaling effector of FcγRIIB. Therefore, the 
MB1-CRE SHIP-1 fl/fl  B cells should phenocopy FcγRIIB ablation. 
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Figure 24. MB1-CRE SHIP-1fl/fl B cells are hyperresponsive to BCR crosslinking. SHIP-1 
fl/fl  (black bars) or MB1-CRE SHIP-1 fl/fl  (empty bars) B cells were treated with F(ab’)2 α-IgM 
(A), GAMIG (B) or 1826 (C). Proliferation was measured by incorporation of [3H]-Thymidine for 
6 hr at 24 hr after stimulation. SHIP-1 fl/fl were representative two 2 biological replicates and 
MB1-CRE SHIP-1 fl/fl were representative of three biological replicates. 
 
		
179
 
Blocking of FcγRIIB with an antibody removed the inhibitory effect on the SHIP-
1fl/fl (Figure 25B). The MB1-CRE SHIP-1fl/fl B cells were refractory to FcγRIIB 
blockade dependent enhancement of BCRAM/PL2-8 response, which was 
consistent with the idea that FcγRIIB acted via SHIP-1 to attenuate BCR-TLR 
responses.  The role of SHIP-1 downstream of FcγRIIB was confounded by the 
hyporesponsiveness of MB1-CRE SHIP-1 fl/fl B cells to BCRAM/PL2-3.  Since 
BCRAM/PL2-3 did not engage FcγRIIB, the hyporesponsiveness of MB1-CRE 
SHIP-1 fl/fl B cells was likely FcγRIIB independent.  Although SHIP-1 is a negative 
regulator of BCR signaling, it appears to have an important role in promoting 
BCR-TLR9 responses. One possible mechanism to explain the role for SHIP-1 in 
BCR-TLR9 responses could be for cellular survival following BCR-TLR9 
engagement. It was found that inhibition of SHIP-1 led to the death of multiple 
myeloma cells (171). Furthermore, inhibition of SHIP-1 in acute lymphoblastic 
leukemia cells led to cell death.  Interestingly, this cell death was rescued by 
inhibition of Syk (172). This suggested that SHIP-1 was protective by inhibiting 
Syk over-activation.   
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Figure 25. SHIP-1 ablation attenuated BCR-TLR9 responses. SHIP-1fl/fl (triangles) or MB1-
CRE SHIP-1 fl/fl (squares) B cells were treated with BCRAM-PL2-3 (A) or BCRAM-PL2-8 (B) 
with or without 2.4G2. Proliferation was measured by incorporation of [3H]-Thymidine for 6 h at 
24 h after stimulation. SHIP-1fl/fl was n=2 mice and MB1-CRE SHIP-1 fl/fl n=3 mice.  
 
		
181
 
 
11. Use of Defined DNA IC to Elucidate Mechanisms of FcγRIIB  
           Attenuation  
     The undefined and spontaneous nature of autoantibody derived ICs made it 
difficult to control for variables such as IC formation and composition.  For 
example, it was not known if an IC was formed with an antigen present in the 
primary cell culture or if the antigen was copurified with the antibody. The level of 
BCR engagement varied between different spontaneous IC. In addition, the 
composition of the IC was undefined, which was exemplified by PL2-3 a 
seemingly DNA IC having an RNA component (84).  Using defined IC consisting 
of streptavidin and biotinylated DNA IC could control for IC formation because 
both the antigen and antibody are premixed. The TLR stimulating composition of 
the IC would be controlled because only biotinylated DNA fragments would be 
incorporated. Thus, defined ICs would control for IC formation and composition. 
     The defined DNA IC used in this studies was anti-SA SA DNA IC formed by 
sequentially mixing: i) Clone 11 DNA that was monobiotinylated at each end of 
the fragment, ii) Fluorochrome or unlabeled streptavidin and iii) A murine IgG2a 
antibody specific for streptavidin (1E11.1). The complexes were formed from a 
molar ratio of 1.3 pmol DNA, 2.2 pmol unlabeled SA or 6.7 pmol labeled SA and 
3.3 pmol anti-SA. The higher concentrations of labeled SA was due to reduced 
activity relative to the unlabeled streptavidin. For the unlabeled streptavidin this 
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would be approximately two streptavidin tetramers and two antibody molecules 
per DNA.  
   
12. Binding of anti-SA SA DNA IC to AM14 B cells 
     The binding assays using spontaneous IC were confounded by uncontrollable 
variables such as antigen availability and IC formation dynamics. The anti-SA – 
SA – DNA IC represented a means to interrogate the role of FcγRIIB in IC 
binding.  To assess the role of FcγRIIB in anti-SA –SA– DNA IC binding to AM14 
B cells, a FACS assay was performed.  Either AM14 or AM14 R2KO B cells were 
treated with a titration of anti-SA SA-AF647 DNA IC on ice for 1 hr. Next, the 
cells were washed thrice with FACS buffer and bound IC was quantified by flow 
cytometry.  
     I expected the anti-SA SA-AF647 DNA IC to bind better to AM14 than AM14 
R2KO B cells because the FcγRIIB sufficient cells had an additional receptor for 
the IC. The anti-SA SA-AF647 DNA IC bound significantly better to AM14 B cells 
than AM14 R2KO B cells. Interestingly, the contribution of FcγRIIB to IC binding 
was apparent with anti-SA SA-AF4647 DNA IC (Figure 26A and 26B).  These 
data demonstrated that more anti-SA SA-AF647 DNA IC bound to AM14 than 
AM14 R2KO B cells 
     The AM14 B cell is a rheumatoid factor B cell and binds the Fc portion of 
IgG2a antibodies. It was difficult to determine if FcγRIIB on B cells was binding IC 
independent of the AM14 BCR.  The binding of IC to FcγRIIB on primary B cells 
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was assessed by comparing anti-SA SA-AF647 DNA IC binding to AM14, AM14 
R2KO, Balb/c and Balb/c R2KO. The purified B cells were treated with a titration 
of anti-SA SA-AF4647 DNA IC on ice for 1 hr. Next, the cells were washed thrice 
with FACS buffer, and then cell surface bound IC was quantified by flow 
cytometry. Interestingly, non-Tg cells (Balb/c or Balb/c R2KO) without a specific 
BCR were unable to bind the IC. This suggested that FcγRIIB cooperated with 
AM14 to bind ICs (Figure 26C).  
 
13. Stimulation of Ca++ flux by Anti-SA SA DNA IC  
 The anti-SA SA DNA IC bound better to AM14 B cells. The binding assays 
were static and performed on ice, which eliminated key steps in BCR 
engagement such a receptor crosslinking. Although BWR4 bound to AM14 B 
cells better than PA4 or PL23, there was no correlation between the magnitude 
of Ca++ flux and TLR dependent proliferation. Alternatively, inhibition of Ca++ flux 
by FcγRIIB correlated with the attenuation of the proliferative response to that 
respective ligand. One potential caveat to these experiments was that the 
undefined spontaneous IC yielded different amounts of IC based on the amount 
of antigen in the culture. This was highlighted when comparing the anti-
nucleosome antibodies PL2-3 and PL9-9. Thus, these defined IC eliminated the 
caveat of antigen abundance and vagaries of spontaneous IC.   
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Figure 26. Anti-SA DNA IC bind better to AM14 than AM14 R2KO B cells. A) AM14 (solid line) 
or AM14 R2KO (dashed line) B cells were treated with increasing concentrations of anti-SA SA-
AF647 DNA IC (anti-SA, 0.5 mg/mL, SA-mg/mL, bio-DNA-bio mg/mL) on ice for 1 hr. The cells 
were washed 3x with ice cold iMag buffer, and surface IgG2a was detected by SA-AF647. B) IC 
binding was quantified by FACS and plotted as MFI (APC) versus antibody concentration. Error 
bars represent SEM of n=3. C) AM14 (open triangles), AM14 R2KO (open squares), BALB/c 
(closed triangles) or BALB/c R2KO (closed squares) B cells were treated with anti-SA DNA IC as 
in figures A and B and representative of three independent experiments D) AM14 (blue) or AM14 
R2KO (red) B cells were loaded with Indo-1-AM, and intracellular flux of Ca++ was monitored by 
flow cytometry for 60 sec at 37° C. anti-SA SA DNA IC was added, and intracellular Ca++ was 
monitored for an additional 240 sec at 37° C. Data are representative of 3 independent 
experiments. E) AM14 (white triangles), AM14 R2KO (white squares), AM14 TLR7/9DKO (red 
triangles) and AM14 R2KO TLR7/9 DKO (red squares) B cells were stimulated with increasing 
concentrations of anti-SA SA DNA Proliferation was measured by incorporation of [3H]Thymidine 
for 6 hr at 24 hr after stimulation. The average of three independent experiments is shown; error 
bars represent SEM.  
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     The Ca++ flux stimulated by anti-SA -SA -DNA IC or anti-bio DNA IC was 
compared on AM14 and AM14 R2KO B cells.  Intracellular concentrations of 
Ca++ were monitored by labeling AM14 and AM14 R2KO B cells with indo-1-AM.  
The labeled cells were analyzed by flow cytometry at 37°C for 1 min and then the 
stimuli were added. After the stimuli were added, the change in intracellular Ca++ 
was monitored for an additional 3-5 min. I expected that the Ca++ flux to anti-SA 
SA DNA IC would be inhibited by FcγRIIB engagement. As expected, the Ca++ 
flux to anti-SA-SA-DNA IC was inhibited by FcγRIIB engagement (Figure 26D).  
Thus, the anti-SA SA DNA IC recapitulated many of the aspects of PA4 and PL2-
3298S 1) FcγRIIB attenuation of Ca++ flux and 2) stimulated TLR9 dependent 
proliferation. 
 
14. TLR9 Dependent Proliferation Induced by α-SA SA DNA IC  
     To recapitulate PL2-3298S and PA4, the responses to anti-SA SA DNA IC 
needed to be attenuated by FcγRIIB engagement and TLR9 dependent. To 
determine if the anti-SA SA DNA IC were regulated by FcγRIIB and TLR9 
dependent, AM14 WT, AM14 R2KO, AM14 TLR7/9 DKO and AM14 R2KO 
TLR7/9DKO B cells were purified from splenic cell suspensions using B220+ 
selection.  The B cells were treated with a titration of anti-SA-SA DNA IC for 24 
hrs and then pulsed with 3H-Thymidine for 6 hr.  I expected the proliferative 
response of anti-SA-SA DNA IC to be TLR7/9 dependent.  
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     The proliferative response to anti-SA SA DNA IC was significantly enhanced 
by FcγRIIB ablation and the response was TLR7/9 dependent. Ablation of 
FcγRIIB enhanced the response to the spontaneous IC, PA4 and PL2-3298S, and 
the responses were TLR7/9 dependent.  Thus, the proliferative response of 
AM14 R2KO to anti-SA SA DNA IC recapitulated the observations with PA4 and 
PL2-3298S. The responses were completely TLR dependent, which suggested 
that the enhancement was a result of enhanced TLR engagement and or BCR-
TLR synergy (Figure 26E).  
 
15. Impact of FcγRIIB on Internalization  
The data from the proliferation experiment demonstrated that anti-SA SA 
DNA IC recapitulated the TLR7/9 dependence of the proliferative response by 
AM14 R2KO to 8D8 and PA4.  Furthermore, the data also suggested that 
FcγRIIB was directly antagonizing TLR engagement and/or BCR-TLR synergy.  
Engagement of FcγRIIB could retain the DNA IC on the surface, thereby 
segregating it from TLR9. To stimulate B cells, DNA ICs are bound by the BCR, 
endocytosed via the BCR and then trafficked to an intracellular compartment to 
engage TLR9. It was previously demonstrated the ablation of btk retarded the 
internalization of the BCR following crosslinking (26).  Furthermore, it was shown 
that via SHIP-1, FcγRIIB inhibited the activity of Btk (28). Together the data 
suggested that FcγRIIB could regulate the rate of internalization of IC; reduced 
activation of SHIP as a result of R2KO should result greater btk activity and 
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accelerated internalization in the R2KO cells.  SA IC could be used to effectively 
test this premise because the total amount of fluorescence associated with the 
complex can be measured independently of the level of IC retained on the cell 
surface by FcγRIIB engagement.   To determine if FcγRIIB abrogated or retarded 
the internalization of DNA IC, the rate of internalization of anti-SA SA-AF488 
DNA IC by AM14 WT vs AM14 R2KO B cells was compared Purified B cells were 
incubated with anti-SA SA-AF488 DNA IC for 1 hr on ice. The cells were washed 
thrice with ice cold complete RPMI to remove unbound IC and resuspended to 
4x106 cells/mL. These anti-SA SA-AF488 DNA IC labeled cells were then 
warmed to 37°C for 180, 90, 60, 30, 15 and 0 min.  After the final time point, the 
cells were washed twice with ice cold iMag buffer and stained for cell surface IC 
using 3A20.2, a monoclonal anti-SA antibody that recognized a different epitope 
of streptavidin than the 1E11.1 IgG2a anti-SA used to form the ICs. The cells 
were again washed thrice with ice cold iMag buffer and both internalized and cell 
surface IC quantified by flow cytometry.  
     As expected, the AM14 R2KO B cells internalized the IC more rapidly than the 
AM14 B cells. However, by 180 min, the AM14 B cells had fully internalized the 
IC (Figure 27). This suggested that FcγRIIB was not retaining the DNA ligand on 
the cell surface topologically segregated from endosomal TLR9 but rather 
retarding internalization
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Figure 27. Engagement of FcγRIIB Retards IC Internalization. AM14 or AM14 
R2KO B cells were incubated with anti-SA(0.15 ug/mL), SA-AF488(0.13 ug/mL), 
bio-DNA-bio(0.15 ug/mL) for 1 hr on ice. The B cells were washed 3x with ice cold 
iMag buffer. Surface IC labeled B cells were incubated at 37 C for 0, 30, 60, 90 or 
180 min. After the final time point the cells were washed 3x with ice cold iMag 
buffer and stained for surface IC. Total IC(AF488) and surface IC(AF647) were 
quantified by FACS. B) Graph of percentage of cells that internalized IC 
 
		
189
 
A previous publication suggested that FcγRIIB1 was not internalized by B cells 
(30). Although, subsequent publications demonstrated that FcγRIIB1 is 
internalized (173-175). The internalization assay demonstrated that 1) FcγRIIB 
was not retaining the DNA on the cell surface and 2) it retarded IC internalization.  
 
16. Role of FcγRIIB in IC Trafficking to Endosomal Compartments 
     In addition to uncoupling BCR engagement and internalization via decreased 
rate of internalization, FcγRIIB could also directly affect TLR engagement by 
modulating endosomal maturation. Since it is known that sensing of DNA by 
TLR9 required an acidic mileu, it could be an additional mechanism of 
antagonizing BCR-TLR9 responses.  Following receptor mediated endocytosis, 
the cargo-containing vesicle can have a variety of fates as the endosome 
matures from high pH to low pH.  The transferrin receptors (TfR) and LDL 
receptors (LDLR) acquire Fe3+ and cholesterol respectively for cells. One cargo, 
Tf, has a non-degradative fate where the receptor and ligand are recycled back 
to the cell surface.  The TfR bound to transferrin is first transited through an early 
endosome of pH 6.0 to 6.5. The low pH releases Fe3+ from TfR.  After being 
trafficked through a recycling endosome, TfR and Tf are recycled to the cell 
surface (176). In this case, the higher pH serves to release Fe+++ from Tf.  
By contrast, the LDL receptor (LDLR) is endocytosed into an early endosome but 
LDL continues along the degradative pathway to late endosomes and finally 
endolysosomes.
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The low pH of the late endosome-lysosome was found to be essential for LDL 
degradation and cholesterol release by acid hydrolases.  Treatment of cells with 
chloroquine, which raises endosomal pH abrogated the release of cholesterol. 
The fate of LDL and the requirement for endosomal acidification is similar to the 
sensing of DNA by TLR9. Instead of the release of nutrients, endosomal pH 
facilities DNA degradation by DNaseII, which functions optimally at pH 5.0.  It 
was recently demonstrated that ablation of DNaseII abrogated sensing by TLR9 
(80, 81). Thus, I hypothesized that signaling or trafficking downstream of FcγRIIB 
antagonized endosomal maturation.  This could inhibit BCR-TLR9 responses by 
inhibiting DNA degradation via DNaseII, which is required for sensing via TLR9.  
The acidification of internalized DNA IC was interrogated by using pH 
sensing anti-SA SA DNA IC described in Chapter 3. Briefly, AM14 and AM14 
R2KO B cells were treated with α-SA SA-FITC/SA-AF647 DNA IC for 24 hr. After 
24hr, the cells were washed thrice with ice cold iMag buffer and analyzed by flow 
cytometry. The use of dual pH sensitive (FITC) and pH insensitive (AF647) 
labeled IC permitted interrogation of both pH and quantity of IC acquired.   I 
expected the AM14 R2KO KO to acquire (AF647) more IC over 24 hr than AM14 
because bound IC was internalized faster by the AM14 R2KO.  Furthermore, I 
expected the IC to reside in a more acidic milieu (FITC/APC) in the AM14 R2KO 
because the AM14 R2KO responded better to DNA IC. As expected, the AM14 
R2KO B cells acquired more IC than the AM14 because the red and blue 
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histograms were offset.  In the internalization assay, the AM14 R2KO had an 
increased rate of internalization.  Over 24 hrs, the increased rate of 
internalization likely accounted for the increased acquisition of the IC (Figure 
28A).  The use of an internal measure of IC acquisition permitted comparison 
between AM14 and AM14 R2KO because pH is calculated as a ratio of pH 
sensitive/pH insensitive fluorochrome in the IC (Figure 28B).    
The anti-SA SA-FITC/AF647 DNA IC was located in a more acidic 
compartment in the AM14 R2KO. There was a ~1 unit pH difference of the IC 
milieu between the AM14 (6.2) and AM14 R2KO (5.3) (Figure 28C).  The 
endosomal pH in the absence of FcγRIIB engagement was consistent with 
previous measurements of pH following BCR engagement alone (177).  Simply 
stated, a single pH unit (a 1 log difference) is a significant difference in the H+ 
concentration. There are several practical consequences of this pH difference for 
TLR9 engagement.  The activity of DNaseII in tissue extracts was found to be 
significantly reduced above pH 5.6 (178).  The sharp decline in DNaseII activity 
above pH 5.5 was thought to restrict activity to acidic intracellular compartments 
(179). As DNaseII activity is required for sensing of DNA by TLR9, this could be a 
mechanism that FcγRIIB uses to attenuate BCR-TLR9 responses (80, 81).  
The pH measurements were repeated over a time course to determine if 
there was kinetic difference in the acidification of IC between AM14 and AM14 
R2KO. AM14 and AM14 R2KO B cells were treated with anti-SA SA-FITC/AF647 
DNA IC, and pH was quantified over a 24 hr time course. 
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Figure 28. pH sensing ICs localized to a more acidic compartment in AM14 R2KO  
AM14(Blue)or  AM14 R2KO (Red) were treated for 24 hrs with anti-SA(0.5 ug/mL) SA-
FITC/AF647 DNA IC. After 24 hr, A)left panel (FITC), B)right panel(AF647), C) Relative 
pH(FITC/AF647) were quantified by FACS. D) pH was calculated from a standard curve 
generate by treating IC stimulated B cells with monensin and nigericin in buffers of known pH, 
SEM, n=3. D) AM14 (Blue)or  AM14 R2KO (Red) were treated for 24 hrs with anti-SA SA-
FITC/AF647 DNA IC. After 1.5, 3, 4, 6, 18, or 24 hr incubation with the IC, pH(FITC/AF647) was 
calculated from a standard curve generate by treating IC stimulated B cells with monensin and 
nigericin in buffers of known pH, n=3,SEM. 
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I expected that the AM14 R2KO would acidify the IC faster as the result of 
trafficking faster to a more acidic compartment.  As expected, the IC appeared to 
acidify more rapidly in the R2KO B cells (Figure 28D).  
     However, one caveat with these data was the possible contribution of surface 
IC to an increase in the pH of the IC observed in the AM14. The retarded 
internalization of the AM14 relative to the AM14 R2KO suggested that there 
would be more IC on the AM14 WT B cell surface than the AM14 R2KO B cell 
surface. From a practical perspective, the pH analysis of experimental samples 
was in FACS buffer of pH 7.4, which would increase the calculated pH of surface 
bound molecules.   
     One way to exclude the contribution of surface IC would be to pulse the cells 
for a defined amount of time with IC, wash away excess IC, stain surface 
retained IC and then measure pH by flow cytometry. The pulse and chase 
methodology would adjust for retarded internalization observed in the AM14 B 
cells by permitting extra time for IC internalization. Staining for surface IC would 
detect IC still bound on the surface.  AM14 and AM14 R2KO B cells were treated 
with anti-SA SA-OG488/BV421 DNA IC for 14 hrs. Next, the cells were either 
washed thrice with RPMI or just centrifuged without washing.  Then the cells 
were returned to 37°C for 10 hrs. After 10 hrs, the cells were washed twice with 
ice cold iMag buffer and stained for cell surface IC using AF647 conjugated 
3A20.2 a monoclonal that recognized a different epitope of streptavidin than 
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IgG2a anti-SA (1E11.1). The cells were washed thrice with ice cold iMag buffer, 
and cell surface IC and pH values were quantified by flow cytometry.  
     The use of the fluorophore OG488 was chosen because it was brighter than 
FITC but had the drawback that it was pH sensitive above ~6.5. This meant that 
accurate pH values could not be calculated because any values between pH 6.2-
7.4 would have the same ratiometric value. I expected that the AM14 that were 
not washed would have higher levels of surface IC than the AM14 R2KO 
because the AM14 has retarded internalization. In addition, I expected that the IC 
would be in a higher pH milieu in the AM14 than in the AM14 R2KO. On the other 
hand, I expected that AM14 that were washed would have similar levels of 
surface IC to the AM14 R2KO because of the extra time for the AM14 to 
internalize the IC.  Furthermore, I expected the IC to be in a more acidic 
compartment in the washed AM14 R2KO and AM14 WT when compared to the 
unwashed because the wash step would remove the contribution of surface IC to 
pH.  Finally, I expected that in the AM14 WT the IC would be in a less acidic 
milieu than the AM14 R2KO.   
     Washing the cells at 14 hrs and then staining for surface IC 10 hrs later 
eliminated most of the surface IC. Consistent with retarded internalization, the 
AM14 B cells had more surface-bound IC than the AM14 R2KO in the absence of 
a wash step (Figure 29A). Interestingly, acquisition of IC was nearly identical at 
14 hrs as exemplified by the similar total IC histograms (BV421) for the cells that 
were incubated with IC for only 14 hrs and washed (Figure 29C).  On the other 
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hand, incubation of the B cells with the IC for an additional 10 hrs led to 
increased IC acquisition by the AM14 R2KO when comparing the vertical grid 
lines relative to the histograms on the left and right panels. This was consistent 
with the faster rate of IC internalization by the AM14 R2KO when compared to 
the AM14.  In both the washed and unwashed cells, the IC in the AM14 R2KO B 
cells was in a more acidic compartment than in the AM14 B cells, as evidenced 
by the ratio of OG488/AF647.  When the surface staining was nearly identical, 
the AM14 R2KO localized the IC to a more acidic milieu than the AM14 (Figure 
2D). Therefore, this demonstrated that even when the contribution of cell surface 
IC is eliminated, the IC still localized to a more acidic milieu in the AM14 R2KO B 
cells. Nevertheless, the interpretation of these data is still potentially confounded 
by a difference in the rate of internalization; it is difficult to normalize for kinetic 
differences in the rate of acidification.  Nevertheless, the remarkably little 
difference between the average IC milieu in the washed and unwashed cells 
suggests that the bulk of the uptake occurs within the first 14 hrs and the 2 hr 
delay in in the IC uptake by the AM14 WT cells is unlikely to account for the 
difference in final pH.   
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Figure 29. AM14 B cells traffic the IC to a more basic milieu. AM14 (Blue)or AM14 R2KO 
(Red) were treated for 14 hrs with anti-SA(0.5 ug/mL) SA-OG488/BV421 DNA IC. After 14 hr,  
the cells were untreated (Right panel) or washed (Left panel). After an additional 10 hrs,A) 
Surface IC (AF647) B)pH sensor (FITC), C)Total IC (AF647), D) Relative pH (FITC/AF647) 
were quantified by FACS. D) pH was calculated from a standard curve generate by treating IC 
stimulated B cells with monensin and nigericin in buffers of known pH. Representative of n=2 
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C. Discussion 
1. Which kinds of undefined complexes (autoAb) are regulated by  														FcγRIIB 
      Immune complexes formed from cell debris and autoantibodies are not well 
characterized and are therefore considered “black box” immune complexes. 
Beyond the nucleic acid content and specificity by ANA, the size, valency and 
target antigen in B cell cultures is not defined.  Previous published data showed 
that the proliferative response of AM14 B cells to BWR4 was significantly 
enhanced by FcγRIIB deficiency, but the proliferative response to PL2-3 was 
unaffected (117).  These data were interpreted as FcγRIIB attenuating BCR-
TLR7 responses but not BCR-TLR9 responses.  The differential regulation of 
BCR-TLR7 but not BCR-TLR9 responses by FcγRIIB engagement did not hold 
because I found that PA4 responses were attenuated by FcγRIIB engagement, 
and PA4 is an autoantibody that recognizes dsDNA, a TLR9 ligand. In addition, 
when FcγRIIB was ablated, the proliferative response to BWR4 and HA310.2 
were TLR7 independent. These data demonstrated that 1) DNA IC induced 
proliferative responses were also attenuated by FcγRIIB and 2) enhanced RNA 
IC response in R2KO were TLR7 independent.  
     On the other hand, it was previously demonstrated that some autoantigen 
associated RNAs activated autoreactive B cells independent of TLR7 but 
dependent on UNC93B1(106). These data suggested TLR3 or the more newly 
discovered endosomal TLR for bacterial RNA, TLR13, could mediate the 
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response to some autoantigen associated RNA because both TLR3 and TLR13 
required UNC93B1 to function (166).  The role of TLR3 or TLR13 in the 
proliferative response to BWR4 could be interrogated using BWR4 DVD-Ig to 
stimulate UNC93B1 B cells. Therefore, my data does not eliminate a role for 
TLR3 or TLR13 in the response BWR4 or HA310.2.  
     The engagement of the BCR and FcγRIIB by spontaneous IC was assessed 
by static binding assays and Ca++ flux. The RNA IC bound significantly better 
than the DNA IC to AM14 B cells. In addition to suggesting a difference in 
receptor engagement between DNA IC and RNA IC, the binding assays also 
suggested that the RNA IC contained more IgG2a.  The AM14 receptor is a low 
affinity receptor that only weakly binds monomeric IgG2a.  The low affinity of the 
AM14 receptor is overcome by multimeric IC.  The RNA IC bound to AM14 B 
cells better than DNA IC, which suggested that the RNA IC were larger or had a 
higher epitope density than the DNA IC. Binding by AM14 B cells is a function of 
IC size and the density of available IgG2a molecules; the IC size reflects the 
affinity of the autoantibody for its autoantigen, and the availability of the 
autoantigen.  The binding assays were performed using the same amount of 
antibody; therefore, they interrogated the ability to form an IC under the 
conditions of the binding assay. One limit of valency would be the surface area 
for antibody binding.  The enhanced binding of BWR4 relative to PL2-3 or PA4 
could have been due to abundance of the antigen for the respective antibodies.  
The overabundance of RNA to DNA is counterintuitive because RNA is more 
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sensitive to degradation than DNA. Furthermore, PL2-3 was able to bind to AM14 
B cells over a wide range of concentrations, which suggested that antigen was 
not limiting in the culture.  
     The minimal effect of FcγRIIB on IC binding was surprising because AM14 is 
a low affinity receptor, and FcγRIIB would be an additional receptor to bind IC.  At 
lower concentration of BWR4 or with PA4, there was a modest enhancement of 
IC binding by FcγRIIB. The lack of enhancement by FcγRIIB could have been the 
result of FcγRIIB requiring coengagement to cluster with the BCR, which would 
not occur on and ice and would require physiological temperatures. Perhaps the 
participation of FcγRIIB in spontaneous IC binding requires physiological 
temperatures so the receptor can cluster in lipid rafts with the BCR. In other 
studies, it was shown that FcγRIIB on B cells needed to enter rafts to function 
(180).  
     The proliferation data demonstrated that the response of AM14 R2KO B cells 
to RNA IC was TLR7 independent at 24 hr in the absence of type I IFN priming.  
The binding data suggested that BWR4 was a more avid complex than PA4 or 
PL2-3. The sensitivity of RNA IC and DNA IC responses to attenuation by 
FcγRIIB could explain the strong connection of FcγRIIB with TLR7 mediated 
disease in murine models (41, 156, 181).  Overexpression of TLR7 was not 
sufficient to drive autoimmune disease. It was the combination of TLR7 
overexpression and FcγRIIB ablation that promoted lupus in murine models 
(113). In my results, the early responses to RNA IC were efficiently inhibited by 
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FcγRIIB engagement. It is possible that FcγRIIB inhibited the initiation of BCR-
TLR7 responses.  In the absence of exogenous interferon, B cells can produce 
IFN-β to enhance BCR-TLR7 responses via up regulation of TLR7 expression 
(105). The regulation of autoreactive B cells response by FcγRIIB independent of 
the nucleic acid (i.e. TLR7KO B cells) suggested that physical characteristics (i.e. 
size, valency) mediated the attenuation.  The ICs studied were composed of 
repeating antigenic sites, which was self-explanatory for the nucleotide polymers 
(i.e. DNA, RNA).  If IC formed from repeating unit antigens were more likely to be 
inhibited by FcγRIIB engagement, than these results may be extendable to other 
autoantigens that lack nucleic acids but form repeating unit structures. For 
example, in rheumatoid arthritis, autoantibodies can be detected against 
polymeric proteins such as collagen, vimentin and fibrinogen (182). The 
association of FcγRIIB hypomorphic mutations with RA could be related to the 
possibility that a functional FcγRIIB would attenuate the response.  
 
2. Calcium Flux Stimulated by Spontaneous ICs 
     Importantly, the Ca++ flux data correlated with the proliferation data where 
Ca++ flux in response to BWR4 and PA4 was enhanced and PL2-3 was 
unaffected by FcγRIIB ablation.  However, I did not expect that Ca++ flux 
response to PA4 and BWR4 of AM14 R2KO B cells would have similar 
magnitudes; the other measure of BCR engagement, IC binding assays, show 
several orders of magnitude difference in binding between PA4 and BWR4. One 
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simple explanation for this was that the maximum values for BWR4 and PA4 
were the maximum range for the assay.   
     Another explanation for why PA4, PL2-3 and BWR4 had similar Ca++ flux 
intensity but only BWR4 stimulated TLR7 and TLR9 independent proliferation via 
strong BCR crosslinking was the duration of the Ca++ flux.  AM14 or AM14 R2KO 
B cells stimulated with (Fab’)2 α-IgM proliferated. In response to α-IgM, the Ca++ 
flux peaked but did not decrease. A secant line drawn between the maximum 
Ca++ flux achieved and the final point on the curve at approximately 420 seconds 
would have a slope near zero because the maximum and final value did not vary.  
A secant line draw from the maximum and final points for BWR4, PA4 and PL2-3 
showed that the slope of BWR4<<PA4 and PL23. This suggested that the 
sustained Ca++ to BWR4 could have accounted for the differential effect of BCR 
engagement on proliferation despite similar maximal Ca++ flux. 
     Relative to the polyclonal stimulus F(ab’)2 α-IgM, the spontaneous IC BWR4, 
PA4 and PL2-3 stimulated significantly more Ca++ in the AM14 R2KO B cells. 
This was interesting because F(ab’)2 α-IgM engages the BCR with higher affinity 
than AM14 binds IgG2a. On possible explanation is that although a polyclonal 
reagent, Fab’2 α-IgM was bivalent, which limited the ability to crosslink the BCR 
relative to an IC.  A single IC could bind multiple BCRs whereas an antibody 
molecule could only bind two.  The spontaneous ICs were multivalent and 
capable of clustering more BCRs. Despite the low affinity of the monomeric 
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IgG2a interaction with AM14, the formation of ICs was able to induce better BCR 
crosslinking than a high affinity bivalent stimulus.  
 
3. Mutation in PL2-3  
     The proliferative response to PL2-3 was refractory to FcγRIIB mediated 
attenuation. After sequencing the Fc region of the antibodies, I found that PL2-3 
had a S298N mutation in a domain critical for binding to FcγRIIB. Finding a 
somatic mutation in the Fc region of a hybridoma requires discussion of the 
possible mechanism of how this mutation may have occurred. PL2-3 was 
isolated from the fusion of an MRL/Mp +/+ spleen from an 18 month old mouse. 
PL2-3 is an IgG2a hybridoma protein that is clonally related to PL2-8, an IgG2b 
hybridoma protein isolated from the same mouse (89). A comparison of the 
heavy chain variable domain sequences of PL2-8 and PL2-3 to the germline 
gene showed that PL2-3 had significantly more mutations (89). As somatic 
mutation and class switch recombination are antigen driven, PL2-3 resulted from 
repeated stimulation via BCR and TLR engagement. The parental cell that 
eventually resulted in the PL2-3-secreting B cells likely entered the germinal 
center, where AID is highly expressed, several times because it is heavily 
mutated. Therefore, one possible explanation for the G to A transition mutation is 
that the PL2-3 progenitor cell had an AID triggered mutation prior to the fusion. 
AID was known to target the switch regions and the V region of antibodies genes 
but not the constant regions.  Despite restricted targeting, AID has been shown 
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to have off target effects. Most notably, these off target effects were within the 
AID hot spot, RGYW, where the C on the non coding strand is targeted (183, 
184).   Interestingly, the mutation in PL2-3 was within an RGYW AID hotspot.  
One result of cytidine deamination is transition of C to T on the non-coding strand 
that would result in a G to A transition on the coding strand if the DNA were 
replicated prior to DNA repair (185, 186). The serine residue at position 298 and 
RGYW hot spot are conserved between mouse and humans, despite differential 
serine codon usage. In the case of PL2-3 or hIgG1, this G to A transition on the 
coding strand would also lead to the S298N mutation.  
 The simplest case for an evolutionary conserved mechanism would 
explore alternative codons that would maintain the serine residue but remove the 
AID target. The amino acid serine can be encoded by the codons, TCT, TCC, 
TCA, TCG, AGT and AGC.  There are 4 serine codons without a G in the second 
position that would silence the AID hot spot. The usage of serine codons that 
introduced an AID site suggested an engineered means to somatically modulate 
IgG effector functions.  It was previously noted that the serine codons AGT and 
AGC were overabundant in the germline v genes.  Using a larger antibody gene 
database, the usage of the AGT and AGC codons in germline V genes in both 
BALB/c and C57BL6 mice were found to be significantly over abundant relative 
to random codon usage (187).  The overabundance of mutable serine residues in 
the V region suggested evolutionary selection for mutability in mice and humans 
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(188). The importance of AID in affinity maturation is well established, which 
suggested codon bias to promote AID dependent mutations.  
     An alternative hypothesis to evolutionary selection of serine codon bias for an 
AID hotspot would be that the codon bias was “frozen in”(189).  That was to say, 
that the codon usage was fixed early in evolution and changing from serine AGY 
to the other serine codons would require more than one mutation.  The 
intermediate mutation would lead to a loss of function and therefore it was not 
favored.  For example, the hIgG1 putative AID hotspot has the sequence 
AGCACG where the bolded letters encompass the AID hotspot. The most 
parsimonious approach would be to change the G residues to C, A or T so as to 
mutate the targeted resides.  This would result in the mutants S298T, S298N, 
and S298I respectively. The S298T and S298N mutations have ~23% and 0% 
binding to FcγRIIB relative to the WT 298S (160) and the S298I mutation has 0% 
binding to FcγRIIA and FcγRIIIA.  The loss of function in FγR derived by 
eliminating the AID site suggested that it was plausible that the AID site was 
“frozen in”.  
 An alternative possibility is that the parental cell of PL2-3 sustained a 
random mutation.  The G to A transition mutation on the non-coding strand was 
the most common mutation found in actively transcribed genes (190). Using 
single cell sorting of human brain cell nuclei and whole genome sequencing of 
single cells investigators found that neuronal cells accumulate somatic mutations 
in transcribed genes (190). It was found that an abundance of C to T transition 
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mutations in transcriptionally active genes (190, 191). It is the C to T transition 
mutation that occurred in PL2-3. The lack of other Fc mutations in the other 
sequenced hybridomas in my studies suggested that a random mutation was not 
a common event.   
     Regardless if the cause of S298N mutations was random or AID mediated, it 
had profound consequences on binding to Fcγ receptors. Previous studies using 
surface plasmon resonance as a readout demonstrated that an S298N mutation 
in human IgG1 abrogated binding to hFcγRIIB, hFcγRIIA and hFcγRIIIA (160). 
Although the S298N mutation in murine IgG2a was never tested for binding to 
activating FcγR by surface plasmon resonance, the hIgG1 N297A mutation 
abrogated binding to both the activating receptors hFcγRIIA, hFcγRIIIA and the 
inhibitory receptor hFcγRIIB. Due to the conservation of the NST motif between 
hIgG1 and mIgG2a, it was not surprising that the S297A mutation had the same 
effect on mIgG2a and hIgG1 binding to activating and inhibitory FcγR. It follows 
that the substitution described here, S298N mutation would have a similar effect 
on binding murine activating FcγR, as I have shown with the macrophage binding 
data above.  The inactivation of FcγR binding would dysregulate host defense 
and negative regulation of immune responses. The immune system evolved to 
defend against pathogens, and the Fc effector functions of antibodies are 
important in a variety of antimicrobial functions such as oposonophagocytosis 
and ADCC (192). Given the importance of Fc receptor in antibody mediated host 
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defense mechanisms, this raises questions regarding the teleology of a somatic 
mechanism to abrogate FcγR binding.  
     One potential selective pressure for a somatic mechanism to abrogate Fc 
binding would be antibody dependent enhancement (ADE) of viral infection.  
ADE occurs when either non neutralizing or cross reactive antibodies enhance 
the infectivity of pathogens (193).  Although ADE has been described for a 
variety of viruses, it is best characterized for dengue fever (194-196).  Dengue is 
a positive strand RNA virus that is vector borne.  The binding of non-neutralizing 
or cross reactive antibodies to the virus enhanced the infection of macrophages, 
monocytes and dendritic cells. One consequence of a non-neutralizing antibody 
response could be viral persistence. A persistent viral infection would lead to 
repeated activation of B cell via the BCR and TLR leading to repeated entry of 
the B cell into the germinal center where AID is highly expressed.  In the course 
of repeated somatic hypermutation, an S298N mutation could occur. This would 
transform a non-protective immune response into a protective immune response.  
     The concept of converting a non-protective antibody response was tested by 
mutation of a monoclonal antibody specific for Dengue. The lethal ADE of a 
nonneutralizing monoclonal against Dengue was abrogated by the N297Q 
mutation, which prevented FcγR binding (193).  In these experiments, this 
mutation was induced in vitro but it is possible that during the course of an 
immune response, a somatic mutation of S298N could transform non-protective 
antibodies to protective by abrogating Fc binding.  In addition to dampening the 
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FcγRII response on B cells, this amino acid change could also prevent the 
infection of cells via FcγR-dependent endocytosis or phagocytosis, a known 
mechanism of action for dengue virus ADE infections (197-200).  
     In the context of autoimmunity, a non-FcγR binding antibody could contribute 
to antibody deposition in the kidney. Binding to FcγRIIB was found to be an 
important mechanism of antibody clearance from circulation (201). On the other 
hand, a non-FcγR binding antibody could be non-pathogenic. In the NZB X NXW 
model of murine lupus, inactivation of activating Fcγ protected the mice from 
disease even with IC deposition in the kidney (55). Therefore, non-FcγR binding 
antibody could deposit in the kidney without causing pathogenesis. Thus, this 
could represent a potentially protective mechanism where autoantibodies lose 
their pathogenic potential by failing to interact with FcγRs. Given the divergent 
pathogenic potential for non-FcγR binding antibodies, the frequency of their 
occurrence and role in disease warrants further examination.  
 
4. Role of Downstream Signaling Effectors in FcγRIIB Mediated  
            Inhibition  
The AM14 B cell response to RNA or DNA IC was driven by BCR-TLR 
signaling because in the absence of TLR7 or TLR9 the response was abrogated. 
The AM14 R2KO proliferative response to the DNA IC PL2-3 and PA4 was TLR9 
dependent because in the absence of TLR9 they were abrogated.  Conversely, in 
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the context of FcγRIIB, the proliferative response to RNA IC was TLR 
independent because they were unaffected by TLR7 or TLR9 ablation.  
The BCR dependence of RNA IC in the context of an FcγRIIB ablation-
driven proliferative response was interrogated using Btk inhibitors and the Btk 
loss of function mutation xid.  The RNA IC BWR4 was more sensitive to Btk 
inhibition, and the proliferative responses to RNA ICs were completely abrogated 
by the xid mutation.  These two pieces of data suggested that, in the context of 
FcγRIIB ablation, the response to RNA IC was dependent on the BCR. These 
data give physiological relevance to the binding data, which suggested that RNA 
IC was larger than DNA IC. A larger IC that binds the AM14 receptor better than 
a smaller IC would engage the BCR better and therefore induce more BCR 
signaling.  
The btk inhibitor and xid data raised an interesting issue as to the role of 
BCR engagement/signaling in BCR-TLR responses.  As the responses were 
entirely TLR9 dependent, it would be reasonable to hypothesize that the BCR 
acted to deliver the nucleic acid to a TLR9 compartment. These data 
demonstrated that, in the absence of a BCR-driven proliferative response, there 
was a role for Btk and clear synergy between the two pathways when the TLR 
ligand was delivered by the BCR.  One molecular mechanism for synergy could 
be the localization of Btk to the endosomal membrane.  In the context of 
naturally-occurring mutations, it was previously demonstrated that MyD88 
mutations were able to act via Btk to stimulate NFκB (202). Furthermore, it was 
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previously demonstrated that Btk was required for TNF-α production downstream 
of TLR2 and TLR4 engagement. The delivery of DNA to TLR9 via the BCR would 
bring Btk in proximity to MyD88 leading to NFκB activation via Btk. Although the 
attenuated proliferation in BCR-TLR stimulated AM14 xid cells correlated with 
increased cell death, the TLR ligands alone showed no such defect (165). In 
addition AM14 xid B cells did not respond to engagement of the BCR.  Therefore, 
engagement of TLR9 and/or TLR7 rescued some of the defects observed 
following BCR-TLR engagement. This suggested that Btk was either participating 
in BCR-TLR synergy or was involved in the delivery of the nucleic acid to the 
TLR-containing intracellular compartment.  
     One mechanism could be spatial and temporal coordination of BCR and TLR 
signaling. It was previously shown that in the absence of Btk, BCR internalization 
was retarded (26). It is known that the temporal trafficking of the BCR following 
endocytosis is coordinated with waves of BCR signaling (203). Previous work 
demonstrated that BCR engagement led to TLR9 relocalization to endosomes 
(204). Therefore attenuating BCR signaling could reduce TLR9 recruitment and 
therefore B cell responses to DNA.  In light of recent work, this mechanism is 
unlikely because BCR engagement does not lead to TLR9 relocalization.  Avalos 
et al., 2014 found that resting B cells have high levels of cleaved TLR9 and that 
BCR engagement did not increase the pool of cleaved TLR9 (79). Furthermore, 
they  showed that in resting B cells, TLR9 localized mainly in acidic 
compartments, not the ER, which also argues against BCR-mediated 
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relocalization. In the context of BCR-TLR responses, this suggested that TLR9-
induced relocalization did not contribute to BCR-TLR synergy.  Furthermore, this 
also suggested that the acidic milieu of the endosome served other functions in 
addition to facilitating TLR9 cleavage (71, 72). Therefore, one mechanism of 
FcγRIIB-mediated inhibition of BCR-TLR9 responses could be the retarded 
delivery of the DNA to a TLR9 containing compartment.  
     Downstream of BCR-FcγRIIB coengagement is the activation of SHIP-1, 
which dephosphorylates PIP3 to PIP2(3,4), which cannot recruit Btk. 
Presumably, the inhibitory functions of FcγRIIB would be mediated through SHIP-
1.  Interestingly, in the absence of SHIP-1, the response to BCR-TLR9 
stimulation was attenuated independent of FcγRIIB. This suggests an activating 
role of SHIP-1 in BCR-TLR9 responses. This was surprising because SHIP-1 is 
considered a negative regulator of BCR responses via inhibition of Btk 
recruitment to the plasma membrane. One possible mechanism could be that 
BCR-TLR9 colligation leads to cell death. SHIP-1 may protects against BCR-
TLR9 cell death by attenuating the BCR signaling cascade.  The negative 
regulatory role of BCR-TLR9 engagement would be consistent with the protective 
role of TLR9 in murine models of lupus.  Recently, it was found that some of the 
inhibitory functions of FcγRIIB on B cell function were recapitulated in the 
absence of a functional ITIM motif (164). In light of the protective role of SHIP-1 
in BCR-TLR9 responses and the ITIM-independent functions of FcγRIIB, the role 
of SHIP-1 in BCR-TLR responses requires further examination.  
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5. Use of Defined DNA IC to Interrogate Mechanisms  
     The proliferative responses of autoreactive B cells to spontaneous DNA ICs 
were enhanced by ablation of FcγRIIB and remained TLR9 dependent. To 
recapitulate spontaneous DNA ICs without the caveats of IC composition or 
formation, I used anti-SA SA DNA IC.  These defined DNA ICs stimulated TLR9 
dependent stimulation, and the proliferative response was attenuated by BCR-
FcγRIIB coengagement.  The development of defined DNA ICs that recapitulated 
spontaneous DNA ICs removed limitations of undefined composition and 
temporal formation of the IC.  This permitted me to address questions that were 
confounded by the limitations of spontaneous ICs.  Using defined DNA IC that 
were preformed and of known compositions, I determined that the anti-SA SA 
DNA IC bound better to AM14 B cells than AM14 R2KO B cells.  This suggested 
that the FcγRIIB synergized with the BCR to bind IC. This was strengthened by 
the finding that in the absence of a specific BCR, FcγRIIB on non-Tg B cells did 
not bind IC appreciably.  
     Previously, it was though that FcγRIIB1, the B cell isoform was not 
internalized (30). This suggested that BCR-TLR9 responses were inhibited by 
FcγRIIB1 by simply retaining the IC on the surface away from TLR9 in 
endolysosomal compartments. Recent studies demonstrated by FACS that 
FcγRIIB1 was internalized (173). Furthermore, the internalization contributed to 
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the consumption of B cell-depleting monoclonals (175). Therefore it was unlikely 
that FcγRIIB1 was retaining the IC on the surface.        
     Using internalization assays and pH sensing, I demonstrated that FcγRIIB 
used several mechanisms to disrupt BCR-TLR9 responses. The coengagement 
of BCR-FcγRIIB retarded the internalization of DNA IC. The IC was not being 
sequestered on the surface away from endosomal TLR9 but was delayed in how 
quickly it was internalized into the cells. Disrupting internalization could decouple 
the initial signaling events following BCR engagement from TLR9 engagement.  
Following BCR internalization, there are waves of signaling (203). Retarding 
internalization could lead to the DNA ligand engaging TLR9 after BCR signaling 
has ceased. Presumably, this would interfere with BCR-TLR9 synergy.  
     Following internalization, the IC were internalized and acidified. Interestingly, 
coengagement of BCR-FcγRIIB led to the IC residing in a higher pH 
compartment. In addition, the AM14 R2KO acquired more IC than the AM14. 
This likely resulted from the faster rate of uptake integrated over 24 hrs. After 24 
hrs, the DNA IC residing in a higher pH compartment which could antagonize 
TLR9 engagement by attenuating degradation of DNA. It was demonstrated that 
if DNaseII was ablated, the cells were unable to respond to DNA. As DNaseII is 
optimally active below pH 5.6, it was possible that this attenuated TLR9 
engagement (178).  
     Although these studies could have been confounded by the presence of 
surface IC, I demonstrated that even when surface IC was normalized, the AM14 
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R2KO still trafficked the IC to a more acidic compartment. This was in agreement 
with studies of FcγR dependent uptake of IC by pDCs. It was demonstrated that 
FcγRIIB led to reduced trafficking to an acidic compartment and reduced IFN-α 
production (205). Taken together these data indicate that in B cells, FcγRIIB was 
inhibiting BCR-TLR9 responses by modulating IC trafficking. 
  
E. Future Directions and Applications of Findings   
1. FcγRIIB KO lead to TLR7 independent RNA IC Responses  
In the absence of FcγRIIB, AM14 B cells proliferate better to RNA ICs but the 
responses are independent of TLR7. My binding data suggest that a difference in 
the size and or shape of the IC accounted for the TLR7 independent proliferation 
stimulated by RNA IC.  Furthermore, attenuation of proliferative responses to 
RNA IC by Btk inhibition phenocopied inhibition of BCR responses by Btk 
inhibition. This suggested that the proliferative response of AM14 R2KO B cells 
to BWR4 was dependent on BCR crosslinking.  The connection between BCR 
crosslinking and size was confounded because the binding data integrated a 
variety of factors and did not speak directly to the relative size of RNA IC versus 
DNA IC. Although the proliferation data suggested a role for size, it is impossible 
to conclusively comment on the relative size of RNA IC versus DNA IC.  Due to 
divergent roles of RNA IC and DNA IC in the pathogenesis of murine models of 
lupus, it is important to understand factors that differentiate the physiological 
responses to RNA and DNA IC by B cells.  
		
214
 
I propose directly interrogating the physical properties of RNA IC and DNA 
IC by fluorescent detection analytical ultracentrifugation (FD-AUC).  Spontaneous 
ICs are preformed by virtue of copurification of the antibody and antigen from 
hybridoma cultures, binding of antigen present in the primary B cell culture, or 
some combination thereof. FD-AUC detects using fluorescence and separates 
molecules over time via centrifugal force (206).  The time dependent migration of 
immune complexes in the centrifugal field results in determinations of size and 
shape.  The source of antigen would be BALB/c B cells left overnight at 37°C in 
dye free complete RPMI because normal RPMI would interfere with fluorescence 
detection.   The nucleic acids would be stained with Sytox Green and RNA select 
to label DNA or RNA respectively.  By comparing media alone, antibody in 
media, cells supernatant fluid alone and supernatant fluid combined with 
antibody the size and shape of the IC could be determined.   
In the context of murine lupus, the activation of autoreactive B cells occurs 
via dual engagement of BCR and TLR7 and/or 9 and data points to a more 
pathogenic role for TLR7 (107, 111, 207, 208).  Furthermore, mounting evidence 
from TLR7 driven models of lupus suggest an important role for BCR dependent 
signaling in TLR7 driven disease (113 , 169, 209). If RNA IC responses are more 
BCR dependent than DNA IC responses, then they should be more sensitive to 
inhibitors of BCR.  There are several FDA approved inhibitors that target the 
BCR signaling pathway. For example, Imbruvica (btk) and Zydelig (PI3K-δ) are 
approved for the treatment of hematological malignancies (210, 211).  In light of 
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my data and murine models, it may be prudent to entertain the use of BCR 
signaling inhibitors in the treatment of lupus as they would inhibit BCR-TLR7 
responses efficiently and attenuate BCR-TLR9 responses.   
 
2. Mutation of Fc domain that reduced FcγR Binding  
   The Fc domain somatic mutation of PL2-3 is surprising because it occurred in 
an AID hot spot and it reduces binding to activating and the inhibitory FcγRs.  
Taken together, this suggests a host mechanism to reduce FcγR binding by class 
switched antibodies. This raises two questions 1) What is the frequency of non-
FcγR binding IgG antibodies in an autoimmune prone mouse? and 2) Are these 
antibodies pathogenic? To address the question of frequency, I would analyze 
the repertoire from an autoimmune prone mouse by making a library of 
hybridomas.   The resulting antibodies would be screened for their ability to 
stimulate proliferation of BALB/c and BALB/c R2KO using BCRAM. This would 
give a functional measure of engagement FcγRIIB for IgG2a and IgG2b 
antibodies. Fc domain mutated antibodies identified through this functional 
screen could then be sequenced to identify mutated residues.  
 The more complex question is the role of IgG antibodies with reduced 
FcγR binding in pathogenesis. On one hand the B cell responses would not be 
attenuated by FcγRIIB engagement, but on the other hand, the IC could not bind 
activating Fcγ receptors. Reduced binding to activating FcγR would affect 
cytokine production and T cell activation and potentially T cell help to B cells.   
		
216
 
One way to attack this question would be to examine in vivo activation of AM14 B 
cells by PL2-3 298N or PL2-3 298S. It was previously demonstrated that adoptive 
transfer of IgG2a specific AM14 B cells and injection of PL2-3298N stimulated 
proliferation of the AM14 B cells (84, 212). A similar experiment comparing     
PL2-3298N to PL2-3298S would interrogate the role of reduced activating and 
inhibitory FcγR binding in the activation of B cells.  
If inflammatory properties of autoantibodies occur via binding of activating 
FcγRs, then IgG ICs that bind FcγR poorly would not be less pathogenic.  
Alternatively, they engage FcγRIIB, the inhibitory receptor poorly and could be 
more pathogenic. The data does not exist to know if these antibodies would be 
pathogenic or non-pathogenic. The clinical significance of reduced FcγR binding 
antibodies would vary greatly if they were i) non-pathogenic or ii) pathogenic. In 
the case that they are non-pathogenic, it could explain the presence of antibodies 
in the absence of disease (213, 214). In the case that antibodies that do not bind 
FcγRs wells are pathogenic, one way to engage FcγRIIB on B cells and attenuate 
IgG production would be via bispecific antibodies. 
 In the absence of FcγRIIB engagement on B cells by ICs, bispecific 
antibodies can coengage the BCR signaling complex and FcγRIIB.  The biologics 
XmAb5871 and MGD010 coengage CD32B and the BCR signaling complex 
(152, 215-218). If non-FcγR binding antibodies are pathogenic, this represents a 
clinical means to inhibit their production by autoreactive B cells via FcγRIIB and 
BCR coengagement independent of the constant domain of IgG.  
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Figure 30. Mechanisms of FcγRIIB Attenuation of BCR-TLR9 Responses Elucidated 
using Anti-SA SA-FITC/SA-AF647 DNA ICs. A) The pH sensing ICs are formed by first 
mixing SA-AF647 (red) and SA-FITC (green) with C11 DNA biotinylated once at both ends (2-
end bio DNA). Immune complexes are formed by adding anti-SA IgG2a (clone 1E11.1) to the 
DNA-streptavidin mixture. A) Coengagement of FcγRIIB and the AM14 BCR by anti-SA SA-
FITC/SA-AF647 DNA IC leads to a reduced rate internalization and trafficking of the IC to a 
higher pH environment. B) In the absence of FcγRIIB, the ICs are internalized faster and 
reside in a lower pH environment.  	
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3. Modulation of IC Trafficking by FcγRIIB 
     The inhibition of BCR responses by FcγRIIB coengagement was thought to 
occur via signaling. One mechanism was via SHIP-1 activation and reduced 
recruitment of Btk (28, 155, 219). An additional mechanism was interference with 
receptor clustering and therefore interaction of the BCR signaling effectors (31).  
I showed that that B cell responses (i.e. BCR-TLR9) that were dependent on 
TLR9 engagement were attenuated by FcγRIIB engagement. Using pH sensing 
Anti-SA SA-FITC/AF647 DNA ICs, I found that this was associated with reduced 
kinetics of IC internalization and the pH trafficking to a higher pH milieu (Figure 
30A).  This not obviate a role for signaling in the attenuation of BCR-TLR9 
responses by FcγRIIB but suggests an additional mechanism, IC trafficking. This 
represents a mechanism by which engagement of a surface receptor modulates 
the subsequent engagement of endosomal engagement (Figure 30B and C).   
Although a next logical step would be to examine the molecular mechanisms that 
regulate FcγRIIB mediated trafficking, this could involve some combinations of 
cytoplasmic sequences, signaling or trafficking of proton pumps to the 
endosome. Deconvolution of these interacting factors would likely give less ROI 
than other studies examining the divergence between TLR7 and TLR9.  
    The regulation of intracellular compartment function by pH is a conserved 
strategy to control enzyme and receptor function (176, 178, 220, 221).  
Therefore, it may serve to explain the divergence between TLR7 and TLR9 
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engagement, more simply stated they function in different pH compartment.  This 
could be easily interrogated by treating AM14 B cells with pH sensing ICs formed 
from biotinylated RNA or DNA oligonucleotides, labeled streptavidin, and α-SA.  
This illustrates the value of the tools presented in this dissertation to deepening 
our understanding the activation of immune cells by nucleic acid immune 
complexes.  
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